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Abstract
CCCTC-binding factor (CTCF) binds DNA, thereby helping to partition the mam-
malian genome into discrete structural and regulatory domains. In doing so, it insu-
lates chromatin and fine-tunes gene activation, repression, and silencing. Complete
removal of CTCF from mammalian cells causes catastrophic genomic dysregulation,
most likely due to widespread collapse of 3D chromatin looping within the nucleus. In
contrast, Ctcf hemizygous mice with lifelong reduction in CTCF expression are viable
but have an increased incidence of spontaneous multi-lineage malignancies. In addi-
tion, CTCF is mutated in many human cancers and is thus implicated as a tumour
suppressor gene. This study aimed to interrogate the genome-wide consequences
of a reduced genomic concentration of Ctcf and its implications for carcinogenesis.
In a genetically engineered mouse model, Ctcf hemizygous cells showed modest
but robust changes in almost a thousand sites of genomic CTCF occupancy; these
were enriched for lower affinity binding events with weaker evolutionary conservation
across the mouse lineage. Furthermore, several hundred genes concentrated
in cancer-related pathways were dysregulated due to changes in transcriptional
regulation. Global chromatin structure was preserved but some loop interactions
were destabilised, often around differentially expressed genes and their enhancers.
Importantly, these transcriptional alterations were also seen in human cancers.
These findings were then examined in a hepatocyte-specific mouse model of Ctcf
hemizygosity with diethylnitrosamine-induced liver tumours. Ctcf hemizygous mice
had a subtle liver-specific phenotype, although the overall tumour burden in Ctcf
hemizygous and wild-type mice was the same. Using whole genome sequencing, the
highly reproducible mutational signature caused by DEN exposure was characterised,
revealing that Braf (V637E), orthologous to BRAF (V600E) in humans, was the
predominant oncogenic driver in these liver tumours.
Taken together, while Ctcf loss is partially physiologically compensated, chronic
CTCF depletion dysregulates gene expression by subtly altering transcriptional
regulation. This study also represents the first comprehensive genome-wide and
histopathological characterisation of this commonly used liver cancer model.

Table of contents
List of figures xiii
List of tables xv
Abbreviations xvii
1 Introduction 1
1.1 Mammalian gene regulation . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.1 Epigenetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.2 CTCF is a multi-functional DNA-binding protein . . . . . . . . . . . . 7
1.2.1 CTCF in development, imprinting, and X inactivation . . . . . 9
1.2.2 Transcriptional regulation . . . . . . . . . . . . . . . . . . . . 10
1.2.3 CTCF-dependent chromatin looping . . . . . . . . . . . . . . 11
1.3 Cancer epigenetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
1.3.1 CTCF is a tumour suppressor gene . . . . . . . . . . . . . . 16
1.3.2 Ctcf haploinsufficiency predisposes to cancer in mice . . . . 18
1.3.3 Mutation of CTCF and its binding sites in human cancers . . 18
1.4 Mouse models of liver cancer . . . . . . . . . . . . . . . . . . . . . . 20
1.5 Thesis outline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2 Materials and methods 25
2.1 Mouse colony management . . . . . . . . . . . . . . . . . . . . . . . 25
2.1.1 Genetically engineered mice . . . . . . . . . . . . . . . . . . 25
2.1.2 Mouse genotyping . . . . . . . . . . . . . . . . . . . . . . . . 26
2.2 Mouse embryonic fibroblast cultures . . . . . . . . . . . . . . . . . . 26
2.3 qPCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.4 Quantitative western blotting . . . . . . . . . . . . . . . . . . . . . . 28
2.5 ChIP-sequencing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.5.1 Computational analyses of ChIP-sequencing . . . . . . . . . 32
x Table of contents
2.6 RNA-sequencing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.6.1 Computational analyses of RNA-sequencing . . . . . . . . . 38
2.7 TMT proteomics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
2.7.1 Computational analyses of proteomic data . . . . . . . . . . 42
2.8 Hi-C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
2.8.1 Computational analyses of Hi-C data . . . . . . . . . . . . . . 46
2.9 Mouse tumour models . . . . . . . . . . . . . . . . . . . . . . . . . . 48
2.9.1 Spontaneous tumourigenesis . . . . . . . . . . . . . . . . . . 48
2.9.2 Chemical model of hepatocarcinogenesis . . . . . . . . . . . 48
2.10 Tissue collection and processing . . . . . . . . . . . . . . . . . . . . 49
2.10.1 Fresh frozen tissue . . . . . . . . . . . . . . . . . . . . . . . . 49
2.10.2 Fixed tissue for histology . . . . . . . . . . . . . . . . . . . . 50
2.11 Tumour histopathology . . . . . . . . . . . . . . . . . . . . . . . . . . 51
2.12 Whole genome sequencing . . . . . . . . . . . . . . . . . . . . . . . 52
2.12.1 Computational analyses of whole genome sequencing . . . . 53
2.13 Data storage and management . . . . . . . . . . . . . . . . . . . . . 56
3 CTCF maintains regulatory homeostasis of cancer pathways 59
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
3.1.1 Project aim and overview . . . . . . . . . . . . . . . . . . . . 62
3.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
3.2.1 Successful generation of embryonic fibroblast cultures . . . . 63
3.2.2 Molecular characterisation of Ctcf hemizygous MEFs . . . . 65
3.2.3 Chronic reduction of CTCF alters its chromatin binding . . . . 66
3.2.4 Labile CTCF binding sites have distinct genomic features . . 67
3.2.5 Ctcf hemizygosity alters transcription of cancer pathways . . 67
3.2.6 Gene expression changes correspond with altered looping . 70
3.2.7 Altered gene expression patterns are found in human tumours 74
3.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
4 Genetic and chemical models of hepatocarcinogenesis 79
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
4.1.1 Project aim . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
4.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
4.2.1 Characterisation of Ctcf hemizygous mice . . . . . . . . . . . 82
4.2.2 Hepatocyte-specific Ctcf knockdown . . . . . . . . . . . . . . 90
4.2.3 Tumour induction using diethylnitrosamine . . . . . . . . . . . 94
Table of contents xi
4.2.4 Pathological characterisation of DEN-induced tumours . . . . 96
4.2.5 Genomic characterisation Ctcf hemizygous liver tumours . . 100
4.2.6 Distinct mutational signatures of liver tumours . . . . . . . . . 102
4.2.7 Braf is the predominant driver of DEN-induced liver tumours 106
4.2.8 Apc is a secondary driver in mouse HCC . . . . . . . . . . . 110
4.2.9 CTCF binding sites are enriched for mutations . . . . . . . . 110
4.2.10 Carmil2 is overexpressed in Ctcf hemizygous tumours . . . . 113
4.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
5 Discussion and outlook 121
5.1 CTCF haploinsufficiency . . . . . . . . . . . . . . . . . . . . . . . . . 121
5.2 Model systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
5.3 Mechanisms of chromatin organisation . . . . . . . . . . . . . . . . . 125
5.4 DNA damage and repair . . . . . . . . . . . . . . . . . . . . . . . . . 127
Publications 131
References 133
Appendix A: List of differentially expressed genes 165
Appendix B: List of significantly mutated genes 171

List of figures
1.1 Eukaryotic transcriptional regulation . . . . . . . . . . . . . . . . . . 2
1.2 Regulation of chromatin by histone modifications . . . . . . . . . . . 5
1.3 Higher-order chromatin structure . . . . . . . . . . . . . . . . . . . . 8
1.4 Models of TAD formation . . . . . . . . . . . . . . . . . . . . . . . . . 13
3.1 Project overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
3.2 Conditional deletion of the mouse Ctcf gene . . . . . . . . . . . . . 63
3.3 MEF cultures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
3.4 Validation of CTCF depletion . . . . . . . . . . . . . . . . . . . . . . 65
3.5 Ctcf hemizygosity results in altered chromatin binding . . . . . . . . 66
3.6 Differentially bound CTCF loci have distinct genomic features . . . . 68
3.7 CTCF depletion dysregulates oncogenic pathways . . . . . . . . . . 69
3.8 Transcriptional perturbations arise from regulatory changes in the
nuclear genome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
3.9 Global-scale chromatin interactions are robust to reduced CTCF levels 73
3.10 Concordant gene alterations in diverse murine and human tumours . 75
4.1 Histology of Ctcf hemizygous mice . . . . . . . . . . . . . . . . . . . 84
4.2 Histological characterisation of hepatocellular neoplasms . . . . . . 89
4.3 Hepatocyte-specific Ctcf knockdown. . . . . . . . . . . . . . . . . . 93
4.4 Overview of tumour induction protocol . . . . . . . . . . . . . . . . . 94
4.5 DEN-initiated tumour characteristics . . . . . . . . . . . . . . . . . . 96
4.6 Histology of hepatocellular neoplasms . . . . . . . . . . . . . . . . . 97
4.7 Macroscopic and microscopic appearance of liver tumours . . . . . . 99
4.8 Independent evolution of DEN-induced tumours . . . . . . . . . . . . 101
4.9 DEN-initiated neoplasms have a high SNV burden . . . . . . . . . . 103
4.10 DEN-initiated tumours have distinct mutational signatures . . . . . . 105
4.11 Mutational signatures of DEN-induced and spontaneous tumours . . 106
xiv List of figures
4.12 DEN-initiated tumours carry Braf and Hras mutations . . . . . . . . 108
4.13 Validation of Apc mutations . . . . . . . . . . . . . . . . . . . . . . . 111
4.14 CTCF binding affinity correlates with mutational burden . . . . . . . 112
4.15 CTCF binding sites are hypermutated . . . . . . . . . . . . . . . . . 113
4.16 Differential gene expression in liver and DEN-induced tumours . . . 114
List of tables
2.1 Primers used for mouse genotyping . . . . . . . . . . . . . . . . . . 27
2.2 Library amplification cycles . . . . . . . . . . . . . . . . . . . . . . . 31
2.3 Antibodies used for immunohistochemistry . . . . . . . . . . . . . . 51
3.1 Genotyping of mouse embryos . . . . . . . . . . . . . . . . . . . . . 64
4.1 Genotyping of Ctcf hemizygous mice . . . . . . . . . . . . . . . . . . 82
4.2 Prevalence of spontaneous tumours in aged Ctcf hemizygous mice 87
4.3 Genotyping of liver-specific Ctcf hemizygous mice . . . . . . . . . . 91
4.4 Pilot experiment to determine time points for sample collection . . . 95
4.5 Hotspot mutations in oncogenes and tumour suppressor genes . . . 109

Abbreviations
AATK apoptosis-associated tyrosine kinase
ALD alcoholic liver disease
APC adenomatous polyposis coli
AR androgen receptor
ATP adenosine triphosphate
AWERB Animal Welfare and Ethical Review Body
BCL2 B-cell lymphoma 2
BCL6 B-cell lymphoma 6
BER base excision repair
bp base pair
BRAF B-Raf proto-oncogene, serine/threonine kinase
bRP basic reverse phase
BSA bovine serum albumin
Carmil2 capping protein, Arp2/3 and myosin-I linker protein 2
Cas CRISPR associated protein
CC cholangiocarcinoma
ChIP-seq chromatin immunoprecipitation followed by high-throughput sequencing
cis-SAGe cis-splicing between adjacent genes
CNV copy number variation
CRC colorectal cancer





DMD differentially methylated domain




DPX distyrene plasticiser xylene
E embryonic day
EDTA ethylenediaminetetraacetic acid
EGF epidermal growth factor
EGFR epidermal growth factor receptor
EGTA ethylene glycol-bis(2-aminoethylether)-tetraacetic acid
EMH extramedullary haematopoiesis





EWAS epigenome-wide association study
F1 filial generation one
FACS fluorescence activated cell sorting
FBS foetal bovine serum
Fbxo6 F-box only protein 6




FOXA1 forkhead box A1
G&T-seq genome and transcriptome sequencing
gDNA genomic DNA
GEM genetically-engineered mouse
GRCh38 Genome Reference Consortium human build 38
GRCm38 Genome Reference Consortium mouse build 38
GTF general transcription factor
GWAS genome-wide association study
H3K27ac acetylation of histone H3 at lysine 27
H3K27me3 trimethylation of histone H3 at lysine 27
H3K4me1 monomethylation of histone H3 at lysine 4
H3K4me3 trimethylation of histone H3 at lysine 4
H3K9me3 trimethylation of histone H3 at lysine 9
H&E haematoxylin and eosin
HAT histone acetyltransferase
HBV hepatitis B virus
HCC hepatocellular carcinoma
HCV hepatitis C virus
HDAC histone deacetylase
HE hemizygous
Hi-C high-resolution chromosome conformation capture sequencing
HIER heat induced epitope retrieval
hMLH1 human MutL homologue 1
HNF4A hepatocyte nuclear factor 4 alpha
xx Abbreviations
HPLC high-performance liquid chromatography
HRAS Harvey rat sarcoma viral oncogene homologue
Hz Hertz
ICGC International Cancer Genome Consortium
IDH1 isocitrate dehydrogenase 1
IGF2 insulin-like growth factor 2
IHC immunohistochemistry
IL-6 interleukin 6
INHAND International Harmonization of Nomenclature and Diagnostic Criteria
for Lesions in Rats and Mice
IP intraperitoneal
IQR interquartile range
KRAS Kirsten rat sarcoma viral oncogene homologue
LB lysis buffer
LC-MS liquid chromatography-mass spectrometry
LCR locus control region
LICA-FR liver cancer (France)
lncRNA long noncoding RNA
LOF loss of function
LOH loss of heterozygosity









mTOR mammalian target of rapamycin
NAFLD non-alcoholic fatty liver disease
ncRNA noncoding RNA




NRAS neuroblastoma RAS viral oncogene homologue
nt nucleotide
NTB no Tween buffer
Nudt11 diphosphoinositol polyphosphate phosphohydrolase 3-beta
ORO oil red O
PBS phosphate-buffered saline
PCA principal component analysis
PCAWG Pan-Cancer Analysis of Whole Genomes
PCI phenol:chloroform:isoamyl alcohol
PCR polymerase chain reaction
PGK phosphoglycerate kinase 1
PGR progesterone
PI protease inhibitor
PIER proteolytic induced epitope retrieval
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
piRNA PIWI-interacting RNA
PLG phase lock gel
Pol II polymerase II
xxii Abbreviations
PTEN phosphatase and tensin homologue
QC quality control
RB1 retinoblastoma 1






ROS reactive oxygen species
RSB resuspension buffer
RT room temperature
scNMT-seq single-cell nucleosome, methylation, and transcription sequencing
scRNA-seq single-cell RNA sequencing
SDS sodium dodecyl sulfate
siRNA small interfering RNA
SMC structural maintenance of chromosomes
SNP single nucleotide polymorphism
SNV single nucleotide variant
SPRI solid phase reversible immobilisation
SPS synchronous precursor selection
SV40 simian vacuolating virus 40






TCGA The Cancer Genome Atlas
TE Tris-EDTA
TEAB triethylammonium bicarbonate
TERT telomerase reverse transcriptase
tet tetracycline
TFIID transcription factor II D
TGF-α transforming growth factor alpha
TIL tumour infiltrating lymphocyte
TLE Tris-low-EDTA
TMT tandem mass tag
TP53 tumour protein p53
TPM transcripts per million reads
TSG tumour suppressor gene
TSS transcription start site
VAF variant allele frequency
WAPL wings apart-like protein
WES whole exome sequencing
WGS whole genome sequencing
WT wild-type




1.1 Mammalian gene regulation
The phenotype-genotype gap – the inability to explain phenotypic diversity on the
basis of DNA sequence alone – is apparent at inter-cellular, inter-individual, and inter-
species levels. Every cell within an individual’s tissues and organs shares the same
genetic sequence, yet each is functionally and morphologically distinct; for example,
hepatocytes are relatively large cells measuring 20-30 µm in diameter specialised for
synthesis, metabolism, and detoxification, while lymphocytes are 7 µm in diameter
and mediate immune processes. At the population level, <0.1% of bases are different
between individual humans (The 1000 Genomes Project Consortium, 2012), and
although 96% of our genes are homologous with chimpanzees (Pan troglodytes)
(The Chimpanzee Sequencing and Analysis Consortium, 2005; Varki and Altheide,
2005) and over 35% are homologous with worms (such as Caenorhabditis elegans)
(C. elegans Sequencing Consortium., 1998) or the common fruit fly (Drosophila
melanogaster ) (Adams et al., 2000), phenotypic differences are obvious. Phenotype
is not simply a product of DNA sequence alone, and many complex extra-genomic
and epigenetic processes contribute to phenotypic diversity. The most important of
these is the regulation of gene expression.
The structural and physiological complexities of multicellular eukaryotes demand
more intricate gene regulation than that described in prokaryotes (Jacob and Monod,
1961). The first novel mechanism of transcriptional regulation to emerge in eu-
karyotes was that of trans-acting sequence-specific transcription factors binding
to cis-regulatory DNA sequences to regulate transcription by RNA polymerases
(Roeder and Rutter, 1969). The default eukaryotic transcriptional state is “off”, with
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gene expression requiring combinatorial binding of multiple transcription factors
to gene promoter or enhancer regions to coordinate transcription (Reményi et al.,
2004). This fundamental control process is fine-tuned by a number of mechanisms
that are not strictly dependent on protein-coding DNA sequences – termed epige-
netic mechanisms – including DNA methylation, histone modification, expression
of noncoding (nc)RNAs, and higher-order chromatin structure (Figure 1.1). These
processes that influence DNA function and their molecular and cellular effects have
given rise to the field of epigenetics.
Fig. 1.1 Eukaryotic transcriptional regulation. DNA looping mediated by CCCTC binding
factor (CTCF) brings distal enhancer elements into close proximity to promoter elements.
The promoter is the DNA sequence where the general transcription factors (GTFs) and
polymerase assemble. These elements are immediately upstream of protein-coding genes
marked by active histone marks such as H3K4me3 and unmethylated CpG islands, and are
bound by tissue-specific transcription factors that recruit GTFs and the RNA polymerase
II (Pol II) machinery. Enhancers are cis-regulatory DNA sequences that are marked by
active histone modifications such as H3K4me1 and are bound by tissue-specific transcription
factors and transcriptional co-activators such as p300, thus affecting the rate of transcription.
These sequences can locate immediately adjacent to the promoter, far upstream of it, within
introns, or entirely downstream of the gene. The length of DNA between the cis-regulatory
sequences and the start of transcription varies, sometimes reaching tens of thousands of
nucleotides in length. Before the start of transcription, the transcription factor IID (TFIID)
complex binds to the TATA box in the core promoter of the gene. Many transcriptional
regulators act through Mediator (a multi-protein complex that functions as a transcriptional
co-activator in all eukaryotes (Kelleher et al., 1990)), while some interact with GTFs and
RNA Pol II directly. Transcriptional regulators also act by recruiting proteins that alter the
chromatin structure of the promoter. Whereas Mediator and the GTFs are the same for many
Pol II-transcribed genes, the transcriptional regulators and the locations of their binding sites
relative to the promoter differ for each gene (Alberts et al., 2014).
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1.1.1 Epigenetics
Epigenetic traits are defined as “stably heritable phenotypes resulting from changes
in a chromosome without alterations in the DNA sequence” (Berger et al., 2009).
This definition has markedly evolved since Waddington originally fused the words
"epigenesis" (cell differentiation) and "genetics" in the context of developmental
biology (Waddington, 1942). His epigenetic landscape metaphor detailed how gene
regulation modulates embryonic development and how mutations alter cell fates and
consequently morphogenesis. Over a decade later, Nanney (1958) adopted the
term "epigenetics" to describe auxiliary mechanisms that determine which genes are
expressed in a particular cell. The definition then stabilised to describe "the study
of mitotically and/or meiotically heritable changes in gene function that cannot be
explained by changes in DNA sequence" (Riggs and Porter, 1996). More recently,
others have included "transgenerational inheritance" of epigenetic marks such as
DNA methylation or histone modifications via gametes, first described in plants
but now also well recognised in mammals (Anway et al., 2005) including humans
(Skinner, 2014), within the umbrella of epigenetics.
Understanding the mechanisms involved in the initiation, maintenance, and
heritability of epigenetic states is an important aspect of current biological research,
since these mechanisms underpin how each cell behaves in the complex system of
the organism. Epigenetics is now known to contribute to several major pathologies
including cancer, chromosomal instabilities, and mental retardation (Egger et al.,
2004). To understand the ways in which epigenetic control contributes to cancer
initiation and development, it is first necessary to be familiar with the main epigenetic
mechanisms.
Methylation
DNA methylation (addition of a -CH3 group) at the C5 position of DNA cytosine
residues is the archetypal epigenetic gene control mechanism (Holliday and Pugh,
1975) and typically has a gene silencing effect (Egger et al., 2004). Methylation is
catalysed by DNA methyltransferases (DNMTs) and, in mammals, typically occurs at
symmetrical CpG dinucleotides. Methylation patterns are defined during embryolog-
ical development and retained during somatic cell division (Messerschmidt et al.,
2014). CpG islands, which are regions ≥500 bp in length with a GC content >55%
present at the 5′ promoter region of approximately 50% of genes (Takai and Jones,
2002), are spared methylation and tend to be transcriptionally active housekeeping
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genes. De novo methylation of these CpG islands may result in aberrant gene
expression such as the silencing of tumour suppressor genes in cancer cells (Jones
and Baylin, 2002) .
Histone modifications
DNA wraps around histone proteins to form nucleosomes, the basic unit of chromatin
and the means by which DNA is packaged in eukaryotic cells. The acetylation,
phosphorylation, or methylation of histone octamers (tetramer of two histone 2A
(H2A) and two histone 2B (H2B) molecules and H3 and H4 dimers) allow dynamic
regulation of chromatin and, therefore, gene expression (Taby and Issa, 2010)
(Figure 1.2A).
Acetylation of lysines is highly dynamic and regulated by the opposing action of
two families of enzymes, histone acetyltransferases (HATs) and histone deacetylases
(HDACs). HATs use acetyl CoA as a cofactor and catalyse the transfer of an acetyl
group to the ε-amino group of lysine side chains, thereby neutralising lysine’s positive
charge; this action has the potential to weaken histone-DNA interactions (Parthun,
2007). De-acetylation of the positively charged N-termini of H3 and H4 results in a
closed and tight chromatin configuration (heterochromatin) around the negatively
charged DNA, whereas acetylation neutralises this charge and chromatin becomes
more open (euchromatin) and, therefore, more permissible to transcription (Struhl,
1998) (Figure 1.2B). Histone phosphorylation is also highly dynamic and takes place
on serines, threonines and tyrosines, predominantly, but not exclusively, at N-terminal
histone tails. Phosphorylation levels are controlled by kinases and phosphatases
that add or remove the modification, respectively (Oki et al., 2007).
Methylation mainly occurs on the side chains of lysines and arginines. Unlike
acetylation and phosphorylation, histone methylation does not alter the histone
protein charge. The epigenetic effect of histone methylation is more variable than
that of acetylation, in part because lysines may be mono-, di-, or tri-methylated
and arginines may be mono-, symmetrically, or asymmetrically di-methylated; the
net result is that regions can be marked as either active or inactive. For example,
H3K4me3 (trimethylation of lysine 4 of histone H3) occurs at active gene promoter
regions (Lachner and Jenuwein, 2002), whereas DNA methylation and repressive
histone marks such as H3K9me3 and H3K27me3 mark silent heterochromatin that
is not being actively transcribed such as centromeres and telomeres (Zhang et al.,
2015). Repeat elements are mostly methylated to prevent their activity (Bedford and
Clarke, 2009).
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Finally, ubiquitination results in a much larger covalent modification than acetly-
ation, phosphorylation, or methylation. Ubiquitin is a 76-amino acid polypeptide
that attaches to histone lysines via the sequential action of three enzymes E1, E2,
and E3, which perform activation, conjugation, and ligation, respectively. Histones
usually become mono-ubiquitylated, and the modification is removed via the action
of isopeptidases called deubiquitinating enzymes, which is important for both gene
activity and silencing (Wang et al., 2004).
Fig. 1.2 Regulation of chromatin by histone modifications. Histone modifications play
fundamental roles in most biological processes involved in the manipulation and expression
of DNA including gene transcription (Bannister and Kouzarides, 2011). (A) Examples of
proteins domains that specifically bind to modified histones are shown (Kouzarides, 2007).
(B) Euchromatin and heterochromatin are biochemically distinguishable by different covalent
histone modifications: de-acetylation of H3 and H4 results in a closed and tight chromatin
configuration (heterochromatin) around negatively charged DNA, whereas acetylation neu-
tralises this charge and chromatin becomes more open (euchromatin) and, therefore, more
permissible to transcription (Struhl, 1998).
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Noncoding RNAs
The vast majority of genomic regions are transcribed into mRNA, but only 2% are
ultimately translated into protein (Liu et al., 2013a). These non-protein coding RNA
(ncRNA) transcripts are important epigenetic gene regulatory mechanisms (Liu et al.,
2013a). ncRNAs are subclassified according to size into long ncRNAs (lncRNAs,
>200 nucleotides (nt)) or short ncRNAs (<200 nt), the latter including microRNAs
(miRNAs), small interfering RNAs (siRNAs), and piwi-interacting RNAs (piRNAs)
(Peschansky and Wahlestedt, 2014).
Small ncRNAs are responsible for RNA gene silencing, with each type exploiting
independent mechanisms of action. For example, piRNAs preserve mammalian
genome integrity by regulating the activity of transposable elements (Ernst et al.,
2017). lncRNAs are far more diverse in structure and function and may behave as
signals, decoys, guides, or scaffolds (Wang and Chang, 2011) to form ribonucleic-
protein (RNP) complexes with other chromatin regulators that coordinate the regu-
lation of gene expression (Rinn and Chang, 2012). They can be broadly classified
into (i) those acting in cis to control expression and/or the chromatin state of nearby
genes, and (ii) those which act in trans to cause a diverse array of functions through-
out the cell. At least three proposed mechanisms for gene expression regulation
are proposed for cis-acting lncRNAs: (i) the lncRNA transcript itself regulates the
expression of neighbouring genes via its ability to recruit regulatory factors to the
locus and/or modulate their function; (ii) the process of transcription and/or splicing
of the lncRNA confers a gene-regulating functionality that is independent of the
sequence of the RNA transcript; or (iii) regulation in cis depends solely on DNA
elements within the lncRNA promoter or gene locus and is completely independent
of the encoded RNA or its production (Kopp and Mendell, 2018).
Higher-order chromatin structure
Mammalian genomes encode genetic information in their linear sequence, but
appropriate expression of their genes requires chromosomes to fold into complex
three-dimensional structures (Gibcus and Dekker, 2013). The human genome
contains approximately three billion bases equating to almost two metres of DNA
in each nucleus with an average diameter of only 6 µm (Bickmore, 2013). Such
packaging requires complex and dynamic spatial organisation to allow selective
access to actively transcribed regions, compact unnecessary regions, and, during
cell division, the ordered unravelling of chromatin (Dixon et al., 2012; Fraser et al.,
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2015). This complex genomic folding necessary for physiological function follows a
structural hierarchy described below from lowest to highest resolution (Figure 1.3).
At the largest scale, chromosomes occupy distinct nuclear territories. Gene-poor,
mid-to-late-replicating chromatin is enriched in nuclear compartments located at
the nuclear periphery and in perinucleolar regions (Cremer and Cremer, 2001).
Individual chromosomes are then folded into A (open/active) and B (closed/silent)
compartments that preferentially interact (Lieberman-Aiden et al., 2009). Within
these compartments, the chromatin forms discrete megabase-scale topologically-
associated domains (TADs) and smaller sub-TADs that correlate with genomic
regions constraining chromatin spread (Dixon et al., 2012). At the kilobase-to-
megabase scale, chromatin forms loop interactions that facilitate lineage-specific
differential gene expression in a cis-regulatory manner by facilitating co-localisation
of distal regulatory elements with gene promoters that span large genomic distances,
even on different chromosomes (Hadjur et al., 2009; Schoenfelder et al., 2010). In
turn, these act as transcriptional insulators by marking boundaries between different
chromatin loops and domains (Ghirlando and Felsenfeld, 2016). TADs are largely
conserved between cell types and across species, whereas sub-TAD topology
varies in a tissue-specific manner, indicating that they are an inherent property of
mammalian genomes (Phillips-Cremins et al., 2013; Vietri Rudan et al., 2015).
An important characteristic of these hierarchical DNA structures is the boundary
elements that define them. In this respect, CCCTC-binding factor (CTCF) binds
directly to a specific DNA motif and recruits the ring-shaped cohesin protein complex
consisting of SMC1, SMC3, and RAD21 (Dixon et al., 2016; Rao et al., 2014).
Therefore, in defining these boundaries, CTCF represents a fundamental epigenetic
control element.
1.2 CTCF is a multi-functional DNA-binding protein
CTCF is a multifunctional eleven zinc finger nuclear phosphoprotein encoded by
the CTCF gene. Combinatorial use of zinc finger domains allows protein binding to
a range of specific ~50-60 bp DNA target sequences and proteins. Depending on
the site of chromatin binding (and other co-bound proteins), CTCF may act as an
activator or repressor of transcription, as described above. Additionally, CTCF forms
methylation-sensitive insulators and regulates X-chromosome inactivation (Ohlsson
et al., 2001). CTCF is, therefore, highly context- and cell type-specific, as described
below.
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Fig. 1.3 Higher-order chromatin structure. Genomic scales of chromatin organisation
are illustrated as a single unravelled chromatin fibre, from low (top) to high (bottom) spatial
resolution. DNA occupies distinct nuclear territories (orange, purple, pink). DNA is broadly
divided into euchromatic and heterochromatic compartments, here termed A (green) and
B (blue), respectively. Self-interacting, megabase-scale topologically associated domains
(TADs) and smaller chromatin loops further organise chromatin into regulatory units defined
by binding of CTCF and cohesin complexes. Three examples of chromatin looping are
shown: enhancer-promoter, enhancer-silencer, and insulator-insulator (Fraser et al., 2015).
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1.2.1 CTCF in development, imprinting, and X inactivation
CTCF is necessary for embryonic development, and deletion of both Ctcf alleles in
mice is embryonic lethal (Fedoriw et al., 2004; Moore et al., 2012). CTCF appears
to play major roles in gene imprinting and X inactivation, which are important for
normal development, gene silencing, and gene dosage control.
In mammals, almost all autosomal genes are expressed simultaneously by both
alleles. However, ~1% of genes are imprinted; that is, one of the two inherited alleles
is silenced, with reciprocal expression of either the maternally or paternally inherited
allele (Wilkinson et al., 2007). CTCF plays an essential role in imprinting, which
is an essential epigenetic mechanism in mammals for normal foetal growth and
development (McGrath and Solter, 1984; Surani et al., 1984). Aberrant imprinting
disturbs development and causes various inherited diseases (Reik and Walter, 2001)
such as Prader-Willi syndrome (Nicholls et al., 1998).
The H19 gene encodes one of the most abundant RNAs in the developing
embryo and has served as a useful model for investigating mammalian imprinting.
H19 overexpression in transgenic mice results in late prenatal lethality, leading to the
conclusion that dosage of its gene product is strictly controlled. RNase protection
assays have been used to demonstrated that H19 is paternally imprinted and only
the maternal copy is expressed (Bartolomei et al., 1991). H19 shares its enhancer
elements with the maternally imprinted insulin-like growth factor 2 (IGF2) gene,
and thus only the paternal copy is expressed (Reik and Walter, 2001). IGF2/H19
locus imprinting is well characterised, and CTCF regulates parent-of-origin-specific
monoallelic expression of IGF2 and H19 in a methylation-sensitive manner (Bell
and Felsenfeld, 2000). A differentially methylated domain (DMD) upstream of H19
contains CTCF binding sites: it is unmethylated on the maternal chromosome and,
therefore, bound by CTCF, thus insulating the IGF2 promoter from its enhancers.
However, this DMD is methylated on the paternal allele, blocking CTCF binding and
allowing downstream enhancers to interact with the paternal IGF2 promoter (Lewis
and Murrell, 2004). Under homeostatic conditions, the DMD remains hypomethylated
during oogenesis, and RNA interference (RNAi) experiments in transgenic mice
have shown that CTCF protects the H19 DMD from de novo methylation (Fedoriw
et al., 2004). Mutations in the CTCF binding region of the DMD of H19 results in
loss of IGF2 imprinting and complex patterns of de novo methylation upon maternal
inheritance (Pant et al., 2004), highlighting the importance of CTCF in the control of
imprinting.
10 Introduction
X chromosome inactivation is a dosage compensation mechanism in females
that equalises gene expression by silencing one of the X chromosomes. In placental
mammals, the chromosome selected for silencing is random but, after inactivation,
the X chromosome of all descendants of that cell are inactivated in the same way.
There is homologous pairing of the two X chromosomes during early embryonic
development, which requires the presence of trans-acting CTCF (Xu et al., 2007).
The lncRNA X-inactive specific transcript (Xist) then recruits specific chromatin
modifiers, which results in the silenced X chromosome becoming a heterochromatic
Barr body (Yang et al., 2015). However, a minority of genes on the inactive X
chromosome, including Xist, are not silenced (Wutz, 2011) and instead are insulated
by CTCF-constrained chromosomal loops (Filippova et al., 2005). This process
is facilitated by lncRNAs including Tsix (the antisense transcript of Xist), which
establishes an epigenetic switch for X inactivation (Chao et al., 2002; Filippova et al.,
2005).
1.2.2 Transcriptional regulation
In addition to its developmental role, CTCF is essential in somatic cells, where it
is integral to homeostatic gene expression. CTCF was initially characterised as a
negative regulator of the proto-oncogene c-MYC, which plays a critical role in normal
growth control, differentiation, and apoptosis (Evan and Littlewood, 1993) and is
one of the most frequently affected genes in human cancers. CTCF binds ~200
bp upstream of the transcription start site (TSS) of c-MYC, which includes three
CCCTC core sequence repeats and was proven experimentally by deleting 110 bp
of the CTCF binding site in chicken embryonic fibroblasts, which resulted in a four-
to eight-fold increase in c-MYC transcription (Lobanenkov et al., 1990). Thus, CTCF
is a direct negative transcriptional regulator of c-MYC.
CTCF has exquisite evolutionary conservation over approximately 300 million
years (Filippova et al., 1996), including in Xenopus laevis (African clawed frog)
(Burke et al., 2002), Danio rerio (zebrafish) (Pugacheva et al., 2006), and Drosophila
melanogaster (Moon et al., 2005). Although the exon-intron gene organisation of
CTCF is different in mammals and birds, the open reading frame remains unchanged
(Klenova et al., 1998). CTCF binding sites are also highly conserved across multiple
mammalian species (Schmidt et al., 2012). This is in contrast to tissue-specific
transcription factors such as hepatocyte nuclear factor 4α (HNF4A) (Odom et al.,
2007; Schmidt et al., 2010b; Stefflova et al., 2013) and enhancers (Villar et al.,
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2015), which evolve much more rapidly. The sequences of some homologous CTCF
DNA-binding regions, such as the c-MYC promoter, diverge between species: in
humans, the c-MYC promoter it is bound by zinc fingers 3-11, whereas in chickens
it is bound by zinc fingers 2-7 (Filippova et al., 1996). This divergence highlights
the plasticity of zinc finger binding in order to maintain CTCF function in different
species.
More recently, CTCF has been shown to regulate gene expression via long-range
chromatin looping. A well characterised example of this phenomenon is at the locus
control region (LCR) of the β -globin cluster, which interacts via long-range chromatin
contacts to target genes in erythroid cells but not in those of other lineages such
as neurons (Palstra et al., 2003; Splinter et al., 2006). The α-globin locus is also
thoroughly characterised: paired convergent CTCF sites flank the α-globin regulatory
region but only interact during erythropoiesis, thus defining a self-interacting erythroid
compartment (Hanssen et al., 2017).
1.2.3 CTCF-dependent chromatin looping
The hierarchical structure of chromatin is necessary for genome function and proper
gene regulation, and CTCF plays a critical role. However, a paradox exists with
regard to the structure versus function of chromatin organisation, in that our knowl-
edge of the global, low-resolution structure of chromosomal arrangement within
the nucleus is very detailed, whereas our knowledge of chromatin function is more
advanced at the finer, intragenic scale (Ruiz-Velasco and Zaugg, 2017). Three-
dimensional chromatin organisation can be analysed using chromosome conforma-
tion capture technology, notably Hi-C, which allows genome-wide associations to
be scrutinised (Dixon et al., 2012). The resolution of this technology has rapidly
improved from megabase (Lieberman-Aiden et al., 2009) to kilobase resolution (Rao
et al., 2014), and the dynamics of chromosomal organisation can now be evaluated
in small cell numbers (Blanco et al., 2018; Hug et al., 2017) or even at single-cell
resolution (Nagano et al., 2015).
As noted above, the boundaries of TADs and loops are enriched for CTCF
binding sites (one at each end of the loop), where CTCF directly binds to specific
DNA motifs to form a dimer (Dixon et al., 2012; Sofueva et al., 2013). The DNA
motif is non-palindromic, and CTCF dimer formation occurs when the two CTCF
binding sites are directionally convergent (de Wit et al., 2015; Guo et al., 2015;
Rao et al., 2014), whereas inverted or disengaged CTCF sites do not necessarily
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form chromatin loops (de Wit et al., 2015). Cohesin complexes are recruited to
these boundary domains via the interaction of CTCF’s C-terminus and the SA2
cohesin subunit (Xiao et al., 2011), where they help to establish and/or maintain
topological domains, although CTCF and cohesin differentially contribute to chro-
matin organisation and gene regulation. For example, cohesin depletion causes a
general loss of local chromatin interactions but the topological domains remain intact,
whereas CTCF depletion reduces intradomain interactions but, notably, increases
interdomain interactions (Zuin et al., 2014). Furthermore, depletion of cohesin or
CTCF dysregulates distinct groups of genes (Sofueva et al., 2013; Zuin et al., 2014).
Two independent mechanisms have been proposed to explain cohesin’s control of
chromatin organisation: (i) cohesin-independent segregation of the genome into
fine-scale compartments defined by local transcriptional activity and the epigenetic
landscape; and (ii) cohesin-dependent formation of TADs, which facilitates enhancer-
promoter interactions (Schwarzer et al., 2017). The latter mechanism is debated but
is currently hypothesised to occur either via the "handcuff model" (Vietri Rudan and
Hadjur, 2015) or the "loop extrusion" model (Sanborn et al., 2015) (Figure 1.4).
The handcuff model proposes that CTCF serves as the initial, static binding factor
that defines a grid of potential insulation sites based on high-specificity sequence
motifs. Cohesin complexes are then recruited to the CTCF grid to engage in
preferential interactions that give rise to long-range chromosomal loops, which
effectively have an insulatory effect and thus organise chromosomes into domains
(Vietri Rudan and Hadjur, 2015). This is supported by the known co-localisation of
CTCF and cohesin at TAD boundaries and that removal of CTCF and/or cohesin
alters chromatin architecture. However, given that there are far more CTCF binding
sites than TADs, it is unclear which, when, and why two sites interact.
The loop extrusion model is more dynamic and proposes that an “extrusion com-
plex” containing two tethered DNA-binding subunits (likely including CTCF-cohesin
heterodimers) is loaded onto chromatin, with both DNA-binding subunits binding in
close spatial proximity to form a tiny chromatin loop. The binding units are thought
to travel along the chromatin fibre in opposite directions until they reach a pair
convergent CTCF binding motifs, while DNA extrudes through the cohesin loops
(Dekker and Mirny, 2016; Sanborn et al., 2015). This model is increasingly favoured,
especially since convergent CTCF sites are a feature of TAD boundaries (de Wit
et al., 2015; Guo et al., 2015; Rao et al., 2014), and genome-editing experiments to
delete (Sanborn et al., 2015) or invert (de Wit et al., 2015) CTCF binding sites result
in alterations rather than collapse of TADs, which could be computationally predicted
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based on known CTCF sites. However, this model raises other questions: what are
the "extrusion complex" proteins; how does the energy expenditure required for such
machinery favour the cell; can the same machinery work in euchromatic and hete-
rochromatic compartments; how is the process affected by (or impact) transcription
and replication; and how does this account for different levels of chromatin structure
(i.e., loops/sub-TADs within TADs) (Dixon et al., 2016)?
Fig. 1.4 Models of TAD formation. (A) The "handcuff" model. TADs are formed by CTCF
(red) and cohesin complexes (grey) connecting two CTCF boundary sequences (purple). (B)
The “loop extrusion” model. A pair of tethered CTCF proteins bound to loop extrusion factors
(orange) extrude the chromatin fibre; two CTCF molecules slide along the chromatin fibre in
opposite directions before pausing at converging CTCF DNA binding motifs (Dixon et al.,
2016).
1.3 Cancer epigenetics
Given the fundamental importance of epigenetics in maintaining DNA, cellular, and
organism homeostasis while simultaneously facilitating appropriate responses to
developmental or environmental cues, it is perhaps unsurprising that epigenetic
dysfunction has been increasingly scrutinised in disease pathogenesis and that
epigenetic defects have been found to contribute to cancer initiation and development
(Berger et al., 2009; Egger et al., 2004; You and Jones, 2012).
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Our >20,000 protein-coding genes (Genome Reference Consortium Human Build
38 (GRCh38)) account for less than 2% of the genome. Epigenetic features of the
non-protein-coding genome such as DNA methylation, histone marks, noncoding
RNAs, and chromatin structure must, therefore, be integral to cellular homeostasis
(Alberts et al., 2014). The proportion of a species’ genome that is non-protein-coding
is thought to positively correlate with its biological complexity (Liu et al., 2013a).
The importance of the non-protein-coding genome in humans is further high-
lighted by human cancer analyses, which show that >80% of mutations that are
significantly associated with disease phenotypes arise in non-protein-coding regions
(Welter et al., 2014). Such genome-wide association studies (GWAS) have revealed
that somatic mutation rates vary between tumour types (Alexandrov et al., 2013)
and frequency varies across the genome (Lawrence et al., 2013). Mutation rate is
also associated with transcriptional activity (Chapman et al., 2011), chromatin state
(Schuster-Böckler and Lehner, 2012), replication timing (Liu et al., 2013b; Stamatoy-
annopoulos et al., 2009), and nuclear topology (Smith et al., 2017). Furthermore,
regulatory sites show elevated substitution rates in cancers (Kaiser et al., 2016),
most notably CTCF/cohesin binding sites (Katainen et al., 2015; Sabarinathan et al.,
2016). The underlying mechanisms are not well understood (Flavahan et al., 2017;
Stricker et al., 2016). The high mutational burden observed in protein-bound DNA
regions of melanomas and lung tumours is caused by impaired nucleotide excision
repair (NER) (Sabarinathan et al., 2016), and the reduced exonic mutation rate is
due to differential mismatch repair (MMR) rather than purifying selection (Frigola
et al., 2017). Such findings have opened up new fields of human disease research
including epigenome-wide association studies (EWAS) (Lappalainen and Greally,
2017; Michels et al., 2013).
Epigenetic diseases may be inherited or somatic: Angelman’s syndrome, Prader-
Willi syndrome (Nicholls et al., 1998), and Beckwith-Wiedemann syndrome (Maher
and Reik, 2000) arise due to faulty imprinting, while many cancers are known to
harbour somatic epigenetic defects (Sandoval and Esteller, 2012). Global changes
in the epigenetic landscape are considered a hallmark of ageing (López-Otín et al.,
2013) and cancer (Sandoval and Esteller, 2012) since histone modifications, DNA
methylation changes, and altered expression of chromatin-modifying enzymes result
in global changes in gene expression and the development and/or progression of
disease (Hanahan and Weinberg, 2011; Sharma et al., 2010).
The first description of the contribution of epigenetics to carcinogenesis was in col-
orectal cancer (CRC). These tumours often harbour inactivating somatic mutations in
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the MMR gene human MutL Homologue 1 (hMLH1). However, a proportion of CRCs
were found to not express hMLH1 despite a normal coding sequence. Instead, all
these cases, in contrast to hMLH1-mutated tumours, exhibited cytosine methylation
of the hMLH1 promoter region (Kane et al., 1997). This epigenetic silencing was
quickly recognised as an alternative loss-of-function pathway satisfying Knudson’s
two-hit hypothesis (Jones and Laird, 1999), and de novo promoter hypermethylation
of tumour suppressor genes is now a well-recognised mechanism contributing to
cancer initiation and progression (Jones and Baylin, 2002).
It has since emerged that chromatin and epigenetic aberrations have the potential
to confer on cells the full range of oncogenic properties represented in the classic
“hallmarks” depiction of cancer (Hanahan and Weinberg, 2000, 2011). Genetic,
environmental, and metabolic factors can make chromatin aberrantly permissive or
restrictive. Restrictive chromatin states may prevent appropriate tumour suppressor
functions or block differentiation, whereas permissive chromatin creates a state of
“epigenetic plasticity” that can activate oncogene expression or cell fate changes
that drive carcinogenesis (Flavahan et al., 2017). As for coding mutations, many
epigenetic aberrations will be stochastic, inconsequential "passengers", whereas
a minority that confer a fitness advantage to a cell will be selected as "drivers"
(Flavahan et al., 2017). For example, specific point mutations in the gene encoding
histone protein H3.3 result in a global reduction of the repressive histone mark
H3K27me3 and DNA hypomethylation. This has been shown to activate gene
expression and promote tumourigenesis in a clinically distinct group of high-grade
gliomas (Bender et al., 2013). Such brain tumours exemplify the interplay between
genetic and epigenetic mechanisms in tumourigenesis, with varying contributions of
each in glioblastoma (a brain tumour that primarily affects adults), ependymomas
(predominantly a paediatric tumour), and anaplastic astrocytomas. As mentioned
above, in glioblastoma, most hallmarks can be traced to genetic drivers, whereas
ependymomas are dominated by epigenetic factors including DNA hypermethylation
but lack recurrent mutations (Lathia et al., 2015; Mack et al., 2014). Anaplastic
astrocytomas are often driven by both genetic and epigenetic lesions, leading to
different hallmarks (Flavahan et al., 2017). As well as the classical epigenetic events
described above, ncRNAs are also implicated in carcinogenesis. For example, the
miRNAs miR-15 and miR-16, which usually silence the anti-apoptotic BCL2 gene,
are downregulated in chronic lymphocytic leukaemia (Ventura and Jacks, 2009).
Finally, systematic enrichment analysis of prostate cancer GWAS hits have been
used to attempt to decipher the underlying molecular mechanisms of cancer. In
16 Introduction
addition to mutations within exonic regions, well-characterised transcription factor
binding sites of androgen receptor (AR), FOXA1, ETS-related gene (ERG), and
CTCF binding regions were significantly enriched for prostate cancer risk single
nucleotide polymorphisms (SNPs) (Chen et al., 2015). This study suggests that
although most cancers occur as a result of multiple regulatory aberrations, CTCF is
an important cancer protein.
1.3.1 CTCF is a tumour suppressor gene
There is mounting evidence that, in addition to its functions described above, CTCF
is involved in the pathogenesis of cancer (Ohlsson et al., 2001). However, its
mechanism of action in the initiation or progression of carcinogenesis is poorly
understood.
The human CTCF gene lies in cytogenetic band 16q22.1 on chromosome 16,
a region found to be frequently deleted in sporadic breast and prostate cancers
over twenty years ago (Filippova et al., 1998). CTCF was, therefore, proposed as a
candidate tumour suppressor gene. Furthermore, microdeletions of CTCF binding
sites on chromosome 11p15 in patients with Beckwith-Wiedemann syndrome leads
to a 600-fold increased risk of Wilms’ tumour, a kidney cancer that contains malignant
cells of different embryological origin (Prawitt et al., 2005). More recently, human
genome sequencing studies have identified CTCF as a putative driver gene in
several human cancers as detailed below, in keeping with the action of a tumour
suppressor gene.
Several studies have been performed that have attempted to characterise CTCF’s
mechanism of tumour suppression. However, these studies have largely considered
how loss of CTCF function (Recillas-Targa et al., 2006) gives rise to cancer hallmarks
such as sustained proliferation, invasion and metastasis, replicative immortality,
genomic instability, and mutations via single gene effects (Hanahan and Weinberg,
2000, 2011). Since CTCF is a global regulator of gene expression, altered CTCF
expression levels and DNA binding affinity are likely to have widespread downstream
effects on the transcriptome and proteome, and these global effects, particularly
from the epigenomic perspective, are poorly characterised.
CTCF is a key transcriptional regulator of the tumour suppressor gene TP53
(Saldaña-Meyer and Recillas-Targa, 2011) via physical interaction with its anti-
sense RNA WRAP53 and miRNAs (Saldaña-Meyer et al., 2014). Mutant CTCF
results in reduced TP53 expression (Saldaña-Meyer and Recillas-Targa, 2011) and
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defective TP53 responses to DNA damage (Saldaña-Meyer et al., 2014), which, if
left uncorrected, leaves the cell susceptible to further mutagenic insults. CTCF is
also responsible for silencing oncogenes such as BCL6: CTCF-mediated silencing
of BCL6 is inhibited by hypermethylation of the intronic DNA-binding site in B cell
lymphoma cell lines (Lai et al., 2010).
Appropriate expression of pro-apoptotic factors is essential for maintenance
of normal cell turnover and tissue homeostasis. Apoptosis-associated tyrosine
kinase (AATK), which acts as a tumour suppressor gene, is epigenetically activated
by CTCF. Promoter hypermethylation silences the gene and is thought to be an
early event in carcinogenesis. The AATK promoter is frequently hypermethylated
in human tumours and cell lines, resulting in deficient CTCF binding and reduced
AATK expression (Haag et al., 2014). As a result, there is failure of growth inhibition,
migration, and apoptosis (Ma and Rubin, 2014).
As detailed above, higher-order chromatin structure is also essential for co-
ordinated gene expression, with CTCF playing an integral role in this process.
CTCF/cohesin complexes selectively bind to unmethylated DNA, and it has been
shown that altered methylation influences CTCF-dependent chromatin looping and
alters downstream gene expression (Kang et al., 2015). Given that de novo methyla-
tion is an epigenetic hallmark of cancer, its effect on CTCF binding and chromatin
loop formation (Kang et al., 2015) provides a possible carcinogenic mechanism.
Large-scale chromosomal rearrangements, which can result in gene fusions, are
well described in cancer (Rabbitts, 1994, 2009). More recently, the discovery of RNA
trans- and cis-splicing between adjacent genes (cis-SAGe) has provided another
mechanism by which fusion RNAs that contain exons belonging to neighbouring
genes from the same strand can be generated. The role of CTCF in generating
these fusion RNAs has been investigated in prostate cancer, where CTCF silencing
resulted in cis-SAGe events, usually resulting in the production of noncoding fusion
RNAs (Qin et al., 2015). This study identified a range of fusion RNAs in cell
lines, human prostate cancers, and control samples. Although CTCF was not
explicitly causative in creating fusion RNAs in cancer, Ctcf silencing did change the
resultant gene fusions, and the possibility of CTCF-induced fusion proteins remains
a possibility.
However, the most convincing experimental evidence that CTCF may act as a
tumour suppressor is from Kemp et al. (2014), who used an in vivo mouse model of
Ctcf halploinsufficiency to demonstrate a multi-lineage predisposition to spontaneous
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carcinogenesis. This study, which provided in vivo rationale for the main hypotheses
tested in this body of work, is described in detail below.
1.3.2 Ctcf haploinsufficiency predisposes to cancer in mice
Using a germline Ctcf haploinsufficient mouse model, Kemp et al. (2014) found
that Ctcf +/- mice were more susceptible to spontaneous, radiation-, and chemically-
induced cancers compared to C57BL6/129 wild-type littermates. Haploinsufficient
mice developed tumours earlier (80% of Ctcf +/- vs. 40% of wild-type littermate
mice were euthanised due to cancer by 100 weeks) and were three-times more
likely to develop multiple tumours. Furthermore, the tumours were histologically
more aggressive, and metastatic disease was more frequent. They concluded
that hemizygous loss of Ctcf enhances malignant progression. They also used
urethane to induce pulmonary neoplasms in Ctcf +/- and wild-type mice: Ctcf +/- mice
developed more frequent and significantly larger lung tumours than wild-type mice,
which resulted in earlier death in Ctcf +/- mice. Furthermore, the type of neoplasms
varied between these groups: 77% of lung tumours from wild-type mice were benign
adenomas, whereas 69% of Ctcf +/- lung tumours were malignant adenocarcinomas,
suggesting that CTCF is important in both cancer initiation and progression.
Methylation analysis of non-neoplastic tissue showed that differentially methylated
sites clustered according to genotype, suggesting that Ctcf hemizygosity results in
altered DNA methylation. Methylation was altered at the Igf2/H19 imprinting region;
however, the tumour-suppressor genes p16, p19, and Mlh1 were not altered and
overall methylation patterns were stable across genotypes. This implies that Ctcf
only regulates DNA methylation at very specific loci and that methylation alone does
not fully account for the predisposition to cancer seen in these mice. Since these Ctcf
mice were germline haploinsufficient, the authors could not delineate the precise
mechanism of cancer susceptibility due to potential global effects on metabolism
and immunity.
1.3.3 Mutation of CTCF and its binding sites in human cancers
In addition to in vitro and in vivo studies, CTCF mutations have been shown to be
important in human cancers. Frequent CTCF mutations (single base substitutions,
deletions, and insertions) have been identified in human malignancies including
uterine, breast, liver, oesophageal, head and neck, and pancreatic cancers and
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lymphoma (ICGC Data Portal, https://dcc.icgc.org/genes/ENSG00000102974). In a
study of 4,623 whole exome sequences from 13 cancer sites, CTCF was identified as
a putative driver gene in uterine endometrioid carcinoma, head and neck squamous
cell carcinoma, and breast carcinoma. All mutations were protein-coding, loss
of function mutations resulting in missense coding alterations or truncation of the
transcript (Gonzalez-Perez et al., 2013; Rubio-Perez et al., 2015), in keeping with the
action of tumour suppressor gene. Lawrence et al. (2014) analysed 4,742 human
cancers of 21 histological types for somatic point mutations and identified CTCF
and only 21 other genes as significantly associated with three or more histological
tumour types. In addition to CTCF, this geneset included well-characterised cancer
drivers including TP53, PIK3CA, PTEN, RB1, KRAS, NRAS, and BRAF. These data
highlight the important biological role for CTCF in different tissue types and implicate
it as a tumour suppressor gene in humans.
Altered CTCF expression levels have also been documented in human cancers.
CTCF expression was measured in 71 pre-invasive and invasive cervical neoplasms
and found to be significantly overexpressed in invasive carcinomas compared to pre-
invasive lesions or normal controls (Velázquez-Hernández et al., 2015). However,
this study was not functionally validated and no mechanism of action was proposed.
Data from COSMIC showed CTCF expression to be up- and downregulated with
almost equal frequency across numerous cancer tissue types (Forbes et al., 2017).
In keeping with this, low CTCF expression was correlated with favourable survival
outcomes in liver cancer but poorer outcomes in renal cancer (Uhlen et al., 2015),
thus illustrating a degree of pleiotropism in CTCF’s action in human cancers.
More recent studies have shown that, in addition to mutations in CTCF itself,
mutations in CTCF DNA-binding sites are common in cancer (Katainen et al., 2015).
Regulatory regions contain mutations under selective pressure, suggesting a greater
role for regulatory mutations in cancer than previously recognised (Kaiser et al.,
2016; Melton et al., 2015). Computational analysis of 1,073 published cancer
genomes across eleven tissue types (Hudson et al., 2010) showed that multiple
cancer types accumulate point mutations at CTCF/cohesin-binding sites, highlighting
that mutational hotspots arise in the non-protein-coding as well as coding cancer
genome (Katainen et al., 2015). The increased rate of mutations at CTCF binding
sites was especially prominent in melanoma, with the accumulation of functional
mutations at CTCF/cohesin-binding sites proposed to be due to uneven nucleotide
excision repair across the motif rather than an inherent susceptibility to mutation
(Poulos et al., 2016). It has also been suggested that this repair process is physically
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impaired by the binding of transcription factors at the motif (Sabarinathan et al.,
2016).
Examples of CTCF binding site mutations can be found in other tumour types.
Gain-of-function IDH1 mutations are initiating events that define major clinical
and prognostic classes of gliomas due to the production of the onco-metabolite
2-hydroxyglutarate by the mutant IDH1 protein. Human IDH1-mutant gliomas have
specific hypermethylation at CTCF binding sites, compromising CTCF binding and
in turn causing loss of insulation between topological domains and aberrant gene
activation. In contrast, clustered regularly interspaced short palindromic repeat
(CRISPR)-mediated disruption of the CTCF motif in IDH1 wild-type gliomaspheres
upregulated PDGFRA and increased proliferation, suggesting that IDH1 mutations
promote gliomagenesis by disrupting chromosomal topology and allowing aberrant
regulatory interactions (Flavahan et al., 2015). In lung cancer, CTCF binding site
variants were analysed in 2,331 lung cancers and 3,077 control samples and the
rs60507107 SNP was identified as a novel lung cancer susceptibility locus, which
was then validated in an independent cohort (Dai et al., 2015).
It is likely that many more noncoding driver mutations at CTCF binding sites
and other regulatory sites will be discovered over the next few years. The Pan-
Cancer Analysis of Whole Genomes (PCAWG) consortium (Campbell et al., 2017)
is expected to identify common mutational patterns in more than 2,800 cancer whole
genomes (Sabarinathan et al., 2017), thereby exploring the nature and consequence
of somatic and germline variations in both coding and noncoding regions. Given that
there is specific emphasis on cis-regulatory sites, noncoding RNAs, and large-scale
structural alterations, this study is likely to yield further insights into CTCF’s role in
cancer.
1.4 Mouse models of liver cancer
Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer and
the second most common cause of cancer death worldwide (Torre et al., 2015). HCC
develops in the context of chronic liver disease in 80% of cases, in which chronic
hepatocyte injury leads to genetic damage that underpins HCC (Hardy and Mann,
2016). The incidence of HCC is increasing globally, but treatment options are limited
and prognosis remains poor. The use of tractable experimental models is, therefore,
essential in order to develop a more meaningful molecular classification of HCC,
in turn offering the promise of predictive and prognostic biomarkers and potential
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therapeutic targets (personalised or precision medicine), or to identify targets to
prevent progression of liver disease from a benign to malignant state (Bakiri and
Wagner, 2013).
An ideal model of liver cancer should: (i) reproduce key biological and cellular
features (hepatocyte damage, degeneration, regeneration, proliferation, and transfor-
mation) in spontaneous models of HCC; (ii) recapitulate the molecular and cellular
events in HCC development and progression; (iii) adequately reflect tumour/host
interactions; (iv) allow the study of the primary tumour and metastases; (v) mimic the
human tumour microenvironment; and (vi) be affordable and easy to manipulate (Li
et al., 2012). There are numerous mouse models of liver cancer, including exposures
to chemical carcinogens and genetic alterations that reproduce different aspects of
the phenotypic, biological, and molecular events that occur during hepatocarcino-
genesis. It is important to select the most appropriate model to address the specific
scientific question of interest, and a few important considerations are detailed below
(Newell et al., 2008).
Mouse strains
Inbred laboratory mice show marked variability in their susceptibility to spontaneous
liver tumours: C3H mice are highly susceptible to hepatocarcinogenesis whereas
C57BL/6 mice (Maronpot, 2009; Puccini et al., 2013) and wild-derived mouse strains
tend to be very tumour resistant (Guénet and Bonhomme, 2003). Such strain differ-
ence provide an opportunity to study spontaneous tumourigenesis in the absence of
chemical induction and/or engineered genetic aberrations. However, this also means
that the strain used is an important variable to consider when planning experiments
since strain selection may affect the experimental results.
Chemical models
By far the most commonly used chemical carcinogenesis model uses intraperitoneal
(IP) diethylnitrosamine (DEN) to induce liver tumours in rodents (Rajewsky et al.,
1966). Bioactivation in centrilobular (zone 3) hepatocytes results in a genotoxic
alkylating agent, which causes strain-dependent oncogenic mutations (Buchmann
et al., 2008), dysplastic changes, and subsequent progression to HCC. If animals are
treated after the proliferative post-natal stage (up to 15 days old), an additional poten-
tiating stimulus is required such as partial hepatectomy or phenobarbital treatment
(Aleksic et al., 2011).
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Genetically-engineered mouse (GEM) models
A wide range of genetically-engineered mouse (GEM) models have been developed
to study the breadth of alterations observed in human cancers. Transgenic mice
can be engineered to express oncogenes or tumour suppressor genes in a non-
physiological manner due to the introduction of ectopic promoter and enhancer
elements. This is traditionally achieved by microinjection of recombinant DNA directly
into the pronucleus of a fertilised mouse egg or, alternatively, by gene targeting
(“knock-in”) and lentiviral transduction in embryonic stem cells (Frese and Tuveson,
2007). Transgene expression can be reversibly and temporally controlled using a
tetracycline (tet)-inducible system (Furth et al., 1994), in which the inducing agent
reversibly activates the target gene of a chimeric transcriptional activator (Newell
et al., 2008). Alternatively, conditional mouse models, such as the Cre-Lox system,
allow both spatial and temporal control of target genes in specific cells, tissues, or
organs. In this system, the target gene is flanked by 34 bp loxP sites, and when Cre
recombinase (isolated from bacteriophage P1) is expressed there is site-specific
recombination between the LoxP sites, resulting in excision of the target gene (Sauer
and Henderson, 1988).
Since mice are resistant to infection by human hepatitis B (HBV) or C (HCV)
viruses, the first transgenic mice were developed to model the chronic carrier state of
HBV infection, in which viral DNA sequences integrate into the host genome (Babinet
et al., 1985; Chisari et al., 1985). Together with similar models of HCV, these trans-
genic mouse models have provided experimental evidence that viral hepatitis genes
can initiate and promote liver cancer independent of oncogenes or environmental
carcinogens (Li et al., 2012). Gene targeting approaches have been used to induce a
range of molecular events in hepatocarcinogenesis including in cell cycling pathways
(p53, Rb, E2F, and SV40), telomeres, growth factor signalling pathways (TGF-α,
c-Myc, hepatocyte growth factor, and c-Met pathway), PTEN/Akt/mTOR signalling
pathway, IGF and EGF signalling pathway, and the Wnt/β -catenin pathway (Newell
et al., 2008).
More recently, CRISPR and CRISPR-associated proteins (Cas) have offered
a powerful means to edit the genome (Jinek et al., 2012). CRISPR/Cas9 can be
applied to mouse models to produce gene knockouts, deletions, point mutations, and
short insertions such as loxP sites (Yang et al., 2013). CRISPR/Cas9 is generally
cheaper and quicker than traditional, directed mutagenesis methods, and provides
the additional option of being able to alter multiple genes simultaneously.
1.5 Thesis outline 23
1.5 Thesis outline
CTCF is, as outlined above, a global regulator of gene expression, and altered CTCF
expression levels and DNA binding affinity are likely to have widespread downstream
effects on the transcriptome and proteome. These global effects, particularly from
the epigenomic perspective, are poorly characterised. CTCF is also regarded as
a putative tumour suppressor in vitro and in vivo, with germline Ctcf haploinsuffi-
cient mice rendered susceptible to spontaneous, radiation-, and chemically-induced
tumours of multiple lineages. Although several plausible tumour suppressor mecha-
nisms for CTCF are postulated, the exact mechanisms by which CTCF mutations
contribute to cancer initiation and progression have not been fully established. This
summary highlights two major knowledge gaps: first, the nature and extent of global
CTCF-mediated changes on the transcriptome and proteome, and second, the
mechanism by which CTCF mutations predispose to cancer. This set of studies
aims to address these knowledge gaps.
We therefore hypothesised that:
1. A reduced genomic concentration of Ctcf increases cancer suscepti-
bility by altering chromatin homeostasis; reducing CTCF concentrations
would be expected to have a quantitative effect on DNA binding, resulting in
downstream effects on transcription and protein expression dependent on their
relationship with altered sites of CTCF activation or repression and/or altered
chromatin CTCF-dependent looping.
2. Liver tumourigenesis is accelerated in Ctcf conditional knockout mice
due to alterations in the expression of cancer-related pathways.
This study first uses functional genomics and quantitative proteomics in an in
vitro model to examine the effect of a reduced genomic concentration of Ctcf on
genome-wide CTCF binding and the downstream consequences for transcription
and translation. In the second set of experiments, a conditional, hepatocyte-specific
Ctcf hemizygous mouse is interrogated to establish the tissue-specific effects of Ctcf





2.1 Mouse colony management
All animal experimentation was carried out in accordance with the Animals (Scientific
Procedures) Act 1986 (United Kingdom) and with the approval of the Cancer Re-
search UK Cambridge Institute Animal Welfare and Ethical Review Body (AWERB).
All animals were maintained using standard husbandry: mice were group housed
in Tecniplast GM500 Mouse IVC Green Line cages in a room with a 12 hour light /
12 hour dark cycle and ad libitum access to water and food (LabDiet 5058). Cages
contained aspen bedding and the following cage enrichments: nesting material,
aspen chew stick, and cardboard tunnel.
The study was designed to be in keeping with the principles of the 3Rs: re-
placement, reduction, and refinement. Animal models cannot be replaced, since
the nature of the study is to investigate Ctcf deficiency in whole organisms using
tissue-specific analysis. Current 3D cell culture or organoid models are inadequate
to answer this biological question. The experiments have been designed to reduce
the number of animals required. Any excess tissue harvested was added to the
biorepository for follow-up studies to ensure maximum utilisation of the biological
material. Refinement was optimised, since the mice were subject to either no
intervention or a single intra-peritoneal injection.
2.1.1 Genetically engineered mice
Cre-Lox recombination was used in the generation of both mouse strains. This
system uses a single enzyme, Cre recombinase, to recombine a pair of short target
sequences called Lox sequences, allowing deletion of a specific genomic locus.
26 Materials and methods
Ctcf hemizygous mice
The following mice were used to generate Ctcf hemizygous mice: male C57BL/6
mice carrying the modified Ctcf allele in which loxP sites are inserted at exon 3 and
exon 12 (Ctcf tm1.1Laat/Ctcf tm1.1Laat) (Heath et al., 2008) (founder mouse was a gift
from the Galjart lab, Erasmus MC, Rotterdam); and female B6.CTg(Pgk1-cre)1Lni/Crs/J
mice (JAX stock #020811) (Lallemand et al., 1998), which express Cre recombinase
under the control of the phosphoglycerate kinase 1 (Pgk1) promoter. When crossed
with a strain containing a loxP site-flanked sequence, Cre-mediated recombination
results in deletion of the flanked sequence. Cre activity commences at the diploid
phase of genesis thus ensuring that all cells of the resulting hemizygous zygote
contain the targeted Ctcf allele.
The resulting Ctcf hemizygous (Ctcf +/-) line was maintained by back-crossing on
a C57BL/6 background to produce Ctcf hemizygous (Ctcf +/-) and wild-type (Ctcf +/+)
offspring. These mice were used to: (i) generate mouse embryonic fibroblast cultures
and (ii) study the reported tumour susceptibility of these mice over prolonged ageing.
Hepatocyte-specific Ctcf hemizygous mice
The following mice were used to generate hepatocyte-specific Ctcf hemizygous mice:
male Ctcf +/- mice (generated above) and female B6.Cg-Speer6-ps1Tg(Alb-cre)21Mgn/J
mice (JAX stock #003574) (Postic et al., 1999). Albumin is highly and uniquely
expressed by hepatocytes and therefore the "Alb-cre" mouse is very efficient for
liver-specific gene knockouts using the Cre/loxP system; all non-hepatocytes in the
mouse retain two copies of Ctcf.
2.1.2 Mouse genotyping
Genotyping of mouse ear biopsies or embryonic tissue was performed by polymerase
chain reaction (PCR) using primers designed for: wild-type Ctcf, floxed Ctcf, excision
of floxed Ctcf, and Cre (Table 2.1). Mice positive for both floxed-Ctcf and Cre are
expected to have hemizygous loss of Ctcf in hepatocytes.
2.2 Mouse embryonic fibroblast cultures
Male Ctcf +/- mice were crossed with C57BL/6J pro-oestrus or oestrus females that
were then monitored daily for the presence of a vaginal plug. The date of plug
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Table 2.1 Primers used for mouse genotyping
Probe Forward primer Reverse primer
Ctcf - wild-tpye ATGGTTGTGAGCCACCATGTGA AAGCACTGATTGCTCTAAAGAAGGTTGT
Ctcf - floxed GCTGGGCTCGACTCTAGACATAT GCTCTAAAGAAGGTTGTGAGTTCGA
Ctcf - excised GCTGGGCTCGACTCTAGACATAT GCAAACTCCATCTCTAGCCTCTCTA
Cre TTAATCCATATTGGCAGAACGAAAACG CAGGCTAAGTGCCTTCTCTACA
identification was considered embryonic day 0.5 (E0.5). Mice were euthanised by
cervical dislocation on day E13.5.
Using sterile technique, both uterine horns containing embryos were removed
from the mouse and placed in ice cold sterile phosphate-buffered saline (PBS). Each
embryo was processed separately in order to eliminate the risk of contamination
with tissue of a different genotype. The amniotic sac and visceral organs were
dissected and discarded; the head was removed and used for genotyping with
real-time PCR. The remaining embryonic tissue was minced and trypsinised at
37°C for 30 min, quenched with “MEF media” (Dulbecco’s Modified Eagle Medium
(DMEM, Gibco; Thermo Fisher Scientific, Waltham, MA) supplemented with 4.5 g/L
D-glucose, L-glutamine and pyruvate, 10% heat-inactivated foetal bovine serum
(FBS, Gibco), 1% amphotericin B antimycotic (Life Technologies, Carlsbad, CA), and
1% penicillin-streptomycin solution), and each embryo suspension was seeded into
a 15 cm dish and incubated at 37°C in 5% CO2. The media was refreshed after 24 h.
When confluent, cultures were split 1:3 in the absence of antibiotics from passage 2
onwards.
ChIP-seq, RNA-seq, proteomic, and Hi-C experiments were all performed from a
single passage 4 (P4) culture. Mouse embryonic fibroblast (MEF) cultures for each
biological replicate were expanded and harvested in pairs, one wild-type and one
Ctcf hemizygous line at a time, to control for culture-related batch effects.
2.3 qPCR
Total RNA was extracted from P4 MEF cultures from six biological replicates from
each genotype using QIAzol Lysis Reagent (Qiagen, Hilden, Germany), according
to the manufacturer’s instructions. cDNA was synthesised from RNA using the High-
Capacity RNA-to-cDNA Kit (Thermo Fisher Scientific), and qPCR was performed in
three technical replicates using TaqMan probes (Thermo Fisher Scientific) according
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to the manufacturer’s instructions. Ctcf mRNA levels were calculated using mean Ct
values normalised to Gapdh signal for each pair of MEF cultures.
2.4 Quantitative western blotting
Protein was extracted from P4 MEFs from six biological replicates from each geno-
type: cells were washed with ice cold PBS, lysed in radioimmunoprecipitation assay
(RIPA) buffer (50 mM Hepes-KOH pH 7.6, 500 mM LiCl, 1 mM EDTA, 1% NP-40,
0.7% Na-deoxycholate), pulse sonicated on ice (3 x 10 s), agitated for 30 min at 4°C,
the cell debris was pelleted by centrifugation, and the supernatant was quantified
using Direct Detect Infrared Spectrometer (Merck Millipore, Burlington, MA). 20 µg
total protein was run on a 4-12% Bis-Tris gel and transferred to a membrane using an
iBlot 2 Gel Transfer Device (Thermo Fisher Scientific). The membrane was blocked
using Odyssey Blocking Buffer in TBS (LI-COR Biosciences, Lincoln, NE), incubated
overnight with CTCF anti-rabbit antibody (Cell Signaling Technology, Danvers, MA;
D31H2 XP) (1:1000) and β -actin anti-mouse antibody (Sigma-Aldrich, St. Louis, MO;
clone AC-74) (1:5000). The membrane was washed 4 x 5 min in TBS + 0.1% Tween
and incubated for 45 min at room temperature (RT) with fluorescent-conjugated
infra-red (LI-COR Odyssey) antibodies: goat anti-mouse antibody (1:20,000) labelled
with 680 LT infrared dye (P/N 925-68070) and goat anti-rabbit antibody (1:5000)
with 800 CW infrared dye (P/N 925-32211). The membrane was washed a further
four times before visualisation and quantification using the Odyssey CLx Imaging
System. Relative CTCF abundance was calculated for each pair of MEF cultures
using normalised fluorescence values using β -actin as the loading control.
2.5 Chromatin immunoprecipitation followed by high-
throughput sequencing
Formaldehyde cross-linking
MEFs for six biological replicates from each genotype were fixed in DMEM containing
1% fresh formaldehyde and incubated at RT for 10 min, quenched with 250 mM
glycine for 10 min, and washed twice with ice cold PBS. The fixed cells were lifted
off the plate, pelleted by centrifugation, washed in PBS containing 1x Complete
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Protease Inhibitor (PI) Cocktail (Roche, Welwyn Garden City, UK), and flash-frozen
at -80°C.
Pre-block and antibody binding to magnetic beads
100 µ l protein G magnetic Dynabeads (Life Technologies) were washed three times
with 1 mL blocking solution (0.5% bovine serum albumin (BSA) (w/v) in PBS) then re-
suspended in 250 µ l blocking solution with 10 µg of antibody and incubated overnight
at 4°C on a rotating platform. The following antibodies were used: CTCF (rabbit
polyclonal, Merck Millipore 07-729, lot 2517762); H3K4me3 (mouse monoclonal IgG
clone CMA304, Merck Millipore 05-1339, lot 2603814); H3K27ac (rabbit polyclonal
IgG, Abcam (Cambridge, UK) 4729, lot GR244014-1); Rad21 (rabbit polyclonal,
Abcam 922, lot GR12688-9). The beads were washed a further three times the
following day immediately prior to adding them to the sonicated chromatin.
Nuclear lysis
Each cell pellet was suspended in 1 ml Lysis Buffer 1 (LB1 (50 mM Hepes-KOH pH
7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% nonyl phenoxypolyethoxylethanol
(NP-40), 0.25% Triton X-100)) containing 1 x PI, incubated at 4°C for 10 min, and
centrifuged at 2000 x g for 5 min at 4°C. The pellet was re-suspended in 1 ml Lysis
Buffer 2 (LB2 (10 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA))
containing 1 x PI, incubated at 4°C for 5 min, and centrifuged again at 2000 x g for 5
min at 4°C. Finally, the pellet was re-suspended in 300 µ l Lysis Buffer 3 (LB3 (10 mM
Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-deoxycholate,
0.5% N-laurolsarcosine)) containing 1 x PI. Cells from four 15 cm dishes were pooled
for each chromatin immunoprecipitation.
Sonication
Sonication was performed using a Bioruptor Plus (Diagenode, Liège, Belgium)
sonicator in cycles of 30 seconds on and 30 seconds off on "high" setting for 30
min. To check that the chromatin was sheared to the desired length (300 bp), a 10
µ l aliquot of sonicated chromatin was reverse cross-linked at 95°C for 10 min and
then 5 µ l was run on 2% agarose e-gel. 30 µ l of 10% Triton X-100 was added to the
sonicated lysate and centrifuged at 20,000 rcf for 10 min at 4°C to pellet debris. The
supernatant was transferred to a fresh 2 ml tube and diluted with LB3 containing 1 x
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PI to give a total volume of 1 ml with a final concentration of 1% Triton X-100. A 50
µ l aliquot of sonicated whole cell lysate was stored to provide control DNA for input
samples.
Chromatin immunoprecipitation
Each mixture containing magnetic bead-bound antibody was added to a separate
aliquot of sonicated cell lysate and incubated overnight at 4°C on a rotator.
Elution and cross-link reversal
The magnetic beads were collected using DynaMag-2 (Life Technologies) and the
supernatant discarded. In a 4◦C cold room, the beads were washed six times with
RIPA wash buffer and once with Tris-buffered saline (TBS) (20 mM Tris-HCl, pH 7.6;
150 mM NaCl). Following centrifugation at 960 rcf for 3 min at 4◦C, all residual TBS
was removed and the beads were suspended in 200 µ l of elution buffer (50 mM
Tris-HCl pH 8.0, 10 mM EDTA, 2% SDS). 150 µ l of elution buffer was added to the
thawed 50 µ l input DNA sample.
The ChIPs and input samples were reverse cross-linked by incubation in a water
bath at 65°C overnight. The mixture was centrifuged at 16,000 rcf for 1 min at RT
and the supernatant was transferred to a new tube.
Digestion of cellular protein and RNA
200 µ l of Tris-EDTA (TE) was added to each tube of ChIP and input DNA. RNA
contamination was removed by incubating with 8 µ l RNaseA (1 mg/ml; Ambion, Life
Technologies) at 37°C for 30 min. Protein contamination was removed by incubating
with 4 µ l proteinase K (20 mg/ml; Invitrogen, Life Technologies) at 55°C for 1 hour.
Phenol-chloroform DNA extraction
Phenol-chloroform extraction was used to further purify the DNA using light Phase
Lock Gels (PLGs) (Flowgen Bioscience, Hessle, UK). The PLG was pelleted by
centrifugation at 16,000 rcf for 1 min. Equal volumes (400 µ l) of aqueous DNA
solution and phenol:chloroform:isoamyl alcohol (P:C:IA, 25:24:1) were added directly
to PLG tube, thoroughly mixed, and separated by centrifugation 16,000 rcf for 5 min.
The aqueous layer was transferred to a new tube with 2 µ l GlycoBlue (20 µg/µ l;
Ambion). 16 µ l NaCl was added to a final concentration of 200 mM.
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DNA was precipitated by adding 800 µ l of 100% ethanol and incubating for at
least 30 min at -80◦C. The DNA was then pelleted by centrifugation at 20,000 rcf for
10 min at 4◦C, washed with 80% fresh ethanol, dried, and re-suspended in 13 µ l of
10 mM Tris-HCl pH 8.0.
Quantification of ChIP and input DNA
The concentration of DNA in each ChIP and input sample was measured using either
a NanoDrop spectrophotometer (Thermo Fisher Scientific) or a Qubit fluorometer
(Thermo Fisher Scientific) using the dsDNA high sensitivity assay.
ThruPLEX library preparation
Immunoprecipitated DNA or 50 ng of input DNA was used for library preparation
using the ThruPLEX DNA-Seq library preparation protocol (Rubicon Genomics).
Briefly, 10 µ l DNA sample was incubated with 3 µ l template preparation mastermix
at 22°C for 25 min and then at 55°C for 20 min. Next, 2 µ l library synthesis mastermix
was added and incubated at 22°C for 40 min. Libraries were amplified by adding
30 µ l library amplification mastermix and 5 µ l indexing reagent and then incubated
as follows: 72°C for 3 min, 85°C for 2 min (extension and cleavage); 98°C for 2 min
(denaturation); four cycles of 98°C for 20 s, 67°C for 20 s, 72°C for 40 s (addition of
indexes); five to sixteen cycles of 98°C for 20 s, 72°C for 50 s (library amplification,
see Table 2.2).
Table 2.2 Library amplification cycles
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Library size selection
Adapters were removed and libraries were size selected using AMPure XP beads
(Beckman Coulter, Brea, CA) according to the manufacturer’s instructions; first, right
side selection using (0.5x beads) followed by left-side selection (1.5x beads). 25 µ l
AMPure XP beads were added to 50 µ l of library, mixed, and incubated at RT for
10 min, placed on a magnetic stand for 5 min, and the supernatant transferred to
a new tube. A further 50 µ l AMPure XP beads were added, incubated for 10 min,
placed on a magnetic stand for 5 min, and the supernatant discarded. The beads
were washed twice with 200 µ l fresh 80% ethanol and then air dried on the magnet
for 15 min. The beads were re-suspended 22.5 µ l 1x TE buffer (pH 8.0), mixed,
incubated for 10 min, placed on a magnetic stand, and finally 20 µ l of supernatant
was transferred to a fresh tube.
Library quantification
Library fragment size was determined using a 2100 Bioanalyzer (Agilent Technolo-
gies, Santa Clara, CA); the ideal library size is 300-400 bp. Library quantification was
performed using a QuantStudio 6 Flex Real-Time PCR System (Life Technologies)
with the KAPA Library Quantification Kit (Kapa Biosystems; Roche, Basel, Switzer-
land). 4 µ l sample or DNA standard and 6 µ l KAPA SYBR FAST qPCR Master Mix
(ROX low) were added to each well and amplified as follows: 95◦C for 20 s followed
by 35 cycles of 95◦C for 1 s and 60◦C for 20 s .
Next-generation sequencing
Pooled libraries were sequenced on an Illumina HiSeq4000 (Illumina, San Diego,
CA) according to the manufacturer’s instructions to produce single-end 50 bp reads.
2.5.1 Computational analyses of ChIP-sequencing
ChIP-seq data alignment and quality control
Raw sequencing reads from ChIP and input libraries were aligned to the mouse
reference genome (GRCm38) using bwa 0.7.12 (Li and Durbin, 2009) backtrack
mode with default options. The resulting SAM files were manipulated with samtools
1.3 (Li et al., 2009). Duplicate reads were marked with MarkDuplicates 1.139 from
Picard tools (http://broadinstitute.github.io/picard).
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Quality control (QC) of samples was performed using Phantompeakqualtools
(https://www.encodeproject.org/software/phantompeakqualtools/; (Marinov et al.,
2014)), and only those with a positive quality tag were used in downstream analyses;
thus, replicate 1 was removed from the CTCF dataset and replicate 6 from the
H3K27ac dataset. All regions within the ENCODE blacklist (http://mitra.stanford.edu/
kundaje/akundaje/release/blacklists/mm9-mouse/mm9-blacklist.bed.gz; (Bernstein
et al., 2012)) were excluded; the liftOver function from the rtracklayer 1.34.1
(Lawrence et al., 2009) Bioconductor package was used to convert the coordinates
to the mm10 (GRCm38) assembly. Furthermore, any regions with high signal in our
own inputs were also excluded; these were identified with the greyListBS function
from the package GreyListChIP 1.6.0 (Brown, 2015) using the merged input datasets.
Differential binding analysis of ChIP-seq data
CTCF differential binding between the two genotypes was performed with csaw
1.8.0 (Lun and Smyth, 2016), with a window size of 15 bp, spacing of 50 bp, and
a fragment length estimated from cross-correlation analysis. Duplicate reads were
retained, but any reads with a mapping quality below 30 were ignored. We checked
for evidence of composition biases in the data, but the estimated size factors to
correct for this were all very close to one. Thus, count data were normalised for
efficiency biases instead. In the differential test we controlled for the batch effect
from sample collection time. Windows were merged into regions if they were within
100 bp of each other, restricting the maximum width to 5 kb; this resulted in 42,336
regions. The combined p-value for each region was computed with the Simes’
method, upweighting the highest abundance windows (peak summit). Regions
with a corrected p-value of 0.05 or lower (FDR <5%) were considered significantly
differentially bound. This yielded a set of 787 differentially bound regions, 79.4%
of which were less bound in the hemizygous cells. The remaining 162 loci showed
a relative enrichment in occupancy compared to the wild-type. Since ChIP-seq
quantification is relative in any given sample, the loss of binding in several hundred
CTCF binding sites leads to a proportional increase in sequencing reads at other
bound loci. We find that these 162 regions are in general of higher affinity (Mann-
Whitney test, p-value = 9.13 x 10-24) and evolutionary conservation (hypergeometric
test, p-value = 5.29 x 10-10; see below), and longer in width, compared to the stable
or less bound binding sites. This is consistent with the compensation expected as a
result of the loss of some binding events.
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To check the validity of the regions defined as peaks with the csaw method,
MACS2 callpeak (Zhang et al., 2008) was run with options -g mm -s 50 -q 0.01
–call-summits, using all ChIP libraries merged together along with the correspond-
ing merged inputs. MACS2 reported 47,075 significant peaks, and these contained
97.9% of all csaw regions, verifying that the regions tested for differential binding
were significant peaks.
To test for differential binding on the histone data, peaks were called with MACS2
as detailed above. For the H3K4me3 dataset, we kept the option --call-summits
and for the H3K27ac dataset we instead used --broad. Then, DiffBind 2.2.7 (Stark
and Brown, 2011) was used to test for differences between the genotypes. Fragment
sizes were determined from cross-correlation analysis. To count reads in peaks,
we used a summit size of 200 bp for the H3K4me3 dataset and the whole peak
for the H3K27ac data. We set bRemoveDuplicates to FALSE and mapQCth to 30.
For differential testing, we controlled for the batch effect from sample collection
time and set the options bSubControl and bFullLibrarySize to FALSE when calling
dba.analyze; we used the edgeR method. For the H3K27ac data, the analysis
was performed for two mutually exclusive sets of peaks: those that overlapped an
H3K4me3 peak (representing promoters) and those that did not overlap an H3K4me3
peak (putative enhancers).
The MACS2 peak calls are provided as processed data in ArrayExpress, acces-
sion code E-MTAB-6261.
Motif analysis on CTCF binding sites
To identify the motifs in the genomic loci occupied by CTCF, the 500 bp DNA
sequences centred at the midpoint of the regions defined in the csaw analysis (see
above) were extracted. These were then fed to the MEME-ChIP suite (Machanick
and Bailey, 2011) for de novo motif identification and comparison to the JASPAR
Vertebrates and UniPROBE Mouse databases. The most significant motif identified
was the canonical CTCF motif (M1), and over 90% of all regions had at least one
match. The third most significant motif identified was M2 as defined in Schmidt
et al. (2012). For Figure 3.6B, one hundred stable and one hundred differential
CTCF binding sites were randomly selected. We then collected the coordinate of
the M1 motif from the MEME output and extracted the genomic sequences plus 20
nucleotides on both sides. For binding sites with multiple motifs, we selected the one
that best matched the motif consensus. The obtained sequences were aligned with
MUSCLE (Edgar, 2004) using default parameters.
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CTCF motif affinity
To quantify the affinity of each CTCF motif instance identified from our ChIP-seq
data, we used DeepBind (Alipanahi et al., 2015), a deep learning algorithm that has
been trained on large amounts of ChIP-seq data and that can be used to score the
affinity of any given sequence for the CTCF motif. The same 500 bp DNA sequences
used for motif discovery (see above) were used to score their motif affinity with
DeepBind v0.11 using motif D00328.018 (CTCF). Similar results were obtained if
we scored only the motif sequence identified by MEME-ChIP.
Mouse conservation analysis
To investigate whether differentially bound CTCF binding sites have different evo-
lutionary dynamics to stable sites, C57BL/6 CTCF peaks were mapped to their
orthologous regions on the genomes of four other mouse species: Mus musculus
castaneus, Mus spretus, Mus caroli and Mus pahari. This was performed using a
multiple whole-genome alignment of 17 eutherian mammals (Herrero et al., 2016)
plus mcast, mspr, mcar, and mpah (Thybert et al., 2018). A CTCF peak was de-
fined as conserved across all five mouse species if its orthologous locus in each
species was also proven to bind CTCF based on ChIP-seq data derived from that
species (Thybert et al., 2018). Significant depletion of conserved peaks in the set of
differentially bound CTCF sites was tested for using a hypergeometric test.
2.6 RNA-sequencing
Cell lysis and RNA isolation
Total RNA was extracted from P4 MEF cultures from six biological replicates from
each genotype using QIAzol Lysis Reagent (Qiagen) according to the manufacturer’s
instructions. 700µ l QIAzol Lysis Reagent was added to a dish containing ~500,000
cells, incubated at RT for 5 minutes. 140 µ l chloroform was added, and the sample
was mixed vigorously for 15 sec, incubated at RT for 2 min, and then transferred to a
PLG heavy tube (Flowgen Bioscience). Aqueous and organic phases were separated
by centrifugation at 12,000 rcf for 10 min; the aqueous phase was transferred to a
new tube, mixed with a 1 x volume of 100% isopropanol, and incubated at RT for 15
min. RNA was precipitated by centrifugation at 20,000 rcf for 20 min at 4◦C. The RNA
36 Materials and methods
pellet was washed twice with fresh 60% ethanol, dried, and resuspended in RNase-
free water. RNA concentration was measured using a Nanodrop spectrophotometer
(Thermo Fisher). RNA quality was assessed on a Total RNA Nano Chip Bioanalyzer
(Agilent).
DNase treatment and removal
DNase treatment and removal was performed using the TURBO DNA-freeTM Kit
(Ambion, Life Technologies) according to the manufacturer’s instructions. 10 µg of
total RNA was incubated with 0.1 volume 10X DNase Buffer (Life Technologies) and
1 µ l TURBO DNase (Life Technologies), mixed gently, and incubated at 37◦C for 30
min. 0.1 volume DNase Inactivation Reagent (Life Technologies) was added, mixed,
and incubated at RT for 5 min. The sample was centrifuged at 10,000 rcf for 90 sec
and the supernatant transferred to a new tube. RNA was precipitated by adding 6
volumes of 100% ethanol and sodium acetate to a final concentration of 75 mM and
incubating at -20◦C for >1 h. RNA was pelleted by centrifugation at 10,000 rcf for 30
min at 4◦C and washed twice with fresh 70% ethanol.
Library preparation
RNA-sequencing libraries were generated using the TruSeq Stranded Total RNA
Library Prep Kit with Ribo-Zero Gold (Illumina) according to the manufacturer’s
instructions.
rRNA depletion: 1 µg of RNA was diluted with nuclease-free ultra pure water
to a final volume of 10 µ l. 5 µ l of rRNA Binding Buffer (Illumina) and 5 µ l of Ribo-
Zero Gold rRNA Removal Mix (Illumina) were added and incubated at 68◦C for 5
min and then at RT for 1 min. The sample was transferred to new tube containing
35 µ l rRNA Removal Beads (Illumina), mixed thoroughly, placed on a magnetic
stand at RT for 1 min, and then the supernatant was transferred to a new tube. 99
µ l RNAClean XP beads (Illumina) beads were added, mixed, incubated at RT for
15 min and then for a further 5 min on a magnetic stand. The supernatant was
discarded, the beads were washed with fresh 70% ethanol, air dried, and then RNA
was eluted in 11 µ Elution Buffer (Illumina). The sample was returned to the magnet,
and 8.5 µ l supernatant was transferred to a new tube containing 8.5 µ l Elute, Prime,
Fragment High Mix (Illumina) and incubated at 94◦C for 8 minutes.
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First strand cDNA synthesis: 0.8 µ l SuperScript II and 7.2 µ l First Strand Synthe-
sis Act D Mix were added to the RNA sample. The synthesis reaction was performed
as follows: 25°C for 10 min, 42°C for 15 min, 70°C for 15 min.
Second strand cDNA synthesis: 5 µ l of Resuspension Buffer and 20 µ l Sec-
ond Strand Marking Master Mix was added to each sample and incubated at 16°C
for 1 h. 90 µ l AMPure XP beads were added to each sample, mixed, incubated at
RT for 15 min, and then placed on a magnetic stand for 5 min. The supernatant
was discarded, beads were washed twice with 200 µ l fresh 80% ethanol, dried,
resuspended in 17.5 µ l Resuspension Buffer, incubated at RT for 2 min, and then
returned to the magnetic stand. 15 µ l supernatant (containing double-stranded
cDNA) was then transferred to a new tube.
Adenylate 3’ ends: 2.5 µ l of Resuspension Buffer and 12.5 µ l A-Tailing Mix was
added to each sample and incubated at 37°C for 30 min and then 70°C for 5 min.
Ligate adapters: 2.5 µ l of Resuspension Buffer and 2.5 µ l of Ligation Mix and
2.5 µ l unique RNA adapters were added to each sample and incubated at 30°C for
10 min. 5 µ l Stop Ligation Buffer was added. Clean up was performed by adding
42 µ l AMPure XP beads to each sample, incubating at RT for 15 min, placing on
a magnetic stand for 5 min, and the supernatant was then discarded. The beads
were washed twice with fresh 80% ethanol, air dried, and resuspended in 52.5 µ l
Resuspension Buffer. After returning to the magnetic stand, 50 µ l supernatant was
transferred to a new tube containing a further 50 µ l AMPure XP beads for a second
clean up. The final resuspension volume was 22.5 µ l, and 20 µ l of cleaned up
sample was transferred to a new tube.
Enrich DNA fragments: 5 µ l PCR Primer Cocktail and 25 µ l PCR Master Mix
were added to each sample and incubated as follows: 98°C for 30 sec; 15 cycles
of 98°C for 10 s, 60°C for 30 s, 72°C for 30 s; and 72°C for 5 min. Libraries were
then cleaned up using AMPure XP beads, as above, with the initial bead volume of
47.5 µ l, resuspension in 32.5 µ l Resuspension Buffer, and 30 µ l of clean, enriched
library was transferred to a new tube.
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Library quantification
Library fragment size was determined using a 2100 Bioanalyzer (Agilent). Libraries
were quantified by qPCR (Kapa Biosystems) and then pooled to ensure an equal
balance of libraries in the final pool.
Next generation sequencing
Pooled libraries were sequenced on a HiSeq4000 according to manufacturer’s
instructions to produce paired-end 150 bp reads.
2.6.1 Computational analyses of RNA-sequencing
RNA-seq data processing and analysis of (MEF libraries)
RNA-seq paired-end fragments were aligned to the mouse reference genome
(GRCm38) with STAR 2.5.2a (Dobin et al., 2013) with options:
--outFilterMismatchNmax 6 --outFilterMatchNminOverLread 0.4
--outFilterScoreMinOverLread 0.4 --outFilterType BySJout
--outFilterMultimapNmax 20 --alignSJoverhangMin 8
--alignSJDBoverhangMin 1 --alignIntronMin 20 --alignIntronMax 1000000
--alignMatesGapMax 1000000 --outSAMstrandField intronMotif.
On average, 77% of the sequencing fragments mapped uniquely. The numbers of
fragments overlapping annotated transcripts were obtained with featureCounts 1.5.2
(Liao et al., 2014) from the Subread package using Ensembl‘s genome annotation
(Aken et al., 2017) version 84 (http://mar2016.archive.ensembl.org/Mus_musculus/
Info/Index). The sequence of the lacZ cassette was added to the genome to
corroborate the genotype of each sample.
For differential expression analysis, hidden batch effects were identified with the
Bioconductor package sva 3.22.0 (Leek et al., 2017), providing known batch effects
(sample collection time). We then used DESeq2 1.14.1 (Love et al., 2014) to test
for differential expression, controlling for both the known and hidden batch effects.
Genes were considered significantly differentially expressed if their adjusted p-value
was lower than 0.05 (equivalent to a false discovery rate of 5% or less).
Significantly enriched gene ontology terms were identified using the functions
goana and kegga from the Bioconductor package limma 3.33.14 (Ritchie et al., 2015),
with gene length as a covariate. The gene lengths supplied were obtained from the
featureCounts output (see above). The reported p-values were corrected for multiple
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testing by the Benjamini-Hochberg method and were considered significant if they
were lower than 0.05. Detailed results of both the differential expression analyses
are provided in Appendix A. The raw and normalised RNA-seq counts are provided
as processed data in ArrayExpress, accession code E-MTAB-6259.
RNA-seq data processing and analysis (tumour libraries)
RNA-seq paired-end fragments were aligned to the mouse reference genome
(GRCm38) with STAR 2.5.2a (Dobin et al., 2013). Transcripts abundances were
quantified using kallisto v0.43.1 (Bray et al., 2016), which uses pseudoalignment
to rapidly determine the compatibility of reads with targets without the need for
alignment. RNA-seq libraries from DEN-initiated tumours were grouped according to
genotype. All 0 values were replaced with 0.01 (giving a minimum log2 value of -6.6).
The log2 fold-change was calculated by the median of the log2 values of the Ctcf +/-
group minus the median of the log2 values of the wild-type group. A Mann–Whitney
U test was performed using the log2 values of each group; transcripts with equal dis-
tribution were removed from further analyses. Multiple correction testing (q values)
were calculated using the Benjamini-Hochberg method. Figure 4.16 was generated
using -log10(q value).
RNA-seq data processing and analysis (published mouse tumour libraries)
The RNA-seq data from mouse liver and tumour samples (Connor et al., 2018)
was processed as detailed above but using the C3H/HeJ genome as a refer-
ence (ftp://ftp.ensembl.org/pub/release-89/fasta/mus_musculus_c3hhej/dna/Mus_
musculus_c3hhej.C3H_HeJ_v1.dna_sm.toplevel.fa.gz) (Lilue et al., 2018). To test
for differential expression between the normal liver and tumour samples we used
DESeq2 (Love et al., 2015) and genes were considered significantly differentially
expressed if their adjusted p-value was lower than 0.05 (FDR < 5%).
To compare to the list of differentially expressed genes in the Ctcf hemizygous
MEFs, we matched genes by their official gene name. Genes that were significantly
differentially expressed in both datasets were deemed concordant if they were up- or
down-regulated both in the Ctcf hemizygous MEFs and in the tumours, compared to
their respective controls. Gene set enrichment analysis was performed as detailed
previously, using only the set of concordant differentially expressed genes as the
test set. The raw and normalised RNA-seq counts of the mouse liver tumour and
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control datasets are provided as processed data in ArrayExpress, accession codes
E-MTAB-6971 and E-MTAB-6972.
RNA-seq data processing and analysis (published human tumour libraries)
To compare the set of dysregulated genes in the Ctcf hemizygous MEFs to alterations
in the transcriptomes of human cancers, we mined The Cancer Genome Atlas
PanCanAtlas to obtain a list of uterine and breast tumour samples with identified
missense, frameshift or stop-gain mutations in CTCF. We collected the RNA-seq raw
counts for these samples, along with all available control normal uterine and breast
tissue samples. The gene annotation used was from https://www.gencodegenes.
org/releases/22.html. We used DESeq2 (Love et al., 2015) to normalise and test
for differential expression between the tumour and control samples, for each tissue
separately.
To compare these results to the genes altered in the Ctcf hemizygous MEFs,
we obtained the orthology relationships between the human and mouse genome
using Ensembl version 84 (Herrero et al., 2016) and restricted our analysis to
one-to-one orthologs. Genes that were significantly differentially expressed in both
datasets were deemed concordant if they were up- or down-regulated both in the Ctcf
hemizygous MEFs and in the tumours, compared to controls. Gene set enrichment
analysis was performed as detailed previously, using only the set of concordant
differentially expressed genes as the test set.
2.7 TMT proteomics
Tissue homogenisation
MEF cultures for five biological replicates of each genotype were washed with ice
cold PBS. Cells were lysed in 200 µ l of 0.1 M TEAB, 0.1% sodium dodecyl sulphate
(SDS) at 90◦C for 10 min, followed by tip sonication. Total protein was quantified
using a Bradford assay (Bio-Rad Quick Start; Bio-Rad Laboratories, Hercules, CA)
according to the manufacturer’s instructions.
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Preparing whole cell protein extracts
90 µg of protein per sample was reduced by the addition of 2 µ l 50 mM tris-2-
carboxyethyl phosphine (TCEP) for 60 min at 60◦C followed by cysteine blocking for
10 min at RT using 1 µ l 200 mM methyl methanethiosulfonate (MMTS).
Protein digestion
5 µ l of 375 mM iodoacetamide was added to the sample and incubated for 30 min in
the dark. Six volumes of pre-chilled acetone were added for overnight precipitation.
The sample was centrifuged at 8000 rcf for 10 min at 4◦C, the supernatant discarded,
and the pellet air-dried for 10 min. Trypsin digestion (protein/trypsin ratio 30:1) was
performed overnight at 37◦C.
Peptide labelling
0.8 mg tandem mass tag (TMT) 10-plex label reagents (Thermo Fisher Scientific)
were added to 41 µ l of ethanol and incubated at RT for 5 min with intermittent
vortexing. This was added to the peptide solution and incubated for 1 h at RT. 8 µ l of
5% hydroxylamine was added to the sample and incubated for 15 min to quench the
reaction. Equal amounts of the ten TMT-labelled samples were pooled for multiplex
analysis.
Liquid chromatography-mass spectrometry analysis
The TMT mixture was then basic reverse phase (bRP) fractionated on a Dionex
Ultimate 3000 system at high pH using the X-Bridge C18 column (3.5 µm 2.1 x 150
mm, Waters Corp., Milford, MA).
Fractions were analysed on a Dionex Ultimate 3000 UHPLC system coupled
with the nano-ESI Fusion Lumos (Thermo Fisher Scientific). Samples were loaded
on the Acclaim PepMap 100, 100 µm x 2cm C18, 5 µm, 100Å trapping column
with the ulPickUp injection method using the loading pump at 5 µ l/min flow rate
for 10 min. For peptide separation, the EASY-Spray analytical column 75 µm x 25
cm, C18, 2 µm, 100Å was used for multi-step gradient elution. Mobile phase was
composed of 2% acetonitrile, 0.1% formic acid and mobile phase was composed
of 80% acetonitrile, 0.1% formic acid. The Lumos was operated in data-dependent
mode for both MS2 and Synchronous Precursor Selection (SPS)-MS3 methods.
The full scan was performed in the Orbitrap in the range of 380-1500 m/z at 120 K
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resolution and the MS2 scan was performed in the ion trap with collision energy 35%.
Peptides were isolated in the quadrupole with isolation window 0.7 Th. The 10 most
intense fragments were selected for SPS HCD-MS3 analysis with MS2 isolation
window 2.0 Th. The HCD collision energy was set at 55%, and the detection was
performed with Orbitrap resolution 60 K and in scan range 100-400.
2.7.1 Computational analyses of proteomic data
Raw data were processed with the Sequest HT search engine in Proteome Discov-
erer 2.1 software. All spectra were searched against a UniProtKB/Swiss-Prot fasta
file containing 16,915 reviewed mouse entries. The parameters for the SequestHT
node were as follows: precursor mass tolerance 20 ppm; fragment mass tolerance
0.5 Da; dynamic modifications were oxidation of M (+15.995 Da), deamidation of
N, Q (+0.984 Da); and static modifications were TMT6plex at any N-terminus, K
(+229.163 Da) and methylthio at C (+45.988). The consensus work flow included S/N
calculation for TMT intensities as previously described (McAlister et al., 2014), and
the level of confidence for peptide identifications was estimated using the Percolator
node.
Peptide intensity data were quantile normalised and summarised into protein-level
counts by summing the intensity values for all peptides for a given protein. Samples
were inspected via hierarchical clustering and principal component analysis (PCA)
to identify outliers of low quality; these were removed from downstream analyses
(WT replicates 2 and 3 and Ctcf hemizygous replicates 1 and 3). Limma 3.33.14
(Ritchie et al., 2015) was used to assess differential protein expression between the
genotypes, controlling for batch effects (sample collection time).
2.8 Hi-C
Hi-C was performed according to published protocols (Harewood et al., 2017;
Lieberman-Aiden et al., 2009; Nagano et al., 2015).
MEF cultures (~20 million cells) for three biological replicates of each genotype
were fixed in DMEM containing 2% fresh formaldehyde and incubated at RT for 10
min, quenched with 1 M glycine for 5 min, and washed twice with ice cold PBS. The
fixed cells were lifted off the plate, pelleted by centrifugation (400 rcf at 4°C for 10
min), and flash-frozen at -80°C.
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Lysis: 1 ml ice-cold lysis buffer (10 mM Tris-HCl, 0.2% NP-40/Igepal CA-420,
10 mM NaCl, and 1x protease mini inhibitor cocktail tablet (EDTA-free)) were added
to the cell pellet and transferred to a 2 ml glass homogeniser. The sample was
dounced up and down 10 times, incubated on ice for 1 min, dounced a further 10
times, and then incubated on ice for 30 min with occasional mixing. The nuclei were
pelleted by centrifugation, the supernatant discarded, and nuclei resuspended in
358 µ l ice cold 1.25x NEBuffer 2 (New England BioLabs, Ipswich, MA). To remove
proteins that were not directly cross-linked to DNA, 11 µ l 10% SDS was added and
incubated at 37°C for 60 min, shaking at 950 rpm. The reaction was quenched by
adding 75 µ l 10% Triton X-100 and incubated at 37°C for 60 min, shaking at 950 rpm.
HindIII digest: Chromatin was digested by adding 1000 units of HindIII (10 µ l
of 100 u/µ l NEB R0104T) and incubating at 37°C overnight while rotating (950 rpm).
Biotinylation of DNA ends: To fill in the restriction fragment overhangs and mark
the DNA ends with biotin, the following was added to each tube: 1.5 µ l 10 mM dCTP,
1.5 µ l 10 mM dGTP, 1.5 µ l 10 mM dTTP, 37.5µ l 0.4 mM biotin-14-dATP (Invitrogen
19524-016), 10 µ l 5 u/µ l Klenow (DNA polymerase I large fragment, NEB M0210L).
This was then mixed and incubated at 37°C for 60 min, shaking at 700 rpm for 10
sec in every 30 sec.
Ligation: 100 µ l T4 ligase reaction buffer (NEB B0202S), 10 µ l BSA (10 mg/ml,
NEB B9001S), and 354 µ l dH2O was added to each sample and 1 u/µ l T4 DNA
ligase (Invitrogen 15224-025) was added to each Hi-C tube and incubated at 16°C
for 4 h and 12°C overnight.
Excess lysis buffer removal: Nuclei were pelleted by centrifugation and 500 µ l of
lysis buffer was removed and discarded.
Proteinase K: Cross-linking was reversed and protein was degraded by adding
10 µ l 10 mg/ml Proteinase K (Roche 03115879001) per tube and incubating the
tubes all day and overnight at 65°C.
DNA purification: 1.8x volume AMPure XP beads were added to the 500 µ l Hi-C
sample, mixed, incubated at RT for 15 min, washed twice with fresh 80% ethanol,
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dried, DNA eluted in 30 µ l TLE, and transferred to a new tube.
Quantification: DNA was quantified using a Qubit fluorometer (Thermo Fisher
Scientific).
Hi-C ligation efficiency control: To detect known short- and long-range inter-
actions in the 3C and Hi-C libraries, PCR was performed using Hotstart Polymerase
Master Mix (5 µ l 5x PCR mix, 1 µ l of each 10 µM primer, 0.5 µ l/2.5u Qiagen HotStar
Taq DNA polymerase) and 100 ng template in a 25 µl reaction volume. The following
PCR protocol was used: 95°C for 15 min; 35 cycles of 94°C for 30 sec, 53°C for 30
sec, 72°C for 1 min; 72°C for 10 min; 12°C forever. The PCR product was run on a
0.8% agarose gel; both libraries were expected to run as a rather tight band over 10
kb. The primers for the short-range interaction were expected to span more than
one restriction fragment and/or be in the same orientation.
Hi-C biotin marking and ligation efficiency was verified by a PCR digest assay.
Successful fill-in and ligation of a HindIII site (AAGCTT) created a site for the re-
striction enzyme NheI (GCTAGC). 25 µ l PCR reactions were set up to amplify a
short-range ligation product formed from two nearby restriction fragments (AlbF1
and AlbF2). PCR products were purified using Qiagen Minelute PCR purification kit
according to the manufacturer’s instructions and eluted in 50 µ l water. The purified
sample was then divided into four 12 µ l aliquots: undigested, digested with HindIII,
digested with NheI, and digested with both HindIII and NheI, and then incubated
at 37°C for 2 h. The HindIII/NheI digestion was: 12 µ l DNA, 2 µ l Cutsmart buffer,
3 µ l water, 3 µ l HindIII-HF or NheI-HF (20,000 u/ml). The combined HindIII/NheI
digestion was: 12 µ l DNA, 2 µ l Cutsmart buffer, 1 µ l water, 2.5 µ l HindIII-HF (20,000
u/ml), 2.5 µ l NheI-HF (20,000 u/ml). Samples were run on a 1.5% agarose gel.
Removal of biotin at non-ligated DNA ends: To avoid pulling down non-ligated
biotinylated fragments, biotin-dATP was removed from these un-ligated ends using
the exonuclease activity of T4 DNA polymerase.
5 µg Hi-C library was mixed with 1 µg 10 mg/ml BSA, 10 µ l 10x NEB buffer 2, 2
µ l 10 mM dATP, and 15 u (5 µ l) T4 DNA polymerase (NEB M0203L). The volume
was adjusted to 100 µ l with water, and the mixture was incubated at 20°C for 2 h.
The reaction was stopped by adding 2 µ l 0.5M EDTA pH 8.0. DNA was purified
using 1.8x AMPure XP beads as described above.
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DNA shearing: A Covaris S220 (Covaris, Woburn, MA) was used to shear the
DNA: duty factor 5%, peak incident power 175 W, cycles per burst 200, for 55
seconds.
End Repair: The following was added to each sample: 25 µ l 10x NEB2, 2.5
µ l 10 mM dATP, 12.5 µ l 2 mM dNTP mix, 30 µ l water, 10 µ l T4 DNA polymerase, 10
µ l T4 PNK, 10 µ l Taq DNA polymerase, and then incubated at 25°C for 20 min and
at 72°C for 20 min.
Double-sided SPRI selection To select fragment sizes 200-700 bp (majority 250-
550 bp), sequential solid phase reversible immobilisation (SPRI) selection was
performed, first by adding 0.6x volume AMPure XP beads to the 230 µ l DNA sample,
incubating as described above, and then transferring the supernatant to a new tube.
A second size selection step was performed using 1x volume beads, incubating,
washing the beads twice in fresh 80% ethanol, drying, and eluting DNA in 30 µ l TLE.
The DNA was quantified using a Qubit fluorometer.
Biotin pull-down: Using LoBind tubes (Eppendorf) and tips (STARLAB), 25 µ l
Dynabeads MyOne Streptavidin C1 beads (Invitrogen) were washed twice with 400
µ l Tween Buffer (TB, 5 mM Tris-HCl pH 8.0, 0.5 mM EDTA, 1 M NaCl, 0.05% Tween)
and resuspended in 30 µ l 2x No Tween Buffer (2x NTB, 10 mM Tris-HCl pH 8.0, 1
mM EDTA, 2 M NaCl). The 30 µ l Hi-C DNA was added, mixed, and incubated at RT
for 15 min. Beads were reclaimed, the supernatant discarded, and beads washed
in 400 µ l 1x No Tween Buffer (1x NTB, 5 mM Tris-HCl pH 8.0, 0.5 mM EDTA, 1 M
NaCl). Beads were washed with 100 µ l dH2O, resuspended in 19 µ l water, and
transferred to new tube.
Adapter ligation: Adapters were ligated to the Hi-C library by the addition of 1
µ l 15 µM stock adapter, 20 µ l 2x Quick Ligation Buffer (NEB M2200), and 2 µ l Quick
T4 DNA Ligase (2,000,000 units/ml, NEB M2200), and incubating at RT for 15 min.
The beads were recaptured, supernatant discarded, beads washed twice with 400
µ l TB, once with 200 µ l 1x NTB, once with 100 µ l, and then 50 µ l 1x NEB2, before
finally being resuspended in 25 µ l 1x NEB2 and transferred to a new tube.
PCR amplification: Each 25 µ l amplification reaction contained: 2.5 µ l Hi-C beads,
1.5 µ l 10 µM TruSeq PCR primer mix, 2.5 µ l 2mM dNTP mix, 5 µ l 5x HF Buffer, 0.3
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µ l NEB Phusion, and 13.2 µ l water. The mixture was then amplified as follows: 98°C
for 30 s; seven cycles of 98°C for 10 s, 65°C for 30 s, 72°C for 30 s; 72°C for 7 min.
The PCR products were purified using AMPure XP beads as described above
using 0.7x bead volume and elution in 50 µ l TLE.
Library quantification
Library fragment size measurement and quantification were performed using a 2100
Bioanalyzer (Agilent). Libraries were pooled to ensure equal representation in the
final sequencing pool.
Next-generation sequencing
Pooled libraries were sequenced on an Illumina HiSeq4000 according to the manu-
facturer’s instructions to produce paired-end 150 bp reads.
2.8.1 Computational analyses of Hi-C data
Each sample was sequenced to a mean depth of ~179 million paired-end reads
totalling over a billion read pairs for the complete dataset. Data were mapped and
QCed with HiCUP 0.5.8 (Wingett et al., 2015) and bowtie2-2.2.8 (Langmead and
Salzberg, 2012) using the GRCm38 mouse reference genome. Over 60% of all
read pairs were properly mapped and paired; from these, over 85% were valid pairs
and the uniqueness percentage after de-duplication was ~70%. The BAM files
produced by HiCUP, which contain only valid, non-redundant read pairs, were used
for downstream analyses.
The HiCUP output BAM files were converted to a format compatible with HOMER
using the hicup2homer utility. Using HOMER (Heinz et al., 2010), tag directories were
created from the merged data of the three wild-type or Ctcf hemizygous samples.
The correlation between the interaction profiles of the two genotypes was calculated
with the getHiCcorrDiff.pl script using a resolution of 100 kb and a super-resolution
of 150 kb.
To identify chromatin loop interactions, the analyzeHiC program from HOMER
(Heinz et al., 2010) was used on the merged data from all six replicates; this ensured
that the definition of significant interactions was agnostic to the genotype, allowing us
to subsequently perform differential analysis of the wild-type and hemizygous profiles
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without compromising FDR control (Lun and Smyth, 2014). We supplied analyze-
HiC with the options –res 20000 –interactions –nomatrix –maxDist 10000000
–minDist 5000 –center. Differential analysis on the identified loops was performed
using diffHic (Lun and Smyth, 2015) on the set of interactions reported by HOMER
with an FDR lower than 0.05 and restricted to the autosomes. The HiCUP output
BAM files were processed with the preparePairs function, keeping data for each
replicate separate; any fragments mapping against the blacklisted regions used
for the ChIP-seq analyses (see above) were discarded. Then, the function con-
nectCounts was used to count the number of fragments mapping specifically to
the loci involved in the loop interactions. Only interactions that had more than 20
average counts per million (90,704 loops) were used for differential testing. Data
were normalised for depth of sequencing by providing the library sizes of the com-
plete dataset. Differential testing was performed, controlling for the batch effect from
sample collection time, and the resulting p-values were corrected for multiple testing
by the Benjamini-Hoechberg procedure. Finally, we used this ranked list to test
whether looping interactions overlapping with differentially expressed genes (plus
5 kb on either side) or differentially bound CTCF sites were enriched at the top of
the list using the function geneSetTest (Wilcoxon signed rank test) from the limma
package.
Definition of gene-enhancer pairs
To determine if the enhancers likely to regulate differentially expressed genes
changed with gene expression, we retrieved all putative enhancer peaks (defined
as H3K27ac peaks that did not overlap with H3K4me3 peaks) that were linked to
a differentially expressed gene via a significant interaction in the Hi-C data (see
above). For each of the 296 dysregulated genes, 261 had at least one and up to 65
linked enhancers (median = 8). Only a subset of these gene-enhancer pairs were
likely to be bona fide regulatory interactions. To increase our signal-to-noise ratio,
we reasoned that we could use the paired nature of our datasets to infer correlations
between the RNA expression levels and H3K27ac abundance, since both measure-
ments were performed in the same MEF cultures. Thus, for each gene-enhancer
pair, we calculated the Pearson correlation coefficient between the RNA-seq- and
ChIP-seq-normalised counts for the five replicates that had successful libraries for
both methodologies. We then retained the gene-enhancer pair with the highest
correlation value for each dysregulated gene. Figure 3.8 was plotted with these
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pairings; for genes with no linked enhancer, the corresponding row in the heatmap
has been left blank.
To generate the heatmaps shown in Figure 3.8, we defined 1 kb windows centred
either at the transcription start site (as defined in Ensembl v84) or the midpoint of the
H3K27ac peak, extending 17 kb up- and downstream. The number of sequencing
reads mapping to such windows in the histone ChIP-seq data were obtained with
bedtools v2.24.0, command intersect –c (Quinlan and Hall, 2010). The counts
for each sample were normalised to account for the total depth of sequencing and
then aggregated into 5 kb bins. For each 5 kb bin, the average abundance across all
replicates was used, and the log2 fold-change between the genotypes was plotted.
2.9 Mouse tumour models
2.9.1 Spontaneous tumourigenesis
A cohort of Ctcf +/- and wild-type mice were aged to 20 months. Full necropsy was
performed and all tissues processed for histological examination. In addition, all
macroscopically identified tumours >2 mm were bisected and processed for parallel
DNA/RNA extraction and histopathology (see below).
2.9.2 Chemical model of hepatocarcinogenesis
15-day-old male offspring from Ctcf +/- x Alb-cre breeding pairs were treated with a
single intraperitoneal injection of DEN (Sigma-Aldrich N0258; 20 mg/kg body weight)
diluted in 0.85% saline. Ear biopsies were taken immediately prior to treatment,
which was therefore blinded to the genotype (hepatocyte-specific Ctcf hemizygous
or wild-type).
In a pilot experiment, to determine the optimal time point for sample collection,
two mice of each genotype were euthanised every two to four weeks from 19 to 35
weeks after treatment with DEN.
Subsequently, liver tumour samples were collected from DEN-treated mice 36
or 42 weeks after treatment. Mouse body and organ weights were recorded. Full
necropsies were performed, livers photographed, all macroscopically identified
tumours measured, and those >2 mm in diameter bisected and processed in parallel
for DNA/RNA extraction and histopathological examination (see below) along with
background "normal" tissues.
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2.10 Tissue collection and processing
2.10.1 Fresh frozen tissue
Ear and tail samples from all mice were flash frozen at the time of necropsy and
used for genotyping and/or as normal genome control samples. Liver tumours were
macroscopically identified and isolated. Nodules of sufficient size (>2 mm diameter)
were bisected; one half was flash frozen in liquid nitrogen and stored at -80°C for
RNA/DNA extraction, and the other half was processed for histology (see below).
Background non-tumour liver was sampled from all mice, again flash frozen and
fixed for histology.
DNA and RNA isolation
Simultaneous isolation of genomic DNA (gDNA) and total RNA from liver tissue and
liver tumours was performed using the AllPrep 96 DNA/RNA Kit (Qiagen, 80311)
according to the manufacturer’s instructions. Briefly, 10 mg tissue was homogenised
in 350 µ l Buffer RLT using a TissueLyser II (Qiagen) at 25 Hz for 2 min, centrifuged
at 5600 rcf for 4 min at RT, and the supernatant transferred to the wells of the AllPrep
96 DNA plate. This plate, containing spin columns, was then centrifuged again at
5600 rcf for 4 min at RT. The flow-through from this plate contained total RNA for
purification, as detailed below. The genomic DNA, still on the membranes in the spin
column plate, was purified as described.
Genomic DNA purification: 800 µ l Buffer AW1 was added to each well of the
plate, centrifuged at 5600 rcf for 4 min at RT, then 800 µ l Buffer AW2 was added
and the centrifugation step was repeated for 10 min to dry the membranes. The
DNA was eluted by adding 70 µ l of pre-warmed Buffer EB, incubated for 5 min, and
centrifuged at 5600 rcf for 4 min at RT. The elution step was repeated with a further
70 µ l EB to ensure complete recovery of DNA.
QC was performed by running 1 µ l of gDNA (diluted 1:20) on a 1% agarose gel.
DNA quantification was performed in triplicate using the Quant-IT dsDNA Broad
Range Kit (Thermo Fisher Scientific).
Total RNA purification: 350 µ l 70% ethanol was added to each well contain-
ing the flow-through, transferred to an RNeasy 96 plate, and centrifuged at 5600 rcf
for 4 min at RT. 800 µ l Buffer RW1 was added to each well of the plate containing
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spin columns, centrifuged at 5600 rcf for 4 min at RT, then 800 µ l Buffer RPE was
added to each well, centrifuged again, and finally another 800 µ l Buffer RPE was
added to each well and centrifuged for 10 min to dry the membranes. RNA was
eluted by adding 50 µ l RNase-free water to each well then incubated for 1 min at RT
and centrifuged at 5600 rcf for 4 min at RT. A further 50 µ l RNase-free water was
added, incubated, and the plate was centrifuged again to ensure complete recovery
of RNA.
2.10.2 Fixed tissue for histology
Tissue samples were fixed in 10% neutral buffered formalin for 24 h, transferred to
70% ethanol, machine processed (Leica ASP300 Tissue Processor; Leica, Wetzlar,
Germany), and paraffin embedded. All formalin-fixed paraffin-embedded (FFPE)
sections were 3 µm in thickness.
Histochemical staining
FFPE tissue sections were stained with haematoxylin and eosin (H&E) for mor-
phological assessment and using Gomori’s method for reticular fibres to assess
liver architecture. Histochemical staining was performed using the automated Leica
ST5020; mounting was performed on the Leica CV5030. Briefly, for H&E staining:
sections were de-waxed with xylene (2 x 10 min), rehydrated with absolute ethanol
(2 x 5 min), 70% ethanol (1 x 5 min), briefly washed in water, and stained with Harris
haematoxylin (5 min) before washing in running tap water (5 min). Differentiation
was performed with 1% acid alcohol (20 s) and then washing in tap water (5 min).
Sections were counterstained with 1% aqueous eosin (5 min), washed in tap water
(10 s), dehydrated through 50% ethanol (20 s), 70% ethanol (20 s), 100% ethanol
(30 s), 100% ethanol (1 min), cleared with xylene (2 x 5 min), and mounted in DPX.
Immunohistochemistry
Immunohistochemistry was performed on FFPE tisse sections with antibodies tar-
geting Ki67, CD31, CD45, β -catenin, CK8, and CK14 (Table 2.3) using the Bond
Polymer Refine Detection Kit (DS9800, Leica Microsystems) with DAB enhancer
(Leica Biosystems, AR9432) on the automated Bond platform. Heat-induced epitope
retrieval (HIER) using sodium citrate or Tris-EDTA pre-treatments were run at 100°C
on the Bond platform. Proteolytic-induced epitope retrieval (PIER) enzyme digestion
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was run at 37°C on the Bond platform using Leica’s Bond enzyme concentrate
(AR9551) containing a proteolytic enzyme (17 mg/ml) and stabiliser (6 µ l/ml). A
mouse-on-mouse protocol was used for β -catenin using the Polymer Refine template
with an additional IgG block (Vector, MKB-2213) and an isotype-specific secondary
antibody (rabbit anti-mouse IgG, Abcam, ab125913, diluted 1:1500). For the anti-
bodies raised in rat, the post primary was substituted for a rabbit anti-rat antibody
(Bethyl Laboratories, Montgomery, TX; reference A110-322A, diluted 1:250).
Table 2.3 Antibody details and conditions used for immunohistochemistry.
Target Manufacturer & cat. no. Isotype Clonality Dilution Retrieval
Ki67 Bethyl Laboratories, 00375 Rabbit IgG Polyclonal 1:1000 Sodium citrate, 20’
CD31 BD Biosciences, 553370 Rat IgG Monoclonal 1:50 Enzyme digestion, 10’
CD45 R&D Systems, MAB1217 Rat IgG Monoclonal 1:750 Sodium citrate, 10’
β -catenin BD Biosciences, 610154 Mouse IgG Monoclonal 1:100 Sodium citrate, 20’
CK8 DSHB, TROMA-1 Mouse IgG Monoclonal 1:100 Sodium citrate, 20’
CK14 BioLegend, 905301 Rabbit IgG Polyclonal 1:5000 Sodium citrate, 10’
Imaging
All tissue sections were scanned using the Aperio XT system (Leica Biosystems) at
20x resolution. H&E-stained tissue section images of the tumours included in whole
genome sequencing experiments are available at BioStudies archive at EMBL-EBI
under accession S-BSST129.
2.11 Tumour histopathology
H&E sections of liver tumours were reviewed (n = 1648). Tumour size, morphological
subtype, presence of portal tracts, mitotic index, and the presence of cystic change,
haemorrhage, necrosis, or vascular invasion were assessed.
In addition, histochemical stains and IHC were performed on a subset of tumours
to aid tumour classification and also on all tumours selected for whole genome
sequencing.
Tissue sections were blinded and assessed twice; discordant results were re-
viewed by an independent clinical hepatobiliary pathologist (Dr Susan Davies).
Tumours were classified according to the International Harmonization of Nomen-
clature and Diagnostic Criteria for Lesions in Rats and Mice (INHAND) guidelines
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(Thoolen et al., 2010). Dysplastic nodules have an expansile growth pattern causing
compression of adjacent hepatic parenchyma, loss of normal lobular architecture (ir-
regular reticulin fibre staining), nuclear atypia, and may show increased proliferation
(increased Ki67 staining). Hepatocellular carcinomas are characterised by thickened
trabeculae (loss of reticulin fibre staining), pseudoglandular structures, more marked
cellular atypia, increased nuclear to cytoplasmic ratios, higher proliferative index
(markedly increased Ki67 staining), and an infiltrative growth pattern.
Sample selection for WGS
A total of 96 samples were selected for whole genome sequencing. Whenever
possible, a paired normal liver sample and tail/ear from the same mouse was
included in addition to the tumours. All spontaneous tumours were selected. Since
carcinogen-induced tumours arising in the same liver are independent (Connor et al.,
2018), multiple tumours were selected from each mouse to optimise the number
of tumour samples sequenced. Six mice were randomly selected from those with
4 to 14 tumours (mean +/- SD) that included both DNs and HCCs. Of these, four
to six tumours per mouse were selected that met the following histological criteria:
(1) diagnosis of either DN or HCC, (2) homogenous tumour morphology, (3) tumour
cell percentage >80%, and (4) adequate tissue for DNA extraction. Neoplasms with
extensive necrosis, mixed tumour types, a nodule-in-nodule appearance (indicative of
an HCC arising within a DN), or contamination by normal liver tissue were excluded.
2.12 Whole genome sequencing
Library preparation
1 µg of 50 ng/ul high molecular gDNA was used to generate sequencing libraries
using the TruSeq PCR-free Library Prep Kit (Illumina) according to the manufacturer’s
instructions. First, DNA was sheared to 350 bp fragments using the Covaris S220
system and then cleaned up using Sample Purification Beads (Illumina). 10 µ l CTE
and 40 µ l ERP2 were added to a final volume of 100 µ l and then incubated at 30°C
for 30 min to convert overhangs. Purification beads were used to perform right- and
then left-sided size selection, and DNA was eluted in 15 µ l resuspension buffer
(RSB). 3’ ends were adenylated by adding 2.5 µ l CTA and 12.5 µ l ATL and then
incubated at 37°C for 30 min and then 70°C for 5 min. Then, 2.5 µ l CTL, 2.5 µ l LIG2,
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and 2.5 µ l unique DNA adapters were added, mixed, incubated at 30°C for 10 min,
and finally 5 µ l STL was added. Libraries were cleaned up using purification beads
and eluted in 50 µ l RSB.
Library fragment size was determined using an Agilent Bioanalyzer 2100 (DNA
1000) and quantified by real-time PCR using the Kapa library quantification kit (Kapa
Biosystems) on the QuantStudio 6 Flex (Applied Biosystems). Libraries were then
diluted to 0.75 nM and pooled in 12-plex according to the D7 indexes (columns).
Pooled libraries were sequenced on an Illumina X Ten according to manufacturer’s
instructions to produce paired-end 150 bp reads. Each pool of 12 libraries was
sequenced over eight lanes.
2.12.1 Computational analyses of whole genome sequencing
Sequencing read alignment
Sequencing reads were aligned to the GRCm38 mouse genome assembly (En-
sembl release 91 (Yates et al., 2016)) with bwa (versions 0.6.1 or 0.7.12 (Li and
Durbin, 2009)). Aligned reads were annotated to read groups using the picard
tool AddOrReplaceReadGroups and minor annotation inconsistencies corrected
using the picard CleanSam and FixMateInformation tools (picard version 1.124;
http://broadinstitute.github.io/picard). The bam files for each sample were merged
together and duplicate reads were then identified using the picard MarkDuplicates
tool. Sequencing coverage was assessed using samtools (version 1.1 (Li et al.,
2009)).
Aligned reads for human samples from the ICGC French liver cancer (LICA-FR)
cohort were downloaded from the European Genome-phenome Archive at EMBL-EBI
(accessions EGAD00001000131, EGAD00001001096 and EGAD00001000737).
Variant calling
A pooled normal sample set was generated by combining all control sample reads
and then sub-sampling these reads to match the mean coverage achieved for the
control and tumour samples. Single nucleotide and indel variants were called using
Strelka (version 1.0.14 (Saunders et al., 2012)) using the recommended configuration
for bwa-aligned reads and setting the isSkipDepthFilters flag for improved calling.
Variant calls were combined into a merged set using bcftools (version 1.1 (Li et al.,
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2009)). Predicted coding sequence changes due to the SNVs were annotated by
comparing the polypeptide sequences coded by the reference and variant alleles.
SNVs were subjected to multiple filtering steps. First, low-confidence SNV calls
were identified and removed by applying the recommended filters for Strelka output
from the gatk-tools package (version 0.2 (Alioto et al., 2015); https://github.com/
crukci-bioinformatics/gatk-tools). In particular, variants were filtered based on low
mapping and base quality scores, proximity to alignment ends, and low absolute read
counts. Secondly, SNVs with an allele frequency of less than 2.5% were omitted to
eliminate possible cross-contamination due to observed low levels of sequence read
index mis-assignment during Illumina sequencing (Owens et al., 2018).
SNV call rates were estimated by fitting the number of variants detected at a
range of sequencing read depths and extrapolating to determine the expected call
rate at saturated sequencing coverage. Variant allele frequencies were calculated
from read counts for reference and variant alleles, excluding those reads having a
MAPQ score less than 5. Confidence intervals for allele frequency estimation were
estimated by applying a normal distribution approximation to bootstrap-resampled
frequency estimates (R boot package version 1.3 (Davison and Hinkley, 1997)). The
SVN data are deposited at the European Nucleotide Archive under accession code
ERZ537503.
Autosomal copy number variations (CNVs) were called with CNVkit (version
0.7.2 (Talevich et al., 2016)) using default parameters. CNV regions were filtered
to remove low-confidence regions where the null hypothesis (i.e., unchanged copy
number) fell within the 95% confidence interval. Further filters removed CNVs where
the absolute log fold-change in copy number was smaller than 0.25. CNV regions
located within 10 kb of each other were merged, and the resulting regions finally
filtered to remove regions smaller than 10 Mb.
SNV validation
Non-synonymous SNVs in the cancer driver genes of interest, Braf, Hras, and
Apc, were validated using conventional Sanger sequencing. In addition, SNVs were
checked by visual inspection of the aligned reads and were called validated if the
total variant reads were greater than ten.
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Mutational signature analysis
Analysis of mutational signatures was constrained to just those regions covered to
at least 20x in all samples. The distributions of 5’ and 3’ nucleotides flanking the
called SNVs were calculated directly from the reference genome. Direct comparison
between human and mouse signatures was facilitated by normalising C57BL/6
nucleotide context distributions using the ratios of known trinucleotide prevalences
in mouse and human genomes, as calculated for the 20x covered regions for each
genome. The proportions of COSMIC mutational signatures (Forbes et al., 2017)
represented in the mutational profile from each sample were calculated using the R
package deconstructSigs (version 1.8.0 (Rosenthal et al., 2016)).
Identification of significantly mutated cancer-related genes
Variants were annotated as to their likely effect on coding sequence by compar-
ing their predicted polypeptide sequences to those from the Ensembl release 91
GRCm38.p5 reference. SNV calls shared between tumours taken from the same
mouse (i.e., SNVs that could be simply ascribed to germline variation) were filtered
prior to analysis of mutated genes.
Cancer-related genes bearing above expected levels of non-synonymous mu-
tations (both across the entire gene and recurring at specific loci) were identified
using the following procedure. The gene list to be analysed was constrained to the
listing of oncogenes and tumour suppressor genes described by Vogelstein et al.
(2013). The total mutation load (nonsense, missense, frame shift, splice site) within
coding and splice-site regions was used to calculate the probability that mutations
had occurred purely by stochastic mutational processes. Within each gene, the
count of mutations at each variant locus was fitted to a Poisson distribution assuming
a background mutation rate calculated across all sequenced regions. The individual
variant loci were combined at the gene level using a multinomial model using the
R XNomial package (version 1.0.4; https://CRAN.R-project.org/package=XNomial).
This model yielded log-likelihood ratios from the observed and expected distributions,
from which a gene-wise p-value was readily calculated. P-values were corrected
for multiple testing across all genes using the Bonferroni method. The analysis was
repeated imposing a gene filter derived from the COSMIC Cancer Gene Census
(http://cancer.sanger.ac.uk/census/). This identified the same cancer-associated
genes that were significantly mutated in the mouse neoplasms.
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Mutational enrichment analysis
Mutation rate estimation, background mutation rates, and enrichment analyses were
performed as Sabarinathan et al. (2016). Briefly, mutation rate was estimated for all
CTCF binding sites identified from ChIP-seq experiments plus flanking stretches of
400 nucleotides at both sides. To avoid bias, windows of 801 nt were excluded if they
contained coding sequences or UCSC Browser blacklisted regions (“CRG Alignability
36’ Track”, score < 1, http://genome.ucsc.edu/cgi-bin/hgFileUi?db= hg19&g= wgEn-
codeMapability). The resulting filtered windows were aligned taking CTCF as the
centre, and the mutation rate of every column i within the window was calculated as
the total number of mutations mapped to nucleotides in column i divided by the total
number of nucleotides observed in column i after filtering.
In order to check if the mutation rate observed at each position was expected
due to the local sequence context, we randomly introduced the same number of
mutations observed at each window following the probability of occurrence of each
mutation according to its trinucleotide context. The mutation rate of each randomly
generated set of changes was computed for each column as explained above. This
procedure was repeated 1,000 times to compute the mean random mutation rate of
every column in the motif.
To test the enrichment for mutations at CTCF binding sites compared to their
flanking regions, we compared the ratio of the total number of mutations to the total
number of nucleotide positions within the motif (+/-15 nt) and that of the flanking
region (16 to 400 nt) on either side using a chi-squared test. In addition, we
computed the fold change of mutation rates through the expected frequencies
obtained from chi-squared tests. P-values were corrected for multiple-testing using
the Benjamini–Hochberg procedure.
2.13 Data storage and management
All data were stored on secure servers at the CRUK Cambridge Institute, and access
to the repository was restricted to Odom group members. In addition, access was
shared on a per-project basis with external collaborators at EMBL-EBI and IRB
Barcelona. All data generated are managed and shared in compliance with the Data
Management Policy at Cambridge University (http://www.lib.cam.ac.uk/dataman/
pages/bidding.html), which is a strong advocate of open access of research data.
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The raw data associated with peer-reviewed publications are deposited in the
ArrayExpress repository under accession codes E-MTAB-6261 for the ChIP-seq
dataset (including peak calls), E-MTAB-6259 for the RNA-seq dataset (including raw
and normalised gene expression counts), E-MTAB-6262 for the Hi-C dataset, and
E-MTAB-6971 and E-MTAB-6972 for the mouse liver tumour and control datasets
(including raw and normalised RNA-seq counts). The SVN data for BL6 mouse
derived tumours are deposited at the European Nucleotide Archive under accession
code ERZ537503. H&E-stained tissue section images of the tumours included
in whole genome sequencing experiments are available at BioStudies archive at




homeostasis of cancer pathways
Since thesis submission, this chapter has been published in full as Aitken et al.
(2018) Genome Biology.
3.1 Introduction
As detailed in Chapter 1, CTCF is a highly conserved nuclear phosphoprotein
(Klenova et al., 1993; Ohlsson et al., 2001) that is ubiquitously expressed in somatic
cells (Phillips and Corces, 2009). It is responsible for diverse regulatory functions
including fine-tuning gene expression, X chromosome inactivation, imprinting, and
3D chromatin organisation (Bell et al., 1999; Bickmore, 2013; Fedoriw et al., 2004;
Filippova et al., 1996; Lieberman-Aiden et al., 2009; Tsai et al., 2008). The global
three-dimensional (3D) organisation of chromatin partitions the mammalian genome
into discrete structural and regulatory domains (Dixon et al., 2012; Lieberman-Aiden
et al., 2009). Chromosome architecture has multiple levels of spatial organisation:
megabase-scale compartments correspond to euchromatin (A) and heterochromatin
(B) (Simonis et al., 2006), sub-megabase regions can be defined as topologically
associated domains (TADs) (Dixon et al., 2012) and, at the tens of kilobases level,
there exist smaller loop structures that connect cis-regulatory elements (Rao et al.,
2017, 2014). CTCF is frequently present at these structural boundaries at all scales
(Moore et al., 2015; Vietri Rudan et al., 2015).
Numerous studies have explored the function of complete disruption of CTCF
binding both in vivo and in vitro. At the whole embryo level, homozygous Ctcf
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deletion is embryonic lethal (Fedoriw et al., 2004), and genetically inducible Ctcf
knockout in specific cell types including oocytes (Wan et al., 2008), lymphocytes
(Ribeiro de Almeida et al., 2011), neurons (Hirayama et al., 2012), and cardiomy-
ocytes (Lee et al., 2017) results in organ-specific failure, characterised by aberrant
enhancer-promoter interactions and transcriptional dysregulation (Dowen et al.,
2014). Complementary biochemical approaches have been used to test the func-
tional impact of acute CTCF depletion in vitro by both RNAi (Schmidt et al., 2012;
Zuin et al., 2014) and transient auxin-mediated depletion (Nora et al., 2017). Acute
depletion in mouse embryonic stem cells results in almost complete removal of
CTCF from the nucleus, causing genome-wide disruption of loops and TADs without
affecting higher-order genomic compartmentalisation (Nora et al., 2017).
Despite strong conservation of the higher-order chromatin structure, such as
TADs, across tissues and individuals (Vietri Rudan et al., 2015), there is substantial
inter- and intra-individual variation in Ctcf expression (Phillips and Corces, 2009)
driven by both genetic heterogeneity and cell type specificity. Up to ten-fold differ-
ences in both Ctcf mRNA and protein expression have been observed across a
variety of tissues (Mele et al., 2015; Uhlen et al., 2015). Since these differences in
expression do not seem to affect the general organisation of chromatin, it is unclear
whether they have a functional impact. To address this, we sought to develop and ex-
ploit a highly controlled system in which we could modulate Ctcf expression without
resorting to a homozygous knockout.
We therefore utilised mice with hemizygous Ctcf deletion (Heath et al., 2008;
Lallemand et al., 1998) in an attempt to dissect direct regulatory targets and function
(Boj et al., 2010). While Ctcf hemizygous mice develop normally, they have are
predisposed to tumour development (Kemp et al., 2014), suggesting that even
physiologically-tolerated changes in CTCF concentration have a detrimental effect on
organismal fitness. CTCF is also implicated as a haploinsufficient tumour suppressor
gene in human cancers (Filippova et al., 1998; Kemp et al., 2014; Ohlsson et al.,
2001).
In contrast to germline variants, somatic missense and nonsense mutations of
CTCF are common in human cancers (Gonzalez-Perez et al., 2013; Rubio-Perez
et al., 2015). CTCF has been identified as a putative driver gene in several cancer
types (Rubio-Perez et al., 2015) and such loss of function is in keeping with the
action of a tumour suppressor gene (Filippova et al., 1998; Ohlsson et al., 2001).
Furthermore, reduced expression of CTCF mRNA in kidney cancer is strongly
correlated with lower five-year survival rates (Uhlen et al., 2017). However, the
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precise role of CTCF in the initiation or progression of carcinogenesis is poorly
understood.
To study the direct impact of altering Ctcf expression, independent of any factors
that may confound human studies such as environmental exposures, we chose an in
vitro model and exploited mouse embryonic fibroblasts (MEFs). Wild-type and Ctcf
hemizygous mouse embryonic fibroblasts MEFs were interrogated using a variety
of functional assays to characterise differences in the molecular portraits between
conditions. MEFs were chosen in these studies because: (i) they are grown in
well-defined culture conditions in vitro and (ii) their rapid growth rate allowed us to
harvest the volume of cells needed for each ChIP-seq, RNA-seq, proteomic, and
Hi-C replicate from a single embryo at a low passage number (P4). The low passage
number was important because extended passage runs the risk of the introduction
of mutations and transformation.
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3.1.1 Project aim and overview
The aim of this project was to investigate the effects of Ctcf haploinsufficiency by
generating, analysing, and integrating genomic, epigenomic, transcriptomic, pro-
teomic, and chromatin-conformation data in a mouse model of Ctcf hemizygosity
(Figure 3.1).
Fig. 3.1 Project overview: Ctcf hemizygosity as a model to subtly perturb nuclear
homeostasis. The engineered Ctcf locus contains loxP sites flanking the protein-coding
exons of the gene (WT, Ctcf +/+), which can be removed using Cre recombinase (Ctcf +/-).
Mouse embryonic fibroblast (MEF) lines were derived from six WT and six Ctcf +/- littermates.
Quantitative analyses of CTCF binding, transcription, proteomics, chromatin state, and
chromatin structure were performed in multiple biological replicates.
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3.2 Results
3.2.1 Successful generation of embryonic fibroblast cultures
To characterise the molecular effects of altering the concentration of CTCF protein
available in the nucleus, we utilised Ctcf hemizygous mice carrying a lacZ reporter
in place of the coding region of Ctcf (Heath et al., 2008) in all cells (Figure 3.2). To
perform high-throughput experiments in homogeneous cell populations, an in vitro
approach was employed.
Fig. 3.2 Conditional deletion of the mouse Ctcf gene. Exons of the wild-type Ctcf gene
(solid boxes) are numbered (10 kb scale indicated). Exon 3 contains the start codon and
exon 12 contains the stop codon. The two targeting constructs with loxP sites (red triangles)
flanking a PMC1-neomycin cassette (neor) or a PGK-puromycin cassette (puror) are shown
with homologous regions (Hoogenraad et al., 2002). Complete Cre-mediated recombination
at the outermost loxP sites deletes the coding exons (3-12) of the Ctcf gene, shown in the
lower panel. Alternative splicing generates a hybrid Ctcf–lacZ transcript by splicing of the
splice acceptor site present at the 5’-end of the reporter LacZ cassette to Ctcf exon 1 or 2.
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Timed mouse matings were used and, after identification of a vaginal plug on day
E0.5, embryos were collected on day E13.5 and MEF cultures generated. Embryos
were harvested from three pregnant females at E13.5 to produce 21 MEF cultures.
PCR analysis of embryos confirmed both wild-type (WT, Ctcf +/+) and Ctcf hemizy-
gous (HE, Ctcf +/-) genotypes (Table 3.1). All cells cultured successfully, reaching
80% confluence by 72 h after splitting (Figure 3.3). MEFs were cultured and cells
were harvested in pairs (one WT and one Ctcf hemizygous) to account for potential
batch effects cause by culture conditions.
Table 3.1 Genotyping of mouse embryos
Maternal Wild-type Hemizygous




Total no. embryos 6 15
Fig. 3.3 MEF cultures. Photomicrographs of wild-type (WT) and Ctcf hemizygous (HE)
MEF cultures 24, 48, 72, and 96 hours after first passage. Original magnification x10.
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3.2.2 Molecular characterisation of Ctcf hemizygous MEFs
We used six of our independently derived embryonic fibroblast lines from mice
carrying a deletion of one Ctcf allele (Ctcf +/-) and six corresponding lines from
littermate Ctcf wild-type controls. Each MEF culture showed significant depletion of
Ctcf mRNA (Figure 3.4A) and a slightly lesser reduction in CTCF protein (Figure
3.4B); the degree of Ctcf depletion varied between biological replicates. qPCR
demonstrated that, on average, Ctcf hemizygous MEFs had a 37% reduction (two-
tailed t-test, p = 1.58 x 10-6) in Ctcf mRNA compared to wild-type MEFs. In turn,
quantitative western blotting showed a 27% reduction (two tailed t-test, p = 8.731 x
10-5) in protein level versus wild-type cells (Figure 3.4C). Thus, although there is
partial compensation at both the mRNA and protein levels, there is a consistently
lower concentration of CTCF in hemizygous mouse cells.
Fig. 3.4 Validation of CTCF depletion. Quantification of Ctcf deletion by (A) qRT-PCR and
(B) quantitative western blot experiments on wild-type (Ctcf +/+) and hemizygous (Ctcf +/-)
MEFs. (C) There is partial compensation from DNA to RNA to protein levels of CTCF.
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Given this haploinsufficient molecular phenotype, we anticipated that this Ctcf
hemizygous model system would provide a powerful tool to delineate the pathophys-
iological consequences of CTCF haploinsufficiency. We therefore used these twelve
independent embryonic fibroblast lines to generate an adequate volume of cells for
multiple biological replicates for diverse functional experiments (Figure 3.1).
3.2.3 Chronic reduction of CTCF alters its chromatin binding
We first assessed the impact of hemizygosity on CTCF occupancy using chromatin
immunoprecipitation followed by sequencing (ChIP-seq). We identified 42,336 loci
directly occupied by CTCF, 787 of which were significantly differentially bound (FDR
<5%) between the two genotypes (Figure 3.5A). Of these, 79.4% were less strongly
bound in the Ctcf +/- MEFs. The changes in occupancy between the genotypes were
generally small but highly reproducible among independent samples (Figure 3.5B).
Thus, reduced availability of CTCF in embryonic fibroblasts leads to its depletion at
a very specific subset of genomic sites.
Fig. 3.5 Ctcf hemizygosity results in altered chromatin binding. (A) Differential binding
analysis identified 787 CTCF binding sites differentially occupied between Ctcf hemizygous
and wild-type MEFs, most of which show reduced genomic occupancy in the Ctcf +/- MEFs.
Significant changes are shown in red (FDR < 5%). (B) Example genome tracks showing
highly consistent loss of CTCF binding at three genomic loci overlapping the genes indicated
at the top of the panels. The same scale is used on all y-axes.
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3.2.4 Labile CTCF binding sites have distinct genomic features
Genomic locations sensitive to subtle and chronic CTCF reduction shared a number
of features. First, most (68%) of the differentially bound sites overlapped annotated
genes or their promoters (defined as 5 kb upstream of the transcription start site),
which represents significant enrichment compared to genome-wide CTCF occupancy
(chi-square test, p = 4.9 x 10-10; Figure 3.6A). Second, CTCF can bind motif
instances of either 20 or 33 bases (Schmidt et al., 2012); we found that differentially
bound CTCF sites were significantly depleted of longer words (hypergeometric test,
p = 1.53 x 10-11; Figure 3.6B). Previous studies have shown that binding sites with
shorter motifs have lower average binding affinity (Schmidt et al., 2012). Consistent
with this, CTCF sites perturbed by hemizygosity had motifs of lower affinity when
compared to all CTCF-bound regions (Mann-Whitney test, p < 2.2 x 10-16; Figure
3.6C). Third, by comparing with the ~11,000 CTCF sites conserved across five
species of mice (Thybert et al., 2018), differentially-bound CTCF sites were found to
be depleted of these conserved binding events (hypergeometric test, 2.55 x 10-6;
Figure 3.6D). In other words, CTCF binding sites stable across the murine lineage
are resistant to chronically reduced levels of CTCF.
In conclusion, our data reveal a set of regions preferentially found near genes
which show reproducible, quantitative changes in CTCF occupancy that show com-
mon motif characteristics and that are enriched for lineage-specific CTCF binding.
3.2.5 Ctcf hemizygosity alters transcription of cancer pathways
To determine what impact changes in CTCF binding had on the global transcriptome,
we sequenced total RNA from six biological replicates of both genotypes. Confirming
the qPCR results, hemizygosity resulted in a significant reduction in Ctcf expression
(p = 2.4 x 10-7, Methods). Consistent with the differences in CTCF occupancy,
transcriptional changes were subtle: differential gene expression analysis identified
296 dysregulated genes (FDR <5%; Appendix A) 69% of which had reduced
expression in Ctcf +/- MEFs (Figure 3.7A).
mRNA and cellular protein levels have a complex relationship (Liu et al., 2016). In
our model, the changes observed in the transcriptome did propagate to the protein
level, as shown by comparison of transcriptomic data to the proteomes of the wild-
type and hemizygous cells obtained using tandem mass tag (TMT) proteomics. For
the differentially expressed genes, the transcriptional and proteomic changes in Ctcf
hemizygous cells were highly correlated (Spearman’s rho = 0.65, p < 2.2 x 10-16;
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Fig. 3.6 Differentially bound CTCF loci are found near genes, occur in shorter motifs,
and have lower binding affinity and evolutionary conservation. (A) Differential CTCF
binding sites were significantly enriched within promoters and gene bodies compared to
stable CTCF binding sites (chi-square test, p = 4.9 x 10-10). (B) Stable CTCF peaks had a
higher proportion of the longer (~33 bp) motif word compared to the differential sites. Multiple
alignments of a randomly chosen subset of a hundred CTCF binding sites that are either
stable or differential are shown. Each position in the alignment is coloured corresponding to
the nucleotide present following the colour scheme used in the logo shown at the top. (C)
Binding sites susceptible to a reduced CTCF concentration have significantly lower motif
affinity (Mann-Whitney test, p < 2.2 x 10-16). (D) Regions bound by CTCF across the mouse
lineage are less sensitive to Ctcf hemizygosity. Example tracks are shown of a stable CTCF
binding site that is conserved in five species of mice compared to a differential site that is
found in only a subset of the species (M. musculus chr6:120,736,800 for the stable site and
chr2:31,887,060 for the differential site). *** p value < 0.001.
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Fig. 3.7 CTCF depletion dysregulates oncogenic pathways. (A) Nearly 300 genes were
differentially expressed between wild-type and Ctcf +/- cells; significant changes are shown
in black (FDR <5%). (B) Transcriptional changes (x-axis) were highly correlated to corre-
sponding changes at the protein level (y-axis); Spearman’s correlation coefficient is noted
in the top left corner. 86% of all genes from (A) had concordant fold-change estimates in
the proteomics dataset. (C) Gene set enrichment analysis performed on the differentially
expressed genes highlights dysregulation of cancer-related pathways. Representative signif-
icantly enriched terms from the Gene Ontology (upper panel) and KEGG pathways (lower
panel) are shown. (D) Differentially expressed (DE) genes are strongly enriched for having
higher numbers of CTCF binding sites (BS) than genes with stable expression, in their gene
bodies or flanking 5 kb.
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Figure 3.7B). Indeed, 85% had fold-change estimates concordant between RNA
transcription and protein expression.
Gene set enrichment analysis revealed that CTCF-dependent transcripts were
strongly enriched for processes related to cell differentiation, proliferation, death, mi-
gration, adhesion, angiogenesis, and protein phosphorylation. The MAPK, ERK1/2
and Ras signalling pathways also showed an excess of dysregulated transcripts.
Consistent with these results, analysis of KEGG pathways revealed that Ctcf hem-
izygosity resulted in perturbation of cancer-related pathways (Figure 3.7C).
Finally, we asked whether these gene expression changes could be caused
directly by altered CTCF binding. We observed that few differentially bound CTCF
sites overlapped, or were in close proximity to, the genes with altered expression.
However, there was a strong tendency for differentially expressed genes to be
associated with higher numbers of CTCF binding sites (Figure 3.7D), even if these
were stable. For example, 83% of all dysregulated genes (+/- 5 kb) overlapped at
least one CTCF binding site, in contrast to only 68% of stable genes (hypergeometric
test, p = 1.32 x 10-8). Further, whereas only 23% of stable genes overlapped with
three or more CTCF bound sites each, 41% of all differentially expressed genes did
(Figure 3.7D). Thus, the set of genes dysregulated in Ctcf hemizygous cells are
strongly enriched for CTCF binding sites, suggesting subtle additive effects regulate
nearby gene transcription.
3.2.6 Gene expression changes correspond with altered loop-
ing interactions
Steady-state transcription can be altered by either changes in transcript stability or
by differences in transcriptional regulation. We therefore examined whether the pro-
moters of CTCF-dependent genes showed corresponding changes in transcriptional
initiation, reflected as changes in H3K4me3 and H3K27ac occupancy. Both of these
histone modifications are associated with an open chromatin state, are permissive of
active transcription (Heintzman et al., 2007; Rada-Iglesias et al., 2011; Santos-Rosa
et al., 2002; Shlyueva et al., 2014), and their occupancy levels at the transcription
start site are positively correlated with gene expression (Santos-Rosa et al., 2002).
The vast majority (>80%) of the CTCF-dependent genes had concordant promoter
and transcriptional changes (Figure 3.8). Thus, most gene expression differences
apparently arise from CTCF-mediated alterations to transcriptional initiation.
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Fig. 3.8 Transcriptional perturbations arise from regulatory changes in the nuclear
genome. Changes in expression of dysregulated genes are accompanied by changes in the
activity of their proximal promoters as well as enhancers linked via chromatin loops. In the
centre, the expression differences between wild-type and Ctcf +/- cells are shown, ordered by
increasing fold-change; genes expressed at lower levels in the hemizygous cells are in blue,
whereas those expressed at higher levels are in red. To the left, a heatmap of the difference
in mean abundance of H3K4me3 occupancy is shown. Each column is a 5 kb window
extending 17.5 kb up- and downstream of each gene’s transcription start site, which is in
the centre. On the right, an equivalent heatmap for the difference in occupancy of H3K27ac,
centred at the midpoint of the peak. Gene-enhancer pairs were inferred from significant
interactions identified from Hi-C data, and thus elements can be separated by large distances.
For each gene, the enhancer with most regulatory potential is shown (Methods). The same
colour scale is used throughout. Transcriptional changes are accompanied by concordant
changes in the activity of their regulatory elements.
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Gene expression can be controlled by looping interactions between regulatory
elements mediated by CTCF (Bonn et al., 2012; Chambeyron and Bickmore, 2004;
Fraser, 2006; Ling et al., 2006; Splinter et al., 2006; Yoon et al., 2007). To determine
the effects of Ctcf hemizygosity on chromatin architecture, nuclear Hi-C experiments
were performed in three biological replicates of wild-type and Ctcf +/- MEFs. First,
we inspected the global-scale interaction profiles in both genotypes using 100 kb
windows covering the whole genome. Consistent with recent studies showing that
acute total depletion of CTCF results only in modest effects on large-scale chromatin
interactions (Nora et al., 2017), we found that 95% of all windows were unaffected by
reduced CTCF, with a correlation coefficient of 0.9 or higher between the genotypes
(Figure 3.9).
To explore whether fine-scale chromatin organisation is affected by reduced
CTCF levels, we merged all replicates to increase the resolution of our data and
identified pairs of loci interacting more often than expected by chance. We then
compared the intensity of such interactions in the wild-type and hemizygous cells and
generated a ranked list. Looping interactions that involved a dysregulated gene or a
differentially bound CTCF site tended to rank higher and were significantly enriched
at the top of the list (Wilcoxon signed rank test, p = 0.017 for genes and p = 2.72 x
10-6 for CTCF sites). Thus, many of the transcriptional changes we observed may
indeed be the result of changes in distal regulatory elements mediated by looping
interactions.
We reasoned that these loops were likely to connect altered genes to distal
enhancer activity changes. We defined putative enhancers as sites occupied by
H3K27ac but lacking H3K4me3 (Heintzman et al., 2007; Rada-Iglesias et al., 2011)
and identified 73,670 loci with this epigenetic profile. We then collected the subset of
enhancers associated with a dysregulated gene via a looping interaction (Methods),
and compared the fold-change between the wild-type and Ctcf hemizygous cells.
75% of these enhancer-gene pairs showed concordant changes between gene
expression and enhancer activity (Figure 3.8). Bulk analysis of enhancer changes
would not have identified these connections, since direct comparison of hemizygous
and wild-type Ctcf cells showed almost no enhancer differences, with only 127 (0.2%)
being significantly differentially bound (FDR < 5%). Thus, the transcriptional changes
observed in the hemizygous cells are likely to result from altered transcriptional
regulation mechanisms that involve both promoters and distal enhancers.
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Fig. 3.9 Global-scale chromatin interactions are robust to reduced CTCF levels. Hi-C
analysis produces a genome-wide contact matrix; the submatrix shown here corresponds
to intrachromosomal interactions on chromosome 8. Each pixel represents all interactions
between one 100 kb locus and another 100 kb locus; the intensity of each pixel represents the
normalised number of contacts between a pair of loci (scale: 0-162). Interactions identified
in wild-type cells are shown above the diagonal and interactions in Ctcf hemizygous cells
are shown below the diagonal. No large-scale differences are identified between the two
genotypes. Genes and TADs are shown; Ctcf is located at chr8:105,636,568-105,682,922.
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3.2.7 Altered gene expression patterns are recapitulated in mouse
and human tumours
In order to assess the relevance of our findings to the process of tumourigenesis
in vivo, we asked whether CTCF-dependent cancer pathways were also activated
in the transcriptomes of primary mouse and human tumours. Notably, CTCF is
detected as a mutational driver in uterine and breast carcinomas, in which most
(68%) variants are truncating mutations (Gonzalez-Perez et al., 2013; Rubio-Perez
et al., 2015); therefore, our Ctcf hemizygous model is a good parallel to this human
molecular phenotype.
First, we selected twenty-five primary liver tumours that spontaneously occurred
during ageing of C3H mice, which were generated in our previous study (Connor
et al., 2018). We then analysed their total RNA transcriptome, with a set of normal
liver controls. We compared the set of differentially expressed genes in these mouse
liver tumours with the genes perturbed by Ctcf hemizygosity in MEFs, and found
that nearly half (47.6%) of the latter were also differentially expressed in the tumours.
The majority (60%) showed concordant fold-changes (Figure 3.10), indicating that a
large proportion of the up- and down-regulated genes in the Ctcf +/- cells were also
up- and down-regulated, respectively, in the mouse liver tumours. Notably, these
concordantly altered genes retained strong enrichment for cancer-related functional
terms and pathways.
We next asked whether the molecular pathways perturbed by Ctcf hemizygosity
in mouse embryonic fibroblasts were similarly perturbed in human tumours. We
identified 104 uterine and 19 breast human tumour samples from TCGA with dele-
terious (missense, frameshift or stop gained) mutations in at least one allele of
CTCF. To compare the gene expression profiles across species, we restricted our
analyses to those genes that are one-to-one orthologs. For both the uterine and
breast cancer datasets, we observed a large overlap (~75%) between the set of
differentially expressed genes in Ctcf hemizygous MEFs and those altered in human
tumours. From these, around 65% showed concordant changes across all datasets
(Figure 3.10), supporting a common signature of transcriptional alterations upon the
loss of one functional copy of CTCF.
In sum, our data indicate that a small reduction in the concentration of CTCF can
significantly perturb the expression of hundreds of transcripts required for normal
cellular homeostasis, as evidenced by their dysregulation in a diversity of mouse
and human tumours.
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Fig. 3.10 Concordant gene alterations in diverse murine and human tumours. The
comparison of the set of CTCF-dependent genes and those differentially expressed in
mouse liver tumours or in human uterine and breast tumours revealed a large overlap. The
majority of these changed in the same direction (concordant) in the Ctcf hemizygous MEFs
and the tumour samples. Additionally, the set of genes unique to MEFs is indicated (not
differential) and those that were either not expressed or did not have a one-to-one ortholog
in the human genome (not common). The concordant gene changes across these diverse
tumours are highly overlapping, as seen in the Venn diagram.
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3.3 Discussion
Complete removal of CTCF has catastrophic effects as a result of massive dysregu-
lation of the 3D genome (Lee et al., 2017; Liu et al., 2016; Schmidt et al., 2012; Zuin
et al., 2014). Here we used Ctcf hemizygosity as a model system to compare how
transcription and genome organisation in otherwise identical cells adapt to differing
concentrations of CTCF. This model closely approximates the normal physiological
variation of CTCF levels across tissues without the confounding effects that arise
from cell-specific trans environments.
These data strongly suggest that mammalian cells can compensate for fluctu-
ations in intra-cellular CTCF concentration from DNA to RNA to protein. In MEFs,
50% removal of Ctcf causes a 37% reduction in mRNA expression, leading to a
27% reduction in CTCF protein, and resulting in only a 2% difference in genomic
occupancy. The homeostatic and functional buffering observed in our model system
offers a clear explanation for how tissues that have highly variable levels of CTCF
expression (Mele et al., 2015; Uhlen et al., 2015; Yu et al., 2015) nevertheless
preserve CTCF genomic occupancy levels.
Our data further indicate that sub-megabase scale chromatin structures are
also robust to variation in the amount of CTCF available in the nucleus. Recent
studies have shown that CTCF is dispensable for the establishment of the A and
B compartments but necessary for the proper insulation of TADs and the integrity
of looping interactions (Nora et al., 2017). We did not observe any changes in
the structure or insulation of TADs in the Ctcf hemizygous cells (data not shown),
consistent with the high conservation of TADs observed across tissues.
The controlled reduction in CTCF expression in hemizygous cells revealed,
however, reproducible changes to the nuclear environment, thus providing insights
into its inherent functions. Almost a thousand loci were directly bound by CTCF that
showed reproducible quantitative changes in their genomic occupancy. These were
accompanied by alterations in the transcription of several hundred genes, which in
turn affected the corresponding protein abundances. Since the promoters of these
genes were differentially deployed between the two genotypes, these transcriptional
changes arose from alterations in nuclear homeostasis not differences in transcript
stability in the cytoplasm. Near these dysregulated genes there was an excess of
unstable fine-scale chromatin interactions and enhancers showing altered activity
connected via loops. Therefore, in contrast to high-order chromatin structures, which
are indifferent to fluctuations in CTCF concentration, fine-scale genome organisation
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is more sensitive, and these alterations impact the regulatory landscape leading to a
perturbed functional state.
The transcriptional alterations seen here may be the result of increased variability
in the expression of these genes. Indeed, the loss of promoter-enhancer interactions
due to CTCF knockdown or the deletion of its binding sites can result in increased cell-
to-cell variability in gene expression (Ren et al., 2017). The use of recently developed
single-cell sequencing technologies would offer the opportunity to address chromatin
accessibility, DNA methylation, and transcriptional variability between cells of a
particular cell population (Clark et al., 2018). A reduction in CTCF results in highly
reproducible changes in population of cells’ epigenomes and transcriptomes, either
due to increased cell-to-cell variability or gene-specific changes occurring uniformly
across cells. These gene expression changes were found disproportionately in
cancer-related pathways and, consistently, a large proportion of these genes are
dysregulated in the transcriptomes of mouse and human tumours from diverse
origins.
In conclusion, our data support the hypothesis that, although mammalian cells
are tolerant to a reduced concentration of CTCF, there is specific dysregulation of
oncogenic pathways that may confer an increased predisposition to cancer.

Chapter 4
Genetic and chemical models of
hepatocarcinogenesis
4.1 Introduction
CTCF as a tumour suppressor gene
CTCF was first proposed as a tumour suppressor gene when 16q22.1 was found
to be frequently deleted in sporadic breast and prostate cancers (Filippova et al.,
1998). More recently, human cancer sequencing studies have shown that tumours
driven by CTCF have loss-of-function mutations, either missense coding alterations
or transcript truncation, in keeping with the action of tumour suppressor genes
(Rubio-Perez et al., 2015). Mouse models of Ctcf hemizygosity show that tissues
with hemizygous loss of CTCF exhibit increased genome-wide variability in CpG
methylation. Furthermore, while Ctcf hemizygous mice develop normally, they
demonstrate a multi-lineage predisposition to cancer (Kemp et al., 2014), thus
establishing Ctcf as a prominent tumour suppressor gene and suggesting that
CTCF-mediated epigenetic stability acts as a major barrier to neoplastic progression.
In addition to CTCF being implicated in tumourigenesis, CTCF binding sites are
mutated many human cancer types (Kaiser et al., 2016; Katainen et al., 2015),
including in liver cancer (Fujimoto et al., 2016; Schulze et al., 2015).
Hepatocellular carcinoma
Liver cancer is a heterogeneous group of diseases, including hepatocellular carci-
noma, cholangiocarcinoma, hepatoblastoma, and hemangiosarcoma. Hepatocellular
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carcinoma accounts for 70-80% of all primary liver cancers and is the second most
common cause of cancer death worldwide (Torre et al., 2015). HCC develops
in the context of chronic liver disease in 80% of cases. Chronic liver disease
most commonly arises from chronic inflammation due to hepatitis B or hepatitis C
virus infections, dietary exposure to aflatoxin B, alcoholic liver disease (ALD), or
non-alcoholic fatty liver disease (NAFLD), which causes fibrosis and subsequent
cirrhosis: liver scarring in the presence of regenerative hepatocytes. Such chronic
hepatocyte injury leads to genetic damage that underpins HCC (Hardy and Mann,
2016). The incidence of HCC is increasing globally, most rapidly in developed
countries, largely due to the rising prevalence of NAFLD (Koh et al., 2016).
The aetiology of liver cancer is diverse, which is reflected in the molecular
heterogeneity of the disease and is thought to contribute to the highly variable
prognosis of patients with HCC. High-throughput sequencing of hundreds of human
liver tumours has identified several different oncogenic pathways and a wide range of
putative driver mutations underlying hepatocarcinogenesis (Ally et al., 2017; Boyault
et al., 2007; Fujimoto et al., 2016; Letouzé et al., 2017; Schulze et al., 2016; Zucman-
Rossi et al., 2015). Investigating the mechanisms by which HCC progresses from a
chronic fibroinflammatory or cirrhotic disease state with macroregenerative nodules
(MRNs) to invasive HCC would allow us to (i) develop a more meaningful molecular
classification of HCC, in turn offering the promise of predictive and prognostic
biomarkers and potential therapeutic targets (personalised or precision medicine); or
(ii) identify targets to prevent progression of liver disease from a benign to malignant
state.
Many cancers, including HCC, carry a high burden of somatic mutations due
to the action of known genotoxic insults. Identifying bona fide cancer drivers in
the context of a dense background mutational load is challenging and requires the
combination of tractable experimental models (Bakiri and Wagner, 2013) and the
application of advanced computational biology approaches (Martincorena et al.,
2017).
Chemical carcinogen model of liver cancer
We recently characterised a commonly-used carcinogen-driven model of liver cancer,
in which tumours are induced using diethylnitrosamine in C3H mice. For the first
time, we performed exome sequencing of these tumours and spontaneously arising
tumours and found that: (i) DEN-induced neoplasms arising in the same mouse
evolve independently; (ii) the tumours have a high, uniform number of somatic
4.1 Introduction 81
single nucleotide variants (SNVs); (iii) DEN exposure creates a distinct mutational
signature; (iv) Hras is the predominant, although not obligatory, oncogenic driver of
hepatocellular tumours in C3H mice (Connor et al., 2018).
Although genetically-engineered mouse models of liver cancer mimic the macro-
scopic and microscopic features of HCC, they often lack the molecular and genetic
complexities of their human counterparts. This means that although GEM models
are invaluable for testing potential mechanism-based therapies, the choice of model
must be carefully evaluated (Bakiri and Wagner, 2013). Such studies have been
performed in other organ systems and compared the genomic landscapes of genetic
and chemical mouse models of Kras-driven lung cancer (Westcott et al., 2014) and
skin squamous cell carcinoma (Nassar et al., 2015). Human lung and skin cancer
are usually driven by mutagens in tobacco or UV light, respectively, and these studies
revealed that the carcinogen-induced mouse models better reflected the genetic
complexity of human neoplasms.
Thus, to delineate the consequences of Ctcf hemizygosity in vivo, we chose
to use our well-established DEN chemical carcinogenesis model. Since DEN-
induced tumours harbour tens of thousands of mutations and CTCF binds to tens of
thousands of DNA sites across the genome, combing these systems allows us to
explore how the subtle differences in CTCF binding influence mutagenesis.
4.1.1 Project aim
The aim of this project was to use genetic and chemical carcinogenesis models in
combination to test in vivo our finding that Ctcf hemizygosity dysregulates cancer
pathways in vitro. This involved (i) comprehensive characterisation of Ctcf hem-
izygous mice, (ii) prolonged ageing to develop spontaneous tumours, and (iii) liver
tumour induction with a chemical carcinogen. We hypothesised that DEN-induced
tumours would be more frequent on a background of Ctcf hemizygosity.
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4.2 Results
4.2.1 Characterisation of Ctcf hemizygous mice
Using the same Ctcf hemizygous mice as in Chapter 3 (Figure 3.1), we sought
to characterise the Ctcf +/- colony in terms of: (i) transmission of the altered Ctcf
allele, and (ii) overt macroscopic and microscopic phenotypes, including the reported
increased incidence of spontaneous tumours (Kemp et al., 2014).
Reduced transmission of the targeted Ctcf allele
Female C57BL/6J mice (i.e., with two intact copies of Ctcf ) were bred with Ctcf +/-
males, also with a C57BL/6J genetic background. Based on this breeding strategy,
Mendelian inheritance predicts equal numbers of wild-type and Ctcf hemizygous
offspring. However, in contrast to our observation in the E13.5 embryos (Table 3.1),
interrogating the inheritance of the modified Ctcf allele in live offspring revealed that
only 30.6% of offspring in our colony were hemizygous for Ctcf (two-tailed t-test,
p = 3.07 x 10-5; Table 4.1). This reduced transmission rate is consistent with the
genotypic ratios observed in previous studies of Ctcf deletion and suggests that
CTCF is required in a dose-dependent manner in development (Heath et al., 2008).
Table 4.1 Genotyping of Ctcf +/- mice, listed according to maternal mouse ID.
Mouse ID Total no. offspring WT (Ctcf +/+) HE (Ctcf +/-) % HE offspring
98683 7 6 1 14.29
97925 7 3 4 57.14
98684 5 3 2 40.00
AN14CUK035892 4 3 1 25.00
AN15CUK011173 5 5 0 0.00
AN15CUK011172 16 14 2 12.50
AN15CUK018388 5 3 2 40.00
AN15CUK025737 4 2 2 50.00
AN15CUK024738 4 3 1 25.00
AN15CUK024737 5 4 1 20.00
AN15CUK027700 9 7 2 22.22
AN15CUK027702 25 14 11 44.00
AN15CUK027701 13 8 5 38.46
AN16CUK002537 12 10 2 16.67
AN16CUK002539 8 6 2 25.00
AN16CUK002476 17 12 5 29.41
AN16CUK002538 18 16 2 11.11
AN16CUK002477 10 5 5 50.00
AN16CUK002535 7 6 1 14.29
AN16CUK015088 14 9 5 35.71
AN16CUK015087 19 16 3 15.79
AN16CUK015089 10 8 2 20.00
AN16CUK015086 27 14 13 48.15
AN16CUK015090 5 4 1 20.00
AN16CUK026234 8 6 2 25.00
AN17CUK002853 6 2 4 66.67
AN17CUK002854 5 2 3 60.00
Total 275 191 84 30.61
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Histological characterisation of Ctcf hemizygous mice
Given the unexpectedly low number of live Ctcf hemizygous pups based on Mendelian
principles and the suggestion that CTCF is required in a dose-dependent manner,
we questioned whether there were any developmental differences between the
genotypes. Both genotypes grew normally and were macroscopically indistinguish-
able. Although the mice had no overt phenotype, we sought to identify microscopic
differences between Ctcf hemizygous mice and their wild-type littermates. At the
time of necropsy, all major organs were dissected and processed for histological
assessment.
Tissue sections of heart, lung, brain, liver, gallbladder, pancreas, luminal gastroin-
testinal tract (oesophagus, forestomach, glandular stomach, duodenum, jejunum,
ileum, caecum, colon, rectum), kidney, adrenal gland, bladder, reproductive organs,
spleen, bone marrow, lymph nodes, and skeletal muscle were examined from all
mice in the cohort (Figure 4.1a-c). Histological examination revealed normal adult
development of all tissues and no morphological differences between genotypes.
In conclusion, and in keeping with Kemp et al. (2014), we did not identify any overt
post-natal developmental defects inCtcf hemizygous mice: pups thrived, weaned
successfully, and matured normally.
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(b) Photomicrographs of tissues from Ctcf hemizygous mice: duodenum, colon, liver,
and pancreas
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(c) Photomicrographs of tissues from Ctcf hemizygous mice: kidney, testis, spleen,
and skeletal muscle
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Fig. 4.1 Histological analysis of tissues from Ctcf hemizygous and wild-type mice.
Representative photomicrographs showing haematoxylin and eosin (H&E) stained tissue
sections from Ctcf hemizygous mice and wild-type littermates. Normal morphological
features are present in the (a) brain frontal cortex; cerebellum; left ventricle of the heart; lung;
(b) throughout the gastrointestinal tract: including duodenum, colon, liver, and pancreas;
and (c) renal cortex, testis, spleen, and skeletal muscle. All scale bars = 200 µm. Original
magnification x100.
Spontaneous tumourigenesis in Ctcf hemizygous mice
Kemp et al. (2014) reported that, with prolonged ageing, Ctcf +/- mice were markedly
predisposed to spontaneous tumour development in a broad range of tissues in-
cluding carcinomas, sarcomas, and haematological malignancies. We therefore
attempted to reproduce this tumourigenic phenotype by ageing a cohort of Ctcf hem-
izygous and wild-type mice up to 20 months old. Unexpectedly, necropsy revealed
that only six out of 36 mice developed spontaneous tumours. Five of the six mice
with neoplasms were hemizygous for Ctcf and one was wild-type (two-tailed Fisher’s
exact test, p = 0.64; Table 4.2).
At the time of necropsy, all macroscopically identified tumours were bisected:
half of the tissue was flash frozen for DNA/RNA extraction, and the remaining tissue
was processed for histopathological examination (Figure 4.2).
Table 4.2 Prevalence of spontaneous tumours in aged Ctcf hemizygous mice
Number of mice
HE (Ctcf +/-) WT (Ctcf +/+)
Tumours identified 5 1
Tumours not identified 19 11
Total 24 12
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Histopathological characterisation of hepatocellular neoplasms
Tumours were classified according to the International Harmonization of Nomen-
clature and Diagnostic Criteria for Lesions in Rats and Mice (INHAND) guidelines
(Thoolen et al., 2010). Four mice in our cohort developed liver tumours: one mouse
had three tumours and the other three mice developed solitary liver tumours (Figure
4.2). A further two mice had solitary lung tumours.
Examination of H&E-stained sections revealed that all liver neoplasms had hepa-
tocellular morphology with characteristic histological features indistinguishable from
human liver tumours. While none of these tumours had any morphological features
suggestive of cholangiocarcinoma (CC), it is possible that they could be of intermedi-
ate HCC-CC subtype. In a human diagnostic setting, this distinction can be assisted
by immunohistopathology (Maximin et al., 2014): biliary cell stains include mucin,
CK7, and CK19, while hepatocellular stains comprise polyclonal CEA, Hep Par 1,
CD10, and glypican-3 (Maximin et al., 2014). In our mouse liver tumours, CK19
staining was negative; however, the use of additional IHC was compromised since
many of the relevant antibodies are raised in mice.
Most tumours had relatively monotonous morphology with high tumour cell
percentages (>85%). Dysplastic nodules (DNs) demonstrated an expansile growth
pattern causing compression of adjacent hepatic parenchyma, loss of normal lobular
architecture, nuclear atypia, and increased mitotic activity. HCCs showed a more
abnormal spectrum of changes including thickened trabeculae, pseudoglandular
structures, more marked cellular atypia, increased nuclear to cytoplasmic ratios,
higher proliferative indices, and an infiltrative growth pattern. Some HCCs also had
areas of haemorrhage, cystic degeneration, and/or necrosis.
In order to confidently distinguish pre-invasive DNs from invasive HCCs, additional
histochemical stains and immunohistochemistry (IHC) were performed on sections
of liver lesions: reticulin staining highlighted the abnormal architecture of DNs and
was completely lost in HCCs; CD31 stained blood vessels including the endothelial
lining of sinusoid-like tumour vessels (Cui et al., 1996; Sugino et al., 2008); and
Ki67, which is expressed during mitosis and all other active phases of the cell cycle
(G1, S, G2), is a commonly used proliferation marker (Scholzen and Gerdes, 2000).
As expected, normal adult liver was mostly quiescent and all tumours showed an
increased mitotic index, most markedly in HCCs. Finally, CD45 staining was used to
assess the presence of tumour-infiltrating lymphocytes (TILs). This clearly identified
Kupffer cells and occasional circulating lymphocytes in similar numbers in normal
and neoplastic tissue. Although CD45 is a pan-leukocyte marker and not specific
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Fig. 4.2 Histological characterisation of hepatocellular neoplasms arising in Ctcf +/-
mice. Representative photomicrographs of serial sections of normal and neoplastic liver
tissue. H&E staining demonstrates tissue morphology, reticulin staining is used to assess
architecture, IHC with antibodies targeting CD31 demonstrates abnormal vasculature, Ki67
identifies mitotic cells, and CD45 identifies lymphocytes. All scale bars = 200 µm. Original
magnification x200.
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to TILs, the negative result allowed us to confidently conclude that TILs are not a
feature of these tumours.
Finally, a comparison of tumours arising in Ctcf hemizygous and wild-type mice
revealed identical morphological features. The small number of tumours did not
provide the statistical power to compare differences in the number of DNs and HCCs
arising in each genotype.
4.2.2 Hepatocyte-specific Ctcf knockdown
The hypothesis that Ctcf haploinsufficiency predisposes to carcinogenesis is based
on our in vitro data showing dysregulation of cancer pathways (presented in Chapter
3) and published evidence of an increased incidence of tumours in Ctcf +/- mice
(Kemp et al., 2014). In order to further test this hypothesis in vivo, we generated a
hepatocyte-specific Ctcf haploinsufficient mouse model and chemically induced liver
tumours in these animals.
In cell type-specific models, haploinsufficiency is present in a particular tissue or
organ so that it can be explored in isolation, negating the systemic immunological
or metabolic effects present in germline hemizygous models that might otherwise
confound the findings. We chose the liver-specific model for several reasons: (i) the
cell population is more homogeneous than other tissues (~85% hepatocytes, with
fewer fibroblasts, endothelial, and inflammatory cells); (ii) it is well characterised
by previous studies in our laboratory (Odom et al., 2007; Schmidt et al., 2010a,b;
Schwalie et al., 2013; Villar et al., 2014); (iii) we have significant experience with a
liver tumour-induction protocol (Connor et al., 2018); (iv) the liver is easily identified
at necropsy; and (v) a single mouse liver provides sufficient tissue for several assays.
Such conditional knock-out mice rely on high expression levels of a cell-type specific
protein. Since albumin is highly and uniquely expressed in hepatocytes, we exploited
B6.Cg-Speer6-ps1Tg(Alb-cre)21Mgn/J mice (Postic et al., 1999) (hereafter referred to as:
Alb-cre), which express Cre recombinase under the control of the mouse albumin
promoter, to target loxP-flanked genes in the liver. Alb-cre-positive female mice
were bred with Ctcfflox/flox males to produce hepatocyte-specific Ctcf hemizygous
knockout mice. Their wild-type littermates were used as controls (Methods).
Genotyping of ear biopsies revealed that this breeding regimen generated
the expected 1:1 Mendelian ratio of offspring, with balanced numbers of pups
with hemizygous deletion of Ctcf in hepatocytes (B6.Ctcf tm1.1Laat/Ctcf+;Speer6-
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Table 4.3 Genotyping of liver-specific Ctcf hemizygous mice. Mice are listed according to
maternal mouse ID including the total numbers of female and male offspring and genotypic
breakdown of the male mice used for experiments
Mouse ID Female mice Male mice
Total no. Total no. HE;WT HE;HE HE;HE (%)
AN15CUK011743 3 6 2 4 66.67
AN15CUK011748 2 5 2 3 60.00
AN15CUK016208 0 7 5 2 28.57
AN15CUK016492 1 9 4 5 55.56
AN15CUK016501 12 3 2 1 33.33
AN15CUK016503 5 3 1 2 66.67
AN15CUK020057 0 3 2 1 33.33
AN15CUK020059 6 4 4 0 0.00
AN15CUK020240 4 3 0 3 100.00
AN15CUK020241 5 0 0 0 -
AN15CUK020714 4 3 2 1 33.33
AN15CUK020863 9 1 1 0 0.00
AN15CUK021703 3 0 0 0 -
AN15CUK024953 4 5 2 3 60.00
AN15CUK025142 1 2 0 2 100.00
AN15CUK026801 3 5 4 1 20.00
AN15CUK027412 2 5 3 2 40.00
AN15CUK028660 5 4 1 3 75.00
AN15CUK028661 4 3 1 2 66.67
AN15CUK029396 3 7 2 5 71.43
AN15CUK029403 5 4 2 2 50.00
AN15CUK029705 4 5 2 3 60.00
AN15CUK029919 3 6 2 4 66.67
AN15CUK030711 3 5 2 3 60.00
AN15CUK030712 1 0 0 0 -
AN15CUK030713 3 2 1 1 50.00
AN15CUK030714 4 3 0 3 100.00
AN15CUK032186 6 3 2 1 33.33
AN15CUK033231 5 3 0 3 100.00
AN15CUK033233 2 2 1 1 50.00
AN15CUK033939 5 2 1 1 50.00
AN15CUK033940 4 5 1 4 80.00
AN15CUK036396 6 3 3 0 0.00
AN15CUK037934 3 3 3 0 0.00
AN15CUK037935 5 1 1 0 0.00
AN15CUK040215 3 4 2 2 50.00
AN15CUK041041 7 0 0 0 -
AN15CUK045623 0 6 4 2 33.33
AN16CUK000627 3 5 3 2 40.00
AN16CUK000628 3 4 2 2 50.00
AN16CUK000972 6 3 3 0 0.00
AN16CUK001248 5 4 3 1 25.00
AN16CUK001251 4 11 6 5 45.45
AN16CUK001256 1 2 2 0 0.00
AN16CUK001257 4 7 5 2 28.57
AN16CUK001258 3 6 4 2 33.33
AN16CUK001263 6 2 1 1 50.00
AN16CUK001264 3 7 3 4 57.14
AN16CUK001265 4 4 3 1 25.00
AN16CUK002780 0 4 4 0 0.00
AN16CUK002782 0 6 4 2 33.33
AN16CUK005346 0 3 2 1 33.33
AN16CUK005348 0 5 5 0 0.00
AN16CUK009302 2 4 2 2 50.00
AN16CUK009304 2 4 3 1 25.00
Total 191 216 120 96 44.44
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ps1Tg(Alb-cre)21Mgn, "HE;HE") and wildtype littermates (B6.Ctcf tm1.1Laat/Ctcf+, "HE;WT")
(two-tailed t-test, p = 0.104, Table 4.3).
Since Ctcf gene expression in the liver was inferred from genotyping the presence
or absence of the germline Alb-Cre status, it was essential to confirm recombinase
efficacy in the liver. Genomic DNA from the tail and liver was analysed by qPCR,
which confirmed successful recombination of the genetically altered Ctcf locus in
liver tissue but not in the tail (Figure 4.3A). CTCF protein levels were quantified by
western blotting, which demonstrated reduced CTCF expression in liver compared
with pancreas and lung (Figure 4.3B). More specifically, IHC for CTCF protein in
liver tissue demonstrated depleted expression in hepatocytes but not in endothelial
cells, Kupffer cells, or lymphocytes (Figure 4.3C).
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Fig. 4.3 Hepatocyte-specific Ctcf knockdown. Validation experiments showed that
hepatocyte-specific Ctcf knockdown was successful. Recombination of the Ctcf allele
from genomic DNA was demonstrated, and consequently there was reduced CTCF protein
expression in hepatocytes. (A) Expected PCR product sizes for wild-type Ctcf (WT), Ctcf
with loxP sites (flox), and excised Ctcf (KO) are shown for control samples from wild-type
(WT) mice, heterozygous (HE), or homozygous (HO) for floxed Ctcf alleles. Recombination
of the Ctcf allele in genomic DNA from the tail (T) and liver (L) is shown for WT and HE
mice in the presence (+) or absence (-) of Alb-cre. (B) Western blots show tissue-specific
reduction in CTCF protein expression in the liver compared with pancreas and lung. (C)
Immunohistochemistry for CTCF in liver tissue from mice heterozygous for the floxed Ctcf
allele in the absence (-) and presence (+) of Alb-cre, demonstrating a hepatocyte-specific
reduction in CTCF expression.
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4.2.3 Tumour induction using diethylnitrosamine
We recently characterised the exome-wide pattern of mutations in diethylnitrosamine
(DEN)-induced tumours from C3H mice and found that: (i) DEN-induced neoplasms
arising in the same mouse evolved independently; (ii) the tumours had a high,
uniform number of somatic single nucleotide variants (SNVs); (iii) DEN exposure
created a distinct mutational signature; and (iv) Hras was the predominant, although
not obligatory, oncogenic driver of hepatocellular tumours (Connor et al., 2018). We
have now employed a similar approach in hepatocyte-specific Ctcf hemizygous and
wild-type mice on a C57BL/6J background and applied whole-genome sequencing
(WGS) to gain insights into the genome-wide mutational landscape and to explore
the impact of Ctcf hemizygosity in this model.
Chemically-initiated liver tumours were generated by treating 15 day-old male
mice with a single intra-peritoneal dose of DEN and aged until tumours developed
(Methods). Mice were euthanised, full necropsies were performed, livers were
isolated, and tumours were dissected together with adjacent normal tissue. Half of
the tumour was flash frozen (FF) for DNA/RNA extraction and sequencing, and the
other half (with adjacent normal tissue) was processed in parallel for histological
examination (Figure 4.4).
C57BL/6 mice are relatively resistant to tumourigenesis (Puccini et al., 2013),
and the literature reports a broad range in tumour latency after the administration of
DEN (Verna et al., 1996). For this reason, we performed an initial pilot experiment to
establish the optimal time-points to collect tumours from our mouse cohort (Table
4.4). Based on this, we selected 36 weeks post-treatment as the primary time to
collect samples: this was the earliest time at which we could confidently expect to
Fig. 4.4 Overview of tumour induction protocol. 15 day-old mice were treated with
diethylnitrosamine (DEN) and aged until tumours developed. The liver was isolated, and
tumours were dissected along with adjacent normal tissue. Tumours were bisected and
processed in parallel for histological assessment and genome sequencing.
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find tumours of adequate size to provide enough tissue to be bisected and processed
in parallel for both histological assessment and genomic characterisation. In addition,
we aged 20 mice of each genotype to 42 weeks post-treatment to see whether the
phenotypic differences between the two genotypes became more pronounced with
prolonged ageing.
Table 4.4 Pilot experiment to determine the optimal time point for sample collection. Two
mice were euthanised at each time point to assess the number of liver tumours. *the second
mouse was excluded due to an unrelated health concern.
Weeks post-DEN Wild-type Ctcf hemizygous
treatment No. mice No. with tumours No. mice No. with tumours
19 2 0 2 0
23 2 0 2 0
27 2 2 1* 1
29 2 1 2 1
31 2 2 2 1
33 2 1 2 2
35 2 2 2 2
Mice of both genotypes developed multiple discrete tumours by 36 weeks after
DEN treatment, concordant with previous studies (Heindryckx et al., 2009). Mice
were euthanised and tumours collected either 36 or 42 weeks after treatment. Mouse
body and organ weights were recorded at necropsy. Liver-specific Ctcf hemizygous
mice aged for 42 weeks were heavier (mean 42.5 g) than their wild-type litter
mates (mean 39.4 g, two tailed t-test, p = 0.049, Figure 4.5A).This was even more
pronounced in the liver weights (4.5 g vs. 3.3 g, two tailed t-test, p = 0.007, Figure
4.5B). There was no difference in the weights of the brains, hearts, or kidneys
There was a wide range in the frequency (1 - 43 tumours per mouse) (Figure
4.5C) and size (1 - 23 mm diameter) of tumours isolated from mice of both genotypes
(Figure 4.5D). At each time point, the total number of tumours (two tailed t-test at
36 weeks, p = 0.73 and 42 weeks, p = 0.33), number of tumours large enough (>2
mm) to sample (p = 0.40, p = 0.15), average tumour size (p = 0.94, p = 0.30), and
tumour burden (calculated as cumulative tumour diameter, p = 0.77, p = 0.07) were
comparable between the two genotypes.
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Fig. 4.5 DEN-initiated tumour characteristics. Wild-type (WT, grey) and liver-specific Ctcf
hemizygous (HE, red) mice were treated with DEN. Liver tumours were sampled 36 weeks
(round markers) or 42 weeks (square markers) after treatment. (A) Mouse body weight (g) at
time of necropsy. (B) Total liver weight, including tumours, at time of necropsy. (C) Number
of tumours identified macroscopically, frequency of tumours plotted per mouse. (D) Liver
tumour diameter, measured at necropsy. Bars indicate mean +/- SD. Two tailed t-tests, * p <
0.05.
4.2.4 Pathological characterisation of DEN-induced tumours
All macroscopically identified tumours were processed for histological assessment us-
ing the same INHAND criteria described above (Thoolen et al., 2010). DEN-induced
tumours all had a hepatocellular phenotype, and the full spectrum of pathologi-
cal entities were present across the cohort including microscopic basophilic and
eosinophilic foci of cellular alteration (phenotypically distinct hepatocytes that are
potential neoplastic precursors), low- and high-grade dysplastic nodules, and well-,
moderately-, and poorly-differentiated HCCs. A subset of tumours had a nodule-
in-nodule appearance, supporting the hypothesis of stepwise progression from DN
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Fig. 4.6 Histology of hepatocellular neoplasms. Representative photomicrographs of
serial sections of normal liver tissue and indistinguishable liver tumours arising in DEN-
treated and untreated mice (DN: dysplastic nodule; HCC: hepatocellular carcinoma). H&E
staining demonstrates tissue morphology; reticulin staining is used to assess architecture;
and Ki67 identifies mitotic cells. All scale bars = 200 µm. Original magnification x200.
Adapted from Connor et al. (2018).
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to HCC (Nam et al., 2005). Tumours arising in wild-type mice and those from Ctcf
hemizygous mice were indistinguishable. Furthermore, DEN-induced tumours were
histologically indistinguishable from spontaneous tumours (Figure 4.6).
HCC in humans usually occurs in the context of chronic inflammation (El–Serag
and Rudolph, 2007). In contrast, there were only scattered lymphocytes present in
the tumours and background liver of both genotypes in our DEN-treated cohort, with
no significant immune component in the tumours (Schneider et al., 2012). A subset
of tumours had prominent extramedullary haematopoiesis (EMH), which is a normal
feature of liver physiology in adult C57BL/6 mice (Thoolen et al., 2010).
Macroscopically, livers from Ctcf hemizygous mice appeared, on average, paler
than their wild-type littermates. This was also reflected in the microscopic appear-
ance of the background liver but not the tumours (Figure 4.7). This is in keeping with
the finding that Ctcf hemizygous mice had heavier, fattier livers and higher overall
bodyweight.
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Fig. 4.7 Macroscopic and microscopic appearance of DEN-initiated liver tumours.
Macroscopically, the liver parenchyma of Ctcf hemizygous mice was paler than their wild-type
littermates and the visceral surface had a "nutmeg" appearance. Microscopic appearance
(H&E) of the background liver of Ctcf hemizygous mice showed steatotic changes, but HCCs
were indistinguishable between genotypes. Macroscopy scale bars = 10 mm. Microscopy
scale bars = 200 µm, original magnification x200.
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4.2.5 Genomic characterisation Ctcf hemizygous liver tumours
Patients with liver cancer often present with late-stage disease and multiple liver
tumours; most commonly one primary HCC with multiple intra-hepatic metastases,
but synchronous multi-focal primary tumours also occur (Zeng et al., 2012). In our
mouse model, most individuals also developed more than one liver tumour following
DEN treatment (mean = 8 tumours (36 weeks), 16 tumours (42 weeks), Figure
4.5C). However, unlike their human counterparts, we recently demonstrated that
these DEN-induced tumours initiate and evolve independently, since tumours arising
from the same DEN-treated mouse were as genomically divergent as those isolated
from separate mice (Figure 4.8 (Connor et al., 2018)). Therefore, in this project we
considered each tumour, rather than each mouse, as an independent sample.
In Chapter 3 we showed that Ctcf hemizygosity dysregulates cancer pathways,
allowing us to hypothesise that conditional Ctcf knockdown in the liver would have a
molecular phenotype when treated with DEN. Therefore, WGS was performed on a
total of 96 samples; whenever possible, a paired normal liver sample and tail/ear from
the same mouse was included in addition to the tumours. All of the spontaneously
occurring liver tumours and a subset of mouse samples collected 36 weeks after
treatment with DEN (Methods) were included. Six Ctcf hemizygous and six wild-
type mice were selected and, for each of these mice, DNA was sequenced from 4-6
tumours (including DNs and HCCs from each mouse), background DEN-exposed
liver tissue, and a tail sample. The non-tumour liver samples were included to assess
the background mutational burden persisting in tissue that had been exposed to
the active metabolite but had not undergone neoplastic clonal expansion. The tail
samples were included to identify germline SNPs or other artefacts resulting from
the compound or genetically altered mouse line. We did not expect any DEN-related
genomic variants in the latter samples, since DEN is metabolised to its active form by
cytochrome P450 enzymes (Kang et al., 2007) in centrilobular hepatocytes (Oinonen
and Lindros, 1998), where the resulting DEN metabolites directly damage DNA by
alkylating nucleobases (Verna et al., 1996).
The SNV rate was calculated for each tumour to compare the frequency of muta-
tions in Ctcf hemizygous and wild-type tumours. The mutation rate (28.5/Mb) was
the same in DEN-induced tumours arising in Ctcf hemizygous and wild-type tumours
(Figure 4.9A). This very high mutational burden was in stark contrast to the very low
frequency of SNVs in spontaneously arising tumours, in spite of indistinguishable
histopathology, similar to that observed in human liver cancers (Schulze et al., 2015).
Tumours of both genotypes had very few somatic indels or copy number variants
4.2 Results 101
Fig. 4.8 Independent evolution of DEN-induced liver tumours is revealed by their
unique SNV profiles. Connor et al. (2018) sampled liver tumours 25 weeks after DEN
treatment. (A) Whole exome sequencing of nine nodules isolated from a single liver, and
single nodules from seven other mice was performed. To evaluate technical noise, triplicate
sequencing libraries were prepared for a single nodule. (B) A phylogenetic tree was con-
structed in R using the ape package (v3.5 (Paradis et al., 2004)), in which branch lengths
correspond to the number of unshared SNVs (Saitou and Nei, 1987). Long branch lengths
indicate no relatedness among the nodules within a single mouse, whereas three replicate li-
braries from the single tumour had short branches, indicating few SNV differences. Branches
are labelled using mouse/tumour identification codes. Adapted from Connor et al. (2018).
(CNVs), again consistent with findings in human tumours in which the number of
copy number alterations in a sample is approximately anticorrelated with the number
of somatic mutations in a sample (Ciriello et al., 2013).
We also compared the mutation rate in dysplastic nodules and invasive HCCs, but
again there was no significant difference between the groups. The similar mutation
rate between DNs and HCCs may be because the vast majority of somatic variants
in both tumour types are caused by an initial single burst of mutagenesis upon
DEN exposure in the originating cell. Only a small number of additional secondary
driver mutation(s) are necessary for a DN to progress to a HCC, and this acquisition
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and subclonal expansion may be masked by the very high burden of pre-existing
passenger SNVs in the DEN-initiated DNs.
Notably, the high mutational burden of SNVs found in the DEN-initiated tumours
was comparable to human cancer cohorts with strong mutagenic drivers such as
lung cancer and melanoma, where tobacco and UV light, respectively, are known to
cause a very high prevalence of somatic mutations (Alexandrov et al., 2013).
The SNV rate varied markedly across the cohorts, so we considered whether
tumours arising from a single mouse might have a similar mutational burden, either
due to dysregulation of a DNA repair pathway (causing a hyper-mutation effect) or
due to technical error in the administration of DEN. We found that the frequency of
somatic variants was very consistent between tumours arising in a single mouse, with
a small proportion of tumours in each mouse accounting for the spread in the data
(Figure 4.9B). Again, the twenty-fold difference in SNV rate between DEN-induced
and spontaneously arising tumours was conspicuous.
4.2.6 Distinct mutational signatures of liver tumours
DEN is metabolised to its active form by cytochrome P450 enzymes (Kang et al.,
2007) in centrilobular hepatocytes (Oinonen and Lindros, 1998), where the resulting
DEN metabolites can directly damage DNA by alkylating nucleobases (Verna et al.,
1996). We have shown experimentally that the promutagenic O6-ethyl deoxyguano-
sine adduct accumulates in zone 3 hepatocytes within four hours of treatment with
DEN in mice (Connor et al., 2018).
DEN-initiated tumours in both Ctcf hemizygous and wild-type mice had distinct
and reproducible mutational profiles including all possible somatic base substitutions.
Transitions and transversions at A and T base pairs were especially prominent
(Figure 4.10A), consistent with persistent alkylated thymidine lesions caused by
metabolically activated DEN (Verna et al., 1996). More specifically, these transver-
sion events occurred more frequently when the T (or A) was preceded by a C
(or A) and followed by a T (or G). In contrast, there was a paucity of C:G to G:C
transversions in DEN-treated samples.
Tumours arising spontaneously in untreated mice not only had far fewer SNVs
but also had a different distribution of mutations that was dominated by C:T variants.
The mutational pattern in spontaneously arising tumours was very heterogeneous,
analogous to the portraits observed in human HCCs (Figure 4.10A), which show
marked aetiological and molecular heterogeneity (Letouzé et al., 2017).
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Fig. 4.9 DEN-initiated neoplasms have a high SNV burden. The single nucleotide variant
(SNV) frequencies are shown for each mouse and human liver tumour cohort. These include
DEN-induced dysplastic nodules (DNs, n = 52) and hepatocellular carcinomas (HCCs, n = 14)
arising in Ctcf hemizygous (red, n = 34) and wild-type mice (grey, n = 32), and spontaneous
tumours (blue, n = 6) arising in untreated mice. Previously reported human HCC (green,
n=50) samples are shown for comparison (ICGC LICA-FR). Each point represents a single
tumour sample. (A) The mutation rate is the same in Ctcf hemizygous and wild-type tumours,
and there is no difference between the mutation rate between DNs and HCCs. Spontaneous
mouse tumours have a comparable SNV rate to human HCCs. (B) SNV frequency varies
between tumours arising in the same mouse liver. Mice are ranked according to median
SNV count from highest (left) to lowest (right), showing that tumours do not cluster according
to genotype. Multiple tumours were sequenced from each mouse, those from the same
mouse are coloured as follows. WT: 15/27262 (red), 15/31651 (orange), 15/33905 (yellow),
15/39018 (green), 15/44043 (blue), 15/44203 (purple); Ctcf hemizygous: 15/41619 (red),
15/44139 (orange), 15/44139 (yellow), 15/44042 (green), 15/44044 (blue), 15/44198 (purple);
Spontaneous: 14/34745 (red), 14/34747 (orange), 15/28671 (green), 15/29027 (purple).
Hierarchical clustering of the tumours according to the 96 possible trinucleotide
substitution contexts showed a consistent mutational pattern shared between tu-
mours arising in Ctcf hemizygous and wild-type mice exposed to DEN. The phy-
logenic tree demonstrated that tumours from the same mouse were no more or
less similar than tumours from another individual mouse (Figure 4.10B). In contrast,
the distribution of mutations occurring in spontaneously arising tumours is more
heterogeneous and, although the sample size is small, it is clearly distinct from the
mutational imprint of carcinogen-initiated neoplasms.
104 Genetic and chemical models of hepatocarcinogenesis
Given this distinct mutational pattern, we sought to define a "DEN signature"
reflecting the consequence of exogenous DEN treatment and the DNA damage,
repair, and replication that follows. Since our sample size was too small to derive
de novo signatures, we reconstructed composite signatures using the profiles of
known mutational signatures (Alexandrov et al., 2013; Nik-Zainal et al., 2012). The
current set of thirty mutational signatures is based on an analysis of 10,952 exomes
and 1,048 whole-genomes across forty distinct human cancer types (Alexandrov
et al., 2015). The proportions of COSMIC mutational signatures (Forbes et al.,
2017) represented in the mutational profile from each sample were calculated
using the R package deconstructSigs (Rosenthal et al., 2016). Reconstruction of
mutational portraits for each DEN-induced tumour from both wild-type and Ctcf
hemizygous mice demonstrated that they were composed almost entirely of six
COSMIC signatures (Figure 4.11). In contrast, spontaneous tumours in mice and
HCCs in the human (ICGC LICA-FR) cohort were more heterogeneous.
The six COSMIC signatures that dominated the "DEN signature" were 8, 12,
21, 22, 24, and 30, half of which are found in human liver cancers: signature 12,
signature 22, and signature 24. Two of these are particularly interesting, since their
proposed aetiologies are clinically tractable to exogenous exposures. Signature 22
has been found in cancers with known patient exposures to aristolochic acid and is
also consistent with profiles seen in experimental systems exposed to aristolochic
acid, and signature 24 has been found in samples with known exposures to aflatoxin
(Fujimoto et al., 2016; Letouzé et al., 2017; Schulze et al., 2015). Although signature
12 does not have a proposed aetiology, it usually only contributes a small percentage
(<20%) of the mutations observed in a liver cancer sample. None of the remaining
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Fig. 4.11 Mutational signatures of DEN-induced and spontaneous tumours. Mutational
portraits of individual mouse and human liver tumours reconstructed using COSMIC muta-
tional signatures. Each column shows the composition of signatures in an individual sample.
DEN-induced tumours from both wild-type and Ctcf hemizygous mice showed reproducible
portraits largely composed of six component COSMIC signatures. In contrast, spontaneous
tumours in mice and HCCs arising in the human cohort were more heterogeneous.
4.2.7 Braf is the predominant driver of DEN-induced hepatocar-
cinogenesis
All carcinogen-induced tumours carried a high burden of somatic mutations due
to the known genotoxic action of DEN. These mutations were widely distributed
across the genome of tumours arising in both Ctcf hemizygous and wild-type mice.
Potential coding changes were detected in the majority (15,093) of protein-coding
genes across the complete dataset, of which 7,257 were common to both genotypes.
Identifying bona fide cancer drivers in the context of such a dense background
mutational load is challenging and requires the combination of tractable experimental
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models (Bakiri and Wagner, 2013) and the application of advanced computational
biology approaches (Martincorena et al., 2017).
In order to identify putative driver genes in this cohort of DEN-initiated tumours,
we identified cancer genes (Vogelstein et al., 2013) carrying non-synonymous protein-
coding mutations more frequently than expected (Figure 4.12), with additional weight
being given to genes with recurrent hotspot SNVs (Table 4.5).
Braf was the most highly mutated gene in carcinogen-induced tumours and was
mutated in 58.8% of Ctcf hemizygous (20/34) and 59.4% of wild-type tumours (19/32;
two-tailed Fisher’s exact test, p = 1). Hras was also significantly mutated in tumours
from mice with both genotypes; in 17.6% of Ctcf hemizygous (6/34) and 15.6% of
wild-type (5/32) tumours (two-tailed Fisher’s exact test, p = 1) (Appendix B). The
predominant activating Braf mutation in both Ctcf genotypes was caused by an A:T
to T:A transversion at the second base of codon 637 in Braf, which causes a valine
to glutamic acid substitution (V637E), in keeping with previous studies in C57BL/6
mice (Buchmann et al., 2008). The mouse Braf V637E mutation is orthologous to
the human BRAF V600E mutation (Rad et al., 2013), which is frequently detected
in certain human cancers including approximately 50% of melanomas (Ascierto
et al., 2012). Although rarer, the Hras mutations occurred almost exclusively at one
hotspot, codon 61, most commonly a glutamine to arginine substitution caused by
an A:T to G:C transition in the second base, consistent with the formation of one
of the major promutagenic adducts, O4-ethyl-thymine, by DEN metabolites. In the
more hepatocarcinogenesis-susceptible C3H mice, we found that these Hras codon
61 mutations were more prevalent than Braf mutations (Connor et al., 2018).
Spontaneously arising tumours had a much lower mutational burden, most
frequently occurring in Ctnnb1 (Figure 4.12, Table 4.5). A putative driver mutation
could not be identified for two tumours, reflecting the polyclonal composition of the
spontaneous tumours and/or involvement of other genetic or epigenetic alterations
during tumourigenesis.
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Fig. 4.12 DEN-initiated liver tumours carry Braf and Hras mutations. DEN-initiated liver
tumours carry recurrent activating mutations in Braf and Hras in both Ctcf hemizygous and
wild-type mice. In addition, there is diversity in non-synonymous SNVs in many other cancer
genes. Each column represents a mouse tumour sample and each row a gene showing the
occurrence of somatic variants in individual samples. Genes mutated in at least two samples
are shown. All plots include the top seven genes mutated in other rodent tumours: Hras,
Braf, Egfr, Kras, Apc, Ctnnb1, Keap1 (unpublished data; indicated with * if not significant).
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Table 4.5 Hotspot mutations in validated oncogenes and tumour suppressor genes. The
frequency of tumours with non-synonymous SNVs in putative driver genes is given for each
mouse cohort.
Driver Mutation DEN-treated mice Spontaneous
gene hotspot Wild-type Ctcf +/- tumours
Braf V637E 19 19 0E205G 0 1 0
Hras
Q61R 4 3 0
Q61K 1 2 0
I24N 0 1 0
Egfr
F254I 3 2 0
F150I 1 0 0
I541N 0 1 0
C506R 1 0 0
M827T 1 0 0
L885* 1 0 0
M1009K 1 0 0
Kras Q61R 2 4 0I21T 1 0 0
Ctnnb1
T41A 1 0 1
S33F 0 0 1
G34R 0 1 0
S45F 0 0 2
L46Q 0 0 1
N121K 0 1 0
I140T 0 1 0
C213* 0 1 0
W383R 1 0 0
V438E 1 0 0
Apc
I402N 1 1 0
T928I 1 0 0
Y1029N 0 1 0
S1200P 0 1 0
C1725S 0 1 0
Keap1 M456V 0 1 0C273R 0 1 0
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4.2.8 Apc is a secondary driver in mouse HCC
Given the high frequency of potentially consequential non-synonymous somatic vari-
ants, including in known oncogenes and tumour suppressor genes, the identification
of secondary drivers was challenging. However, WGS of the thirteen DEN-initiated
HCCs revealed that six of these had missense mutations in Apc and an additional
six harboured β -catenin mutations (Figure 4.12). In contrast, these mutations were
not found in pre-invasive dysplastic nodules. Furthermore, two thirds (4/6) of the
spontaneously arising tumours had missense β -catenin mutations. This is compara-
ble to human HCC cohorts in which the WNT/β -catenin pathway is disrupted in 54%
of patients (Schulze et al., 2015).
The highly conserved WNT/β -catenin pathway is complex and can be perturbed
in a number of ways (Chien et al., 2009). β -catenin protein, encoded by CTNNB1, is
physiologically present in cells in three distinct pools: at cellular adherens junctions,
in the cytoplasm, and in the nucleus (White et al., 2012). Cytoplasmic and nuclear
β -catenin are maintained at low baseline levels by cytoplasmic phosphorylation of
the N-terminus of β -catenin by a complex of proteins including APC (Yost et al.,
1996). However, this process is imbalanced by canonical Wnt signalling, which
prevents the degradation of β -catenin and causing it to accumulate in the cytoplasm,
translocate to the nucleus, and in turn trans-activate target genes responsible for
diverse processes including differentiation, proliferation, migration, and adhesion
(White et al., 2012).
In order to assess whether the Apc mutations in our tumour cohort disrupted
the Wnt/β -catenin pathway, IHC was performed on tissue sections using antibodies
targeting β -catenin. All Apc-mutant tumours showed aberrantly elevated nuclear
β -catenin (Figure 4.13), while, as expected, the same IHC on DNs and HCCs with
wild-type Apc and Ctnnb1 showed normal membranous staining. These data support
the hypothesis that mutant Apc disrupts the canonical Wnt/β -catenin pathway to
play a role in the progression to carcinoma in this model.
4.2.9 CTCF binding sites are enriched for mutations
Human cancer studies have highlighted that the somatic mutation rate is unevenly
distributed across the genome (Lawrence et al., 2013) and is associated with tran-
scriptional activity, the chromatin state, replication timing, and nuclear topology. In
particular, regulatory sites show elevated substitution rates in cancers (Kaiser et al.,
2016), most notably CTCF/cohesin-binding sites (Katainen et al., 2015; Sabari-
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Fig. 4.13 Immunohistochemical validation of Apc mutations. Representative photomi-
crographs of serial tissue sections of DEN-induced HCCs. H&E staining demonstrates
similar tumour morphology in tumours with wild-type Apc (left panels) and Apc mutations
(right panels). IHC using antibodies targeting β -catenin protein demonstrates aberrantly
elevated nuclear β -catenin protein expression in tumours with mutant Apc. All scale bars =
200 µm. Original magnification x100. These data are presented in a similar form in Connor
et al. (2018)
.
nathan et al., 2016). The underlying mechanisms are not fully understood (Flavahan
et al., 2017; Stricker et al., 2016), although the high mutational burden observed
in protein-bound DNA regions of melanomas is proposed to be due to impaired
nucleotide excision repair (Sabarinathan et al., 2016).
Whole genome sequencing of our mouse liver tumour cohorts demonstrated a
very high mutational burden that was non-uniformly distributed across the genome
and that showed distinct mutational signatures, as described above. The distribution
of mutations in tumours arising in both wild-type and Ctcf hemizygous mice recapitu-
lated the features identified in previous analyses of human cancer cohorts (Frigola
et al., 2017; Liu et al., 2013a; Park et al., 2012). The mutation rate was lowest in
early replication timing regions of the genome and highest in late replication timing
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regions, the SNV rate was anti-correlated with gene expression levels, and the SNV
rate was lower in exons compared to introns.
Next, we focussed on mutations arising in the immediate vicinity of CTCF binding
sites. All CTCF binding sites across all tumours of the same genotype were centred
on their core CTCF motif, and mutations were quantified 400 bp upstream and
downstream of these regions. This analysis showed that the mutation rate was
elevated at the centre of the CTCF motif compared with its flanking regions (Figure
4.15). The frequency of observed mutations was significantly greater than the
expected probability rate of mutations based on their trinucleotide context. Within the
flanking regions, there was an oscillating distribution of mutations with a periodicity
that correlated well with nucleosome positioning. There was no significant difference
between the mutation rate or distribution between the two Ctcf genotypes. Next,
using our CTCF ChIP-seq data from liver tissue, all CTCF binding sites were grouped
into quartiles according to their affinity score and the number of somatic variants at
each of these sites quantified. Higher affinity CTCF binding sites also accumulated
a greater number of SNVs in both genotypes (Figure 4.14).
Fig. 4.14 CTCF binding affinity correlates with mutational burden. CTCF sites identified
from ChIP-seq data in liver tissue were binned in quartiles according to number of read
counts, and mutational burden was quantified for each site. Sites with stronger CTCF
binding harbour more mutations than those with weaker CTCF binding. This is consistent
with Sabarinathan et al. (2016), who showed that DNA motifs with high-affinity binding of
transcription factors have a lower rate of DNA repair and thus accumulate more mutations.
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Fig. 4.15 CTCF binding sites are hypermutated. (A) The total (pale red) and average
(dark red) number of observed mutations are shown at CTCF binding sites +/- 400 nt. The
predicted mutation rate, based on trinucleotide context, is shown in black. Mutation rate
is elevated at the CTCF motif compared with the flanking sites. There is a periodicity to
the mutation rate in flanking regions which correlates with nucleosome positioning (DNA
wrapped around a nucleosome is ~146 nt). (B-C) Mutation rate at each base within the core
CTCF motif. (B) The observed frequency of mutations (red) varies across the CTCF motif
and is not explained by the trinucleotide context-predicted mutation rate (black). (C) Nature
of mutated nucleotides at each position of the CTCF motif. (D) The underlying CTCF motif.
4.2.10 Carmil2 is overexpressed in Ctcf hemizygous tumours
To characterise the transcriptional consequences of chemically inducing liver tu-
mours in Ctcf hemizygous mice, total RNA sequencing of the same tissues was
undertaken. As expected, Ctcf expression levels in the background liver tissue of
DEN-exposed mice remained lower in hemizygous mice compared to their wild-type
littermates (Figure 4.16A). Surprisingly, however, although all Ctcf isoforms had
lower expression in Ctcf +/- tumours compared to wild-type tumours, the difference
was no longer significant (q value = 0.435). After correcting for multiple testing,
only four genes were significantly differentially expressed between DEN-induced
tumours of each genotype: Carmil2 (log2 fold change = 3.68), Fbxo6 (log2 fold
change = 0.89), Nudt11 (log2 fold change = 2.79), Mnd1 (log2 fold change = 0.66,
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Figure 4.16B). Of note, Carmil2, which is very significantly overexpressed in Ctcf
hemizygous tumours, lies less than 3.5 kb downstream of Ctcf and is transcribed in
the same direction. In these mice, coding exons 3 - 12 have been excised in one
allele but exons 1 and 2 are still present (although noncoding). It is possible that
the overexpression of Carmil2 this is due to transcriptional read-through from the
promoter of the genetically altered Ctcf locus.
Fig. 4.16 Differential gene expression in liver and DEN-induced tumours. (A) Ctcf gene
expression in liver tissue from wild-type (grey) and Ctcf hemizygous (red) 15-day-old mice
(time 0) and non-tumour liver tissue 36 weeks after mice were treated with DEN. There is a
significant reduction in Ctcf at both time points. (B) Differential gene expression analysis of
total RNA-sequencing of DEN-induced tumours in Ctcf hemizygous versus wild-type mice
revealed that only four genes are significantly differentially expressed (red): Carmil2, Fbxo6,
Nudt11, and Mnd1, as indicated. Log2 fold change of median expression differences are
plotted against -log10 q value.
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CTCF is a principal nuclear protein that is essential for chromatin organisation and
necessary for embryonic development. We and others (Heath et al., 2008) have
shown that genetically-engineered mice with a germline deletion of one Ctcf allele
have reduced transmission and/or survival of Ctcf hemizygous embryos compared
to wild-type littermates. Surviving Ctcf hemizygous mice did not display any overt
post-natal developmental defects: pups thrived, weaned successfully, and matured
normally despite having lower CTCF expression. We also generated hepatocyte-
specific Ctcf hemizygous mice and, in this instance, there was no detrimental
impact on survival of the offspring. These mice were challenged with a potent
carcinogen and, although there was no influence of the genotype on tumourigenesis,
hemizygous mice showed a subtle phenotype of higher body and liver weights than
their wild-type littermates after ageing.
In contrast to prior findings that CTCF haploinsufficiency predisposes to cancer
(Kemp et al., 2014), our mouse cohort with hemizygous deletion of Ctcf did not
have an increased incidence of spontaneous neoplasms compared to their wild-type
littermates. However, far fewer tumours were found overall in our cohort compared
with the Kemp et al. study. There are at least three possible explanations for these
differences. First, Kemp et al. performed a survival study and, as such, were able
to generate Kaplan Meier curves extending to later timepoints than in our study.
Several of our mice developed health concerns at 18 - 20 months that meant that we
had to use this as our fixed end point (due to Procedure Project Licence constrains).
It is likely that, had we been able to extend our study, the tumour incidence in the
population as a whole would have been higher and it is possible that there would have
been differences between the genotypes. Second, our study was performed using
C57BL/6J mice (the Ctcf deletion was originally engineered in a hybrid C57BL6/129
mouse but has now been back-crossed on a C57BL/6J background for over twenty
generations), whereas the Kemp et al. study was carried out using C57BL6/129 F1
Ctcf +/- mice. C57BL/6 mice are refractory to many tumour types (Puccini et al., 2013),
so the relatively more tumour-resistant genetic background used here may have
delayed a tumourigenesis phenotype beyond the duration of our study or masked a
more subtle phenotype. Finally, we only included male mice in our study whereas
Kemp et al. used both male and female mice. Overall, liver tumour incidence is
three-times higher in male mice than female mice, and this is reflected in the findings
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of these two studies. However, many of the tumours in Kemp’s study were uterine
tumours, which were of course not present in our male cohort.
The Ctcf hemizygosity model was challenged with DEN, a potent genotoxin.
Such chemical carcinogen-initiated mouse models of liver cancer are important
tools that are widely used to study the molecular pathogenesis of human HCC
(Heindryckx et al., 2009). Genomic and transcriptomic studies have provided detailed
characterisation of the aberrations found in the human disease (Ally et al., 2017;
Fujimoto et al., 2016; Letouzé et al., 2017; Schulze et al., 2015, 2016; Zucman-Rossi
et al., 2015), and it is important to have similar analyses from mouse models to
inform human disease studies (Nassar et al., 2015; Westcott et al., 2014). Mice of
both genotypes, Ctcf +/- and Ctcf +/+, developed multiple liver tumours by 36 weeks,
and the frequency and size of tumours was independent of the mouse genotype. Of
note, liver-specific Ctcf hemizygous mice aged for 42 weeks were, on average, 3.1 g
heavier than their wild-type littermates, and the liver weights were also higher in the
hemizygous mice. Tumour burden (both number and size of tumours) was equal in
each genotype, suggesting that there was a genuine increase in the parenchymal
liver weight. Increased liver weight accounted for over a third of the total body weight
difference (1.2 g) between genotypes. Furthermore, at necropsy, Ctcf hemizygous
mice had a pale "nutmeg" appearance to the visceral surface of the liver and a
marked increase in intra-abdominal visceral fat. These subjective observations
were not quantified in this series of experiments due to difficulties in applying a
histochemical stain (oil red-O) to quantify fat. However, these differences - suggestive
of fatty liver disease - could be due to hepatocyte-specific Ctcf hemizygosity causing
either (i) steatosis resulting in fatty liver disease and subsequent weight gain due
to dysregulated fat metabolism, or (ii) increased appetite/food consumption in turn
leading to steatosis.
Whole genome sequencing revealed that, overall, the distribution of mutations
in this carcinogen-initiated mouse model was consistent with results from human
cancer sequencing studies. The SNV frequency was significantly higher in late DNA
replication timing regions (Liu et al., 2013b), anti-correlated with gene expression
levels (Park et al., 2012), and lower in exons compared with introns (Frigola et al.,
2017). We confirmed that Braf is the predominant, although not obligatory, oncogenic
driver of hepatocarcinogenesis in 15-day-old male C57BL/6J mice administered
a single dose of DEN. Hras also harboured recurrent mutations, and many other
oncogenes and tumour suppressor genes contained more sporadic SNVs. Apc
was implicated as a secondary driver mutation since it was mutated in HCCs but
4.3 Discussion 117
not DNs, and these Apc-mutant tumours expressed aberrant levels of nuclear β -
catenin. This is noteworthy because the WNT/β -catenin pathway is altered in 54%
of human HCCs, second only to TERT promoter mutations activating telomerase
expression (Schulze et al., 2015). Spontaneous and DEN-induced tumours were
macroscopically and microscopically indistinguishable but showed very different
molecular signatures. Although the DEN model of tumourigenesis does not perfectly
mimic the molecular portraits of the human disease, it may be a useful model in
certain scenarios. In particular, this genomic study highlights the importance of
undertaking molecular characterisation of mouse models in order to select the
optimal model for a given scientific question. For example, pre-clinical models to
test the efficacy of targeted therapeutics may rely on the presence (or absence) of
specific mutations or expression profiles and will therefore need to be tested for prior
to conducting the experiments.
Integrating the WGS and CTCF ChIP-seq datasets demonstrated that CTCF bind-
ing sites were enriched for mutations at their core motif and that higher affinity CTCF
binding sites accumulated a disproportionate mutational burden. These findings are
concordant with those seen in human melanoma samples. Sabarinathan et al. (2016)
showed that the somatic mutation rate was highly increased at active transcription
factor binding sites and nucleosome embedded DNA compared with their flanking
regions. This important finding supports that this is a more generalisable feature
of cancer genomes rather than being specific to a particular tumour type and/or its
initiation and/or repair mechanism, e.g., UV light in the case of human melanoma or
DEN in our mouse liver tumours.
RNA-sequencing of the tumours revealed that Ctcf expression levels in the back-
ground liver tissue of DEN-exposed mice remained lower in hemizygous mice than
their wild-type littermates. Surprisingly, Ctcf expression in liver tumours was not
significantly different between the two genotypes. One possible explanation for this
could be the polyploid state of the liver. Unlike most mammalian tissues, the adult
liver is composed of largely polyploid hepatocytes (up to 90% in adult mice) (Duncan
et al., 2010). Polyploid hepatocytes arise due to cytokinetic failure (resulting in binu-
cleated hepatocytes (Margall-Ducos et al., 2007)) or endoreduplication (replication of
the nuclear genome in the absence of cell division) (Gentric and Desdouets, 2014).
Tetraploid or octaploid hepatocytes can, therefore, be bi- or mononuclear. In the
context of a hemizygous allele in the original diploid cell, selective pressure may
mean that the mutant allele becomes enriched or depleted over time. This polyploid
state is thought to serve an important tumour suppressive role in the liver, and it
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has been shown experimentally that polyploid livers are protected against tumour
suppressor loss of heterozygosity (Zhang et al., 2018). However, this is unlikely to
have occurred in our mice since the majority of somatic variants were caused by an
initial single burst of mutagenesis in the originating cell upon DEN exposure at 15
days, whereas liver ploidy in rodents only begins around weaning (postnatal day 14
to 21) and increases with ageing (Margall-Ducos et al., 2007; Schwartz-Arad et al.,
1989). However, the presence or absence of this phenomenon could be investigated
by performing DNA-FISH in tumour tissue sections using probes against wild-type
Ctcf and the excised region of Ctcf, relative to the total count of chromosome 8.
Analysis of the tumour RNA-seq data revealed that only four genes were dif-
ferentially expressed between tumours arising in Ctcf hemizygous and wild-type
mice: Carmil2, Fbxo6, Nudt11, and Mnd1. Most significantly, Carmil2 was 13.5-
fold overexpressed (q value = 2.58 x 10-7) in Ctcf hemizygous mice. Carmil2 is a
cell membrane-cytoskeleton-associated protein that plays roles in the regulation of
actin polymerisation at the barbed end of actin filaments (Liang et al., 2009), cell
migration, and invadopodia formation (Lanier et al., 2015); the latter is associated
with epithelial-mesenchymal transition (EMT) and metastasis in cancer (Murphy and
Courtneidge, 2011). Carmil2 is encoded immediately downstream of Ctcf, so it is
possible that the observed overexpression was due to transcriptional read-though
from a Ctcf promoter upregulated in an attempt to compensate for depleted CTCF
levels.
Of the other three genes, the most relevant to tumourigenesis is Fbxo6, which
is involved in DNA damage responses by specifically recognising activated CHEK1
(phosphorylated Ser-345), promoting its ubiquitination and degradation. Ubiquiti-
nation of CHEK1 is required to ensure that activated CHEK1 does not accumulate
as cells progress through S phase or when replication forks encounter transient
impediments during normal DNA replication (Yoshida et al., 2005; Zhang et al., 2009).
Mnd1 is required for homologous chromosome pairing and efficient cross-over and
intragenic recombination during meiosis (Petukhova et al., 2005). Nudt11 is involved
in signal transduction by cleaving beta-phosphate from diphosphate groups, and it
also catalyses the hydrolysis of dinucleoside oligophosphates (Fisher et al., 2002).
An important future direction is to use the RNA-seq data to validate the functional
impact of putative drivers identified in WGS analyses.
In this study we used a genetically engineered mouse model to study spon-
taneous tumourigenesis with a reduced germline genomic concentration of Ctcf.
Further, we generated a tissue-specific model of CTCF depletion and used chemical
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carcinogenesis to challenge this further to characterise the resulting phenotypes.
In contrast to previously published findings, mice hemizygous for Ctcf either at
the whole organism level or in a tissue specific manner did not have an increased
propensity to develop spontaneous or carcinogen-initiated tumours. However, these
experiments provide a detailed histological, genomic, and transcriptomic character-






CTCF is a pleiotropic DNA-binding protein with in vitro and in vivo evidence of a
tumour suppressor role. Complete Ctcf knockout in mice is non-viable, and Ctcf
hemizygous mice have been reported to be susceptible to spontaneous, radiation-,
and chemically-induced tumours of multiple lineages. This series of experiments
tested the hypothesis that a reduced genomic concentration of Ctcf increases
susceptibility to cancer by altering chromatin homeostasis. We aimed to directly test
this by performing a systems-level characterisation of the cells and tissues of Ctcf
hemizygous mice and subsequently inducing and profiling liver tumours to identify
(epi)genomic features predicting hypersensitive loci. Reducing the concentration of
CTCF was expected to have a quantitative effect on DNA binding, either a reduced
number of occupied binding sites or a partial global reduction in binding at all sites.
Furthermore, we expected the downstream effects on gene transcription and protein
expression would be dependent on their relationship to altered sites of activation or
repression and/or altered CTCF-dependent chromatin looping. We also predicted
that liver tumourigenesis would be accelerated in Ctcf conditional knockout mice.
We found that Ctcf hemizygous mammalian cells exquisitely compensate for
fluctuations in intra-cellular CTCF concentration. In vitro removal of 50% of the Ctcf
gene content caused a 37% reduction in mRNA expression and a 27% reduction in
CTCF protein levels, which resulted in only a 2% difference in genomic occupancy
by CTCF. In spite of this degree of compensation, genetic and epigenetic profiling
of Ctcf hemizygous MEF cultures revealed reproducible changes in the nuclear
environment, thus providing insights into the inherent functions of this essential
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protein. Several hundred genes and their corresponding proteins were differentially
expressed and were enriched for cancer-related pathways. The effect sizes were not
as great as we hypothesised, although are in keeping with Zuin et al. (2014), who
found only 161 differentially expressed genes in CTCF RNAi experiments.
Induction of liver tumours with a carcinogen provided detailed insights into the mu-
tational signatures and transcriptional profiles of DEN-initiated tumours in C57BL/6J
mice. Tumourigenesis was not accelerated in Ctcf conditional knockout mice, and
tumours arising in wild-type and Ctcf hemizygous mice were only subtly phenotyp-
ically different. However, this WGS dataset represents an important resource to
study the effects of controlled mutagenesis in vivo. Future directions in this regard
are described below.
Although we adopted a high-throughput approach to examine CTCF loss in vitro
and in vivo, future studies could adopt a locus-centric approach to complement
these data and functionally test the consequences of CTCF depletion or the loss of
CTCF binding. For example, CRISPR techniques could be used to delete specific
CTCF binding sites. By studying the presence (or absence) of transcriptional and
chromatin conformational changes, the functional role for transcriptional or structural
homeostasis could be characterised. This has proven to be a powerful way to dissect
the roles of individual regulatory elements of the α-globin super-enhancer (Hay et al.,
2016) and proving the insulator role of CTCF in IDH1-mutant gliomas (Flavahan
et al., 2015).
5.2 Model systems
Model systems provide powerful experimental tools to study fundamental biological
processes and address particular biological questions. There is of course a wide se-
lection of model organisms to choose from including bacteria (e.g., Escherichia coli)
and bacteriophage viruses, bakers’ yeast (Saccharomyces cerevisiae), nematode
worms (Caenorhabditis elegans), fruit flies (Drosophila melanogaster ), zebrafish
(Danio rerio), frogs (Xenopus laevis), and mice (Mus musculus). The choice of
model depends upon the question being asked and the suitability of the organism for
answering that question (Fields and Johnston, 2005). For instance, a mammalian
model is far more applicable for pharmacokinetic and pharmacodynamic studies on
new drugs than, say, the fruit fly or worm, since to test these parameters a whole
organism with a blood circulation, liver, and kidneys is needed. In this study we used
mice and derived cell lines to study CTCF in a mammalian system and to induce
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tumours. We also took advantage of Cre recombinase technology to genetically
engineer the Ctcf locus in order to manipulate its expression in the germline and in
a conditional, cell-type specific manner. While this represented a sophisticated set
of approaches to test our hypotheses, these models (like any experimental model)
had their limitations.
Experiments in MEFs were performed in bulk culture of millions of cells. There
may well be more cell-to-cell variability in the Ctcf hemizygous state, but the nature
of this heterogeneous and unsynchronised cell culture may mean that quantitatively
large changes in some cells were masked. Single-cell sequencing technologies
(Schwartzman and Tanay, 2015; Wang and Navin, 2015; Wu et al., 2017) are
rapidly becoming more accessible and less expensive, and represent one way
to examine individual cell variability. For example, single-cell RNA-seq (scRNA-
seq) can be performed by fluorescence activated cell sorting (FACS) and then
capture of hundreds of individual cells for library preparation, for example with Smart-
seq2, followed by sequencing. Alternatively, more recent droplet-based RNA-seq
(drop-seq) technologies allow thousands of individual cells to be profiled in parallel,
with drop-seq having the advantage that biases introduced by FACS sorting and
capturing are negated (Habib et al., 2017; Klein et al., 2015; Macosko et al., 2015).
However, this latter technology has relatively low gene-per-cell sensitivity compared
to other scRNA-Seq methods (Ziegenhain et al., 2017). It is also possible to parallel
sequence the genome and transcriptome of single cells (G&T-seq) (Macaulay et al.,
2016) or to simultaneously profile chromatin accessibility, DNA methylation, and
transcription in single cells (scNMT-seq) (Clark et al., 2018). In addition, the dynamics
of chromosomal organisation can now be performed at single-cell resolution (Nagano
et al., 2017). Although these technologies were not available during the course of
this project, they represent exciting new ways to interrogate in vitro cultures and
will undoubtedly reveal more complexity within the cell population as a whole than
previously appreciated.
The Ctcf hemizygous mice were not born with equal numbers of wild-type and
Ctcf hemizygous offspring as expected by Mendelian inheritance. This discrepancy
in fertilisation, embryogensis, and/or full-term development may have introduced
bias into downstream experiments. While the reduced transmission rate (30.6%) is
consistent with the genotypic ratios observed in previous studies using a C57BL/6
background (Heath et al., 2008), it is in contrast to the findings of Kemp et al. (2014)
who reported that "C57BL6/129 (B6/129) F1 Ctcf +/- mice were born at the expected
Mendelian frequency". The reduced transmission rate may be explained by the
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hybrid 129sv background used by Kemp et al. (2014), since breeding transgenic
animals in F1 animals has been shown to be more efficient than a homogeneous
C57BL/6 background (Owenab et al., 1997; Taketo et al., 1991). Nevertheless,
important CTCF-mediated effects may have been missed if the reason for offspring
imbalance was due to the effects of Ctcf hemizygosity in utero.
Strain-specific differences may also explain the reduced rate of spontaneous
tumours in our CB57BL/6J animals compared with BL6/129 since the 129 family is
particularly diverse, with numerous substrains across four separate genetic lineages
containing known phenotypic differences (Kiselycznyk and Holmes, 2011). Although
the reported overall tumour incidence in 129 mice was relatively low (7% in males,
21% in females), it was higher than in CB57BL/6J animals, which are refractory
to many tumour types (Smith et al., 1973). The most frequently reported tumour
types in 129 mice are lymphoma, soft tissue sarcomas, lung tumours, and testicular
teratomas (Smith et al., 1973), which reflects those seen by Kemp et al. (2014). We
also know from our own mouse colonies that tumour latency - both spontaneous
and induced - varies widely between inbred laboratory strains (including C57BL6/J
and C3H (Connor et al., 2018)) and wild-derived strains (including Mus musculus
castaneus and Mus caroli (unpublished data)).
We also used a combination of hepatocyte-specific Ctcf deletion with a carcino-
gen tumour-induction protocol. We generated a detailed genomic and transcriptomic
characterisation of this model but did not identify marked differences between Ctcf
hemizygous and wild-type mice. The similarity between genotypes is likely due to a
combination of factors: the choice of liver as the target organ, and the carcinogen
model used. A hepatocyte-specific model was selected for several valid reasons
outlined in Chapter 4. To recap, the liver was chosen because: (i) the liver cell popula-
tion was regarded as relatively homogeneous for these studies (i.e., hepatocyte-rich
in the loosest terms); (ii) it is well characterised by previous studies in our laboratory
(Odom et al., 2007; Schmidt et al., 2010a,b; Schwalie et al., 2013; Villar et al., 2014);
(iii) we have significant experience with a liver tumour-induction protocol (Connor
et al., 2018); (iv) the liver is easily identified at necropsy; and (v) a single mouse
liver provides sufficient tissue for several assays. However, an alternative target
organ might have better bridged the phenotype-genotype gap. CTCF has been iden-
tified as a mutational cancer driver gene in uterine corpus endometrioid carcinoma
(Rubio-Perez et al., 2015), and uterine neoplasms were found in 40% of all female
mice studied by Kemp et al. (2014). It would, therefore, be interesting to test the
same hypothesis in uterine-specific Ctcf hemizygous mice. This could be achieved
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using a mouse expressing the modified progesterone allele: Pgrtm1.1(cre)Shah (PRCre),
which harbours a Cre recombinase gene downstream of the progesterone receptor
(Pgr ) transcriptional stop codon. Spatiotemporal expression of cre therefore follows
endogenous progesterone expression. This nuclear hormone receptor is expressed
in the uterus but is also highly expressed in all other female reproductive organs
(including ovaries, fallopian tubes, and mammary glands), as well as the pituitary
gland and hypothalamus. Therefore, although heterozygous mice are viable, fertile,
normal in size and do not display any gross physical or behavioural abnormalities,
the results might be obscured or confounded by Ctcf deletion in other tissues.
In relation to the carcinogen model, we found that Braf (V637E) was the most
common oncogenic mutation in both genotypes, consistent with previous findings
in C57BL/6 mice (Bakiri and Wagner, 2013). This is in contrast to the Hras and
Egfr mutations predominating in C3H mice (Connor et al., 2018). We now know that
the mutational signatures caused by DEN are not only the same between the two
Ctcf genotypes but that the signature is also the same in C3H (Connor et al., 2018),
Mus musculus castaneus, and Mus Caroli mice (unpublished data). Thus, mouse
strain is the strongest determinant of mutational drivers, whereas the mutational
signature caused by DEN is universal and was unlikely to be significantly altered by
Ctcf hemizygosity alone.
Other model systems continue to evolve and that might provide interesting options
for future investigation of Ctcf and liver cancer. Organoid models now allow human
(or mouse) physiology and disease to be recapitulated three dimensionally in vitro,
even in tissues with complex structure and architecture such as the brain (Lancaster
et al., 2013) or liver (Broutier et al., 2017; Huch et al., 2013). Organoid (or tumouroid)
culture systems can capture and maintain many features of the original human
tissue (or tumour) sample including morphological subtype, immunohistochemical
profile, gene expression, and mutational profile. In addition to providing a model for
fundamental biology and pathophysiology, such systems also present options for
drug screening and validation of actionable therapeutic targets for personalised and
precision medicine programmes (Huch and Koo, 2015).
5.3 Mechanisms of chromatin organisation
The importance of CTCF in the three-dimensional organisation of chromatin is well
established and, although the precise mechanisms are not fully resolved, several
important discoveries have recently been made.
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There is an increasing body of in vitro, in vivo, and in silico evidence to support
the loop extrusion model of chromatin folding (see Chapter 1, Figure 1.4). One
of these advances relates to the interplay between loop extrusion of TADs and
compartmental segregation of interphase chromatin. Very recent reports over the
last few months support that although TADs are subunits within compartments, their
structures are distinct, and that loop extrusion of TADs actually counteracts the
formation of compartments (Nuebler et al., 2018). These two independent modes
of chromosome organisation have been demonstrated by: (1) targeted degrada-
tion of CTCF from mouse embryonic stem cells, which caused disruption of TADs
because loop extrusion was no longer insulated within specific domains, but local
chromatin compaction was maintained to counteract compartmental segregation
(Nora et al., 2017); (2) removing Nipbl, a cohesin loader, revealed the intrinsically
segregated compartmental structure in the absence of its suppression by loop extru-
sion (Schwarzer et al., 2017); and (3) removing Wapl, a cohesin unloading factor,
resulted in increased loop length and abundance due to prolonged occupancy of co-
hesin on the DNA to strengthen TADs and weaken compartmentalisation (Haarhuis
et al., 2017). Nuebler et al. (2018) have since used polymer models of chromosomes
to quantitatively reproduce these experimental findings.
These studies strongly support the process of loop extrusion for interphase
chromosome folding and the essential complementary roles of CTCF and cohesin.
However, there are some aspects that remain unresolved, since these studies do not
directly address the mechanism of loop extrusion. The process of extrusion requires
the protein complex to travel continuously for thousands of kilobases along the
chromatin in spite of obstructing nucleosomes and DNA-binding proteins (Fudenberg
et al., 2018). Another aspect briefly discussed in Chapter 4 is the energy expenditure
required for the active process of extrusion. However, more recent estimates show
that the energy burden of ATP consumption by loop-extruding cohesins in interphase
is negligible compared with total ATP production in a mammalian cell (Terakawa
et al., 2017) and therefore unlikely to be a limiting factor.
Loop extrusion is also proposed to be the mechanism of chromosomal folding
and compaction in mitosis, with condensin (rather than cohesin) acting as the
mechanochemical motor (Terakawa et al., 2017). Polymer simulations based on
a combination of high-resolution imaging and Hi-C of synchronous cell cultures
(including condensin depletion studies) showed that the interpahse organisation of
chromatin is rapidly lost in prophase and 60 kb loops are formed. These inner loops
become nested within ~400 kb outer loops in prometaphase, which progressively
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increase to ~12 Mb as the loop array extends in a helical "spiral-staircase" condensin
scaffold (Gibcus et al., 2018).
This detailed description was followed almost immediately by the first real-time
imaging of DNA loop extrusion by condensin. Time-lapse imaging unambiguously
demonstrated the formation and progressive extension of DNA loops by condensin,
thus providing clear and direct evidence for active loop extrusion. Direct visualisation
showed that a single condensin complex extrudes tens of kilobase pairs of DNA at
speeds of up to 1.5 kb per second (Ganji et al., 2018). An unexpected finding that
had not been proposed by in silico experiments was that condensin-dependent loop
extrusion is strictly asymmetrical: condensin anchors onto DNA and reels it in from
only one side (Ganji et al., 2018).
Although cohesin-dependent looping has not been directly visualised in inter-
phase chromatin, this powerful evidence for condensin-dependent loop extrusion in
mitosis further supports the role of an active loop extrusion process for other aspects
of genome organisation.
5.4 DNA damage and repair
DEN is a potent genotoxin that causes DNA damage by two parallel processes:
first, as a DNA alkylating agent, DEN leads to the formation of mutagenic DNA
adducts (Bakiri and Wagner, 2013). Second, its bioactivation by cytochrome P450 in
centrilobular hepatocytes generates reactive oxygen species (ROS) that damage
DNA, proteins, and lipids and kills hepatocytes (Qi et al., 2008). In turn, hepatoxicity
triggers an inflammatory response resulting in elevated expression of mitogens
such as interleukin-6 (IL-6), which promote compensatory proliferation of surviving
hepatocytes (Naugler et al., 2007). The alkylation adducts can be removed by
the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT), which
encodes O6-alkylguanine-DNA alkyltransferase (Pegg, 1990).
Genome-wide, we showed that DEN-initiated liver tumours possess a repro-
ducible mutational signature that can be attributed to the initial treatment with DEN,
whereas driver mutations are strain/species-dependent (Connor et al., 2018). This
mutational signature is the consequence of several interacting processes: the intrin-
sic infidelity of the DNA replication machinery, exogenous (e.g., DEN) or endogenous
(e.g., ROS) mutagenic exposures, enzymatic modification of DNA, and defective
DNA repair (Alexandrov et al., 2013). The incidence of mutations was not evenly
distributed across the genome and was in keeping with previous reports of a re-
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duced mutation rate in exons. In melanoma, this is thought to be due to differential
mismatch repair (Frigola et al., 2017), and oxidative damage is also reduced at
promoters, exons, and termination sites but not introns (Poetsch et al., 2018).
We found that CTCF binding sites were hypermutated in tumours of both Ctcf
genotypes. This has also been shown in human melanomas, which are almost
entirely driven by UV mutagenesis, and it has been proposed that this is due to
impaired nucleotide excision repair (NER) (Poulos et al., 2016) due to DNA-bound
transcription factors interfering with the NER machinery (Sabarinathan et al., 2016).
More generally, analysis of over a thousand cancer genomes across 14 cancer
types found increased mutational density at gene promoters, which was linked to
transcription initiation activity and impairment of NER (Perera et al., 2016).
Therefore, one future direction will be to examine the impact of DNA repair on
hypermutated CTCF binding sites. DEN causes predictable mutations due to its
intrinsic chemistry and our tumours harboured a specific DEN signature. However,
the presence of hypermutated CTCF binding sites showed that the DEN mutagenic
effect was not evenly distributed across the genome. It is unclear how this uneven
distribution relates to the balance between damage and repair occurring either at
the time of initial insult or over time. Experimental mapping of early DNA damage
and/or repair immediately after treatment with DEN would help to dynamically map
the evolution of mutations and thus better interpret the final mutational signature. We
know that the promutagenic O6-ethyl deoxyguanosine adduct accumulates in zone 3
hepatocytes within four hours of treatment with DEN and DNA double-strand breaks
(as seen by the rapid accumulation and elimination of phosphorylated histone H2AX)
peaks over the same time frame (Connor et al., 2018). Therefore, in order to directly
assess DNA damage and before repair has occurred, liver samples would have to be
taken within the first few minutes to hours after pups were treated with DEN. Several
new protocols have been developed to map DNA damage and/or repair in vitro and
ex vivo, as follows.
In replicating cells, ribonucleotides are the most common non-canonical nu-
cleotides incorporated into the genome, and they are removed by ribonucleotide
excision repair initiated by RNase H2 cleavage. In the absence of RNase H2, such
embedded ribonucleotides can be used to track DNA polymerase activity in vivo
to study DNA replication and repair at single nucleotide resolution. Strand-specific
genome-wide mapping of embedded ribonucleotides (emRiboSeq) can be performed
using recombinant RNase H2 to selectively create ligatable 3’-hydroxyl groups, in
contrast to alternative methods that use alkaline hydrolysis. Non-canonical bases
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can be mapped by substituting RNase H2 with specific nicking endonucleases:
endonuclease sequencing (EndoSeq) (Ding et al., 2015). Alternatively, AP-seq
can be used to map apurinic sites and 8-oxo-7,8-dihydroguanine bases at ~300
bp resolution on a genome-wide scale (Poetsch et al., 2018). Such techniques
allow genome-wide maps of alkylation damage, repair, and mutagenesis at single
nucleotide resolution to reveal mechanisms of mutational heterogeneity (Mao et al.,
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List of differentially expressed genes
Table 1 Differential expression results of RNA-seq experiments performed in wild-type and
Ctcf hemizygous mouse embryonic fibroblasts. Differential expression analysis of the RNA-
seq, performed using DESeq2, controlling for both the known and hidden batch effects.
baseMean is the mean of normalised counts of all samples, normalising for sequencing
depth. Genes were considered significantly differentially expressed if their adjusted p-value
was lower than 0.05.
Ensembl gene ID Gene Chr Start End baseMean Log2FoldChange p value Adjusted p value
ENSMUSG00000044080 S100a1 3 90511034 90514392 327.7706364 -0.834560741 5.13E-18 8.28E-14
ENSMUSG00000028031 Dkk2 3 132085292 132180304 1405.339917 -0.696904508 2.55E-16 2.05E-12
ENSMUSG00000062380 Tubb3 8 123411424 123422015 1656.794211 -0.557823603 6.24E-16 3.35E-12
ENSMUSG00000052353 Cemip 7 83932857 84086502 13392.54319 0.547217942 2.38E-15 8.94E-12
ENSMUSG00000057751 Megf6 4 154170730 154275713 635.4414121 0.769519438 2.77E-15 8.94E-12
ENSMUSG00000027009 Itga4 2 79255426 79333123 1324.029672 -0.645207921 6.01E-14 1.62E-10
ENSMUSG00000027827 Kcnab1 3 65109384 65378223 349.7014279 -0.711456325 8.38E-14 1.93E-10
ENSMUSG00000054690 Emcn 3 137341067 137432185 156.5416287 -0.784392219 3.50E-13 7.05E-10
ENSMUSG00000027347 Rasgrp1 2 117279993 117343001 93.63284528 0.761366767 1.14E-12 2.03E-09
ENSMUSG00000034161 Scx 15 76457438 76459468 694.5414233 0.547242439 2.30E-11 3.37E-08
ENSMUSG00000045827 Serpinb9 13 33003250 33017957 1883.135215 0.487883922 2.17E-11 3.37E-08
ENSMUSG00000070327 Rnf213 11 119393100 119487418 5424.823794 -0.456292951 4.57E-11 6.14E-08
ENSMUSG00000076441 Ass1 2 31470207 31520672 4678.467071 -0.49656652 1.22E-10 1.51E-07
ENSMUSG00000031825 Crispld2 8 119992438 120052793 1393.667197 -0.532977475 1.46E-10 1.56E-07
ENSMUSG00000056758 Hmga2 10 120361275 120476469 4116.823937 -0.460716584 1.54E-10 1.56E-07
ENSMUSG00000074896 Ifit3 19 34583531 34588731 272.0103622 -0.643617453 1.36E-10 1.56E-07
ENSMUSG00000005698 Ctcf 8 105636568 105682922 1579.87131 -0.457815754 2.54E-10 2.40E-07
ENSMUSG00000029671 Wnt16 6 22288227 22298522 905.201436 0.60125982 4.58E-10 4.11E-07
ENSMUSG00000000120 Ngfr 11 95568818 95587735 197.1525474 0.658935595 4.92E-10 4.18E-07
ENSMUSG00000015766 Eps8 6 137477245 137654876 2278.150851 -0.44639976 5.84E-10 4.71E-07
ENSMUSG00000072621 Slfn10-ps 11 83028130 83040042 67.2856275 -0.656404501 6.32E-10 4.85E-07
ENSMUSG00000061353 Cxcl12 6 117168535 117181367 20110.88015 -0.412378116 6.98E-10 5.11E-07
ENSMUSG00000027087 Itgav 2 83724397 83806916 18570.59646 -0.351619782 3.80E-09 2.67E-06
ENSMUSG00000029778 Adcyap1r1 6 55451978 55501451 233.0226462 -0.623787885 5.49E-09 3.69E-06
ENSMUSG00000050357 Rltpr 8 105690906 105698178 26.7341123 0.514268484 5.79E-09 3.74E-06
ENSMUSG00000035385 Ccl2 11 82035571 82037453 779.2040822 -0.485277037 6.46E-09 4.01E-06
ENSMUSG00000026109 Tmeff2 1 50900647 51187270 561.4977155 -0.560674028 7.40E-09 4.42E-06
ENSMUSG00000005087 Cd44 2 102811141 102901665 12408.64082 -0.43986125 1.03E-08 5.96E-06
ENSMUSG00000025150 Cbr2 11 120729489 120732114 1706.469054 0.463213545 1.35E-08 7.50E-06
ENSMUSG00000036412 Arsi 18 60911780 60918561 532.2748015 0.562510283 1.47E-08 7.88E-06
ENSMUSG00000021614 Vcan 13 89655312 89742509 21654.92819 -0.360126007 2.16E-08 1.12E-05
ENSMUSG00000032359 Ctsh 9 90054152 90076089 1185.159355 -0.403522197 3.50E-08 1.76E-05
ENSMUSG00000029061 Mmp23 4 155650655 155653384 1964.753004 -0.440869707 4.41E-08 2.16E-05
ENSMUSG00000022544 Eef2kmt 16 5244152 5255983 506.1441695 0.463625316 5.51E-08 2.61E-05
ENSMUSG00000032492 Pth1r 9 110722085 110747145 595.0992815 0.469161569 6.27E-08 2.89E-05
ENSMUSG00000047414 Flrt2 12 95692226 95785215 7013.008857 -0.353549686 9.53E-08 4.15E-05
ENSMUSG00000054580 Pla2r1 2 60417543 60553308 658.6523683 -0.511934523 9.53E-08 4.15E-05
ENSMUSG00000028370 Pappa 4 65124174 65357509 17361.8346 0.39254509 1.02E-07 4.33E-05
ENSMUSG00000024747 Aldh1a7 19 20692953 20727562 139.1952329 -0.566649659 1.22E-07 5.03E-05
ENSMUSG00000030036 Mogs 6 83115496 83118898 2231.283832 0.367100288 1.46E-07 5.90E-05
ENSMUSG00000022114 Spry2 14 105891949 105896819 888.0415273 -0.415840026 1.60E-07 6.20E-05
ENSMUSG00000045777 Ifitm10 7 142325837 142373753 87.15619384 0.563975709 1.62E-07 6.20E-05
ENSMUSG00000035356 Nfkbiz 16 55811375 55838899 1400.031916 -0.392742378 1.86E-07 6.97E-05
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Ensembl gene ID Gene Chr Start End Mean Log2FoldChange p value Adjusted p value
ENSMUSG00000022464 Slc38a4 15 96994823 97055956 2612.144702 -0.40650444 1.94E-07 7.10E-05
ENSMUSG00000029664 Tfpi2 6 3962595 3988919 229.5366558 -0.549442076 2.35E-07 8.42E-05
ENSMUSG00000022799 Arhgap31 16 38598340 38713274 1387.061476 -0.348778658 2.52E-07 8.64E-05
ENSMUSG00000103585 Pcdhgb4 18 37720369 37841870 516.7890821 0.481967035 2.51E-07 8.64E-05
ENSMUSG00000005357 Slc1a6 10 78780496 78814825 1497.542603 0.421615633 2.92E-07 9.80E-05
ENSMUSG00000005397 Nid1 13 13437602 13512275 22540.12252 -0.296782038 3.10E-07 0.000102139
ENSMUSG00000001493 Meox1 11 101877510 101894374 500.8871802 0.449004298 3.31E-07 0.000106861
ENSMUSG00000016200 Syt14 1 192891233 193035775 195.3019047 0.529038541 3.45E-07 0.000108624
ENSMUSG00000030616 Sytl2 7 90302252 90410719 1803.593124 -0.358656625 3.50E-07 0.000108624
ENSMUSG00000025492 Ifitm3 7 141009586 141010770 4180.106245 -0.353287459 3.81E-07 0.000115967
ENSMUSG00000049420 Tmem200a 10 25991186 26079052 340.3231611 -0.526988482 5.07E-07 0.000151445
ENSMUSG00000026547 Tagln2 1 172500047 172507380 4865.751659 -0.315757003 5.51E-07 0.000161662
ENSMUSG00000041559 Fmod 1 134037254 134048277 1192.804191 0.452635099 5.76E-07 0.00016574
ENSMUSG00000001123 Lgals9 11 78962974 78984946 512.9420761 -0.461757975 5.94E-07 0.000168149
ENSMUSG00000025504 Eps8l2 7 141338880 141363020 191.2155767 -0.536002828 6.18E-07 0.000171878
ENSMUSG00000041596 Nlrp5-ps 7 14530652 14622479 234.997219 0.497723962 6.53E-07 0.000178366
ENSMUSG00000021253 Tgfb3 12 86056744 86079041 13582.02791 0.307180553 8.92E-07 0.000239822
ENSMUSG00000053846 Lipg 18 74939322 74961263 547.0001425 -0.443530541 9.50E-07 0.000251122
ENSMUSG00000031391 L1cam X 73853778 73896105 334.8813357 0.481549112 1.10E-06 0.000287039
ENSMUSG00000043289 Mei4 9 81863670 82206007 131.7684453 0.516838024 1.21E-06 0.000308707
ENSMUSG00000049723 Mmp12 9 7344381 7369499 249.1602682 -0.521844884 1.23E-06 0.000308707
ENSMUSG00000000275 Trim25 11 88999376 89020293 1019.466578 -0.375065653 1.51E-06 0.000373984
ENSMUSG00000029648 Flt1 5 147561604 147726011 1892.713187 -0.406941254 1.74E-06 0.000425758
ENSMUSG00000022122 Ednrb 14 103814625 103844173 296.8078163 -0.498954804 1.85E-06 0.00044443
ENSMUSG00000043943 Naalad2 9 18321951 18402995 83.69413571 -0.510860992 1.90E-06 0.00045023
ENSMUSG00000041658 Rragb X 153139981 153171943 122.157914 0.510510938 2.14E-06 0.000500772
ENSMUSG00000015312 Gadd45b 10 80930091 80932204 1323.091768 0.386973458 2.21E-06 0.000510017
ENSMUSG00000029121 Crmp1 5 37241940 37292133 204.8444027 -0.4876146 2.35E-06 0.000533153
ENSMUSG00000020027 Socs2 10 95385362 95417180 279.8906471 -0.482858098 2.51E-06 0.00056184
ENSMUSG00000006731 B4galnt1 10 127165156 127172340 799.0366279 -0.380441249 2.55E-06 0.000562757
ENSMUSG00000029231 Pdgfra 5 75152292 75198215 2193.1792 -0.38361821 2.59E-06 0.000563832
ENSMUSG00000032420 Nt5e 9 88327197 88372092 581.4099365 0.412851207 2.81E-06 0.000603844
ENSMUSG00000052727 Map1b 13 99421464 99516602 8155.249681 -0.295171936 3.05E-06 0.000647242
ENSMUSG00000013846 St3gal1 15 67102875 67113992 468.5961735 -0.422557612 3.27E-06 0.000684297
ENSMUSG00000024084 Qpct 17 79051906 79090243 288.8812849 -0.470397535 3.31E-06 0.000684905
ENSMUSG00000021678 F2rl1 13 95511732 95525240 366.799389 -0.450088191 3.62E-06 0.000739082
ENSMUSG00000031557 Plekha2 8 25039144 25102194 1343.402313 -0.340137939 3.70E-06 0.000745632
ENSMUSG00000064345 mt-Nd2 MT 3914 4951 2810.039625 -0.390517493 4.11E-06 0.000818001
ENSMUSG00000030827 Fgf21 7 45613907 45615490 117.5041029 0.491233162 5.71E-06 0.001122483
ENSMUSG00000020023 Tmcc3 10 94311949 94590956 555.9607442 -0.38699573 5.86E-06 0.001124608
ENSMUSG00000036109 Mbnl3 X 51117269 51206532 491.3732573 -0.441227241 5.81E-06 0.001124608
ENSMUSG00000030468 Siglecg 7 43408204 43418358 519.2261293 -0.426030315 6.17E-06 0.001170965
ENSMUSG00000033066 Gas7 11 67455437 67688990 674.4684719 -0.411850634 6.62E-06 0.001241988
ENSMUSG00000038932 Tcfl5 2 180621956 180642708 415.4583111 0.464458327 6.88E-06 0.001275052
ENSMUSG00000026399 Cd55 1 130439027 130462744 649.2070936 -0.454598263 7.02E-06 0.001287221
ENSMUSG00000006360 Crip1 12 113146316 113153879 412.4452981 -0.424873209 7.24E-06 0.001311143
ENSMUSG00000033544 Angptl1 1 156838562 156861078 215.2232128 -0.475929158 7.77E-06 0.001391977
ENSMUSG00000034765 Dusp5 19 53529109 53542431 772.0216032 -0.39676695 7.98E-06 0.001414061
ENSMUSG00000025921 Rdh10 1 16105774 16133734 974.7566534 0.342008029 8.61E-06 0.001509081
ENSMUSG00000026042 Col5a2 1 45374321 45503282 237346.7503 0.291872784 8.94E-06 0.001549884
ENSMUSG00000009376 Met 6 17463800 17573980 1113.996245 -0.361361632 9.07E-06 0.001555097
ENSMUSG00000032368 Zic1 9 91358058 91365810 365.4673467 0.462237146 9.59E-06 0.001596907
ENSMUSG00000053062 Jam2 16 84774123 84825928 211.1981342 -0.464812362 9.42E-06 0.001596907
ENSMUSG00000074415 2610203C20Rik 9 41376397 41617772 2336.49848 -0.28548231 9.61E-06 0.001596907
ENSMUSG00000054720 Lrrc8c 5 105519388 105613018 1377.563495 -0.355356371 9.90E-06 0.001628926
ENSMUSG00000031616 Ednra 8 77663031 77724464 331.797627 -0.468009521 1.01E-05 0.00165194
ENSMUSG00000002325 Irf9 14 55603571 55610030 938.0007915 -0.35391027 1.22E-05 0.00194943
ENSMUSG00000047735 Samd9l 6 3372257 3399572 1652.134436 -0.371535207 1.22E-05 0.00194943
ENSMUSG00000036986 Pml 9 58218076 58249786 802.8430406 -0.341189777 1.26E-05 0.001993477
ENSMUSG00000020357 Flt4 11 49609263 49652739 277.160189 -0.434896052 1.37E-05 0.002143034
ENSMUSG00000022512 Cldn1 16 26356642 26371841 258.5499926 -0.448021568 1.39E-05 0.002150849
ENSMUSG00000062151 Unc13c 9 73479422 73968966 73.32136551 -0.443369845 1.47E-05 0.002255065
ENSMUSG00000051951 Xkr4 1 3205901 3671498 91.1478604 0.465914579 1.52E-05 0.002288072
ENSMUSG00000057534 Gm15698 11 88964658 88966931 130.5730439 -0.453348603 1.50E-05 0.002288072
ENSMUSG00000062098 Btbd3 2 138256565 138589292 1295.635035 -0.309077769 1.71E-05 0.002546172
ENSMUSG00000038418 Egr1 18 34859823 34864984 464.3403941 -0.417154391 1.77E-05 0.002615656
ENSMUSG00000059970 Hspa2 12 76404176 76406934 855.4904407 0.34591884 2.10E-05 0.003081735
ENSMUSG00000096965 3300005D01Rik 17 5798657 5803240 183.2336572 -0.453036761 2.24E-05 0.003247111
ENSMUSG00000024501 Dpysl3 18 43320979 43438286 20372.5474 -0.279250597 2.31E-05 0.00332163
ENSMUSG00000025068 Gsto1 19 47854970 47864790 9105.01178 -0.261065929 2.45E-05 0.003471258
ENSMUSG00000087247 Fam150a 1 6359218 6394731 763.1317967 0.36529284 2.45E-05 0.003471258
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ENSMUSG00000057596 Trim30d 7 104470014 104507849 213.3824073 -0.441369707 2.54E-05 0.003568188
ENSMUSG00000060988 Galnt13 2 54436317 55118309 311.5604182 -0.431538593 2.63E-05 0.00365547
ENSMUSG00000030208 Emp1 6 135362545 135383173 17406.7732 -0.243845519 2.66E-05 0.003669473
ENSMUSG00000033063 Cntnap3 13 64737591 64903888 28.39363177 -0.371652855 2.72E-05 0.003722291
ENSMUSG00000028217 Cdh17 4 11758147 11817895 201.7429846 0.437587176 3.09E-05 0.004180726
ENSMUSG00000020601 Trib2 12 15791727 15816877 1453.241475 -0.300597937 3.18E-05 0.004278242
ENSMUSG00000040010 Slc7a5 8 121881150 121907694 4005.822434 0.329676208 3.23E-05 0.004299276
ENSMUSG00000001657 Hoxc8 15 102990607 102994111 492.5635641 -0.406368737 3.49E-05 0.004566025
ENSMUSG00000028885 Smpdl3b 4 132732966 132757252 93.46094942 -0.446775174 3.46E-05 0.004566025
ENSMUSG00000036009 Mettl25 10 105763189 105841380 263.2763806 0.409098976 3.51E-05 0.004566025
ENSMUSG00000027533 Fabp5 3 10012548 10016607 2511.94828 0.268226708 3.64E-05 0.004689502
ENSMUSG00000040263 Klhdc4 8 121796313 121829569 840.9006279 -0.321971195 3.88E-05 0.004961366
ENSMUSG00000025743 Sdc3 4 130792537 130826319 3652.770721 -0.257145434 4.59E-05 0.005823934
ENSMUSG00000046711 Hmga1 17 27556620 27563674 1750.873358 -0.34246055 4.94E-05 0.006219496
ENSMUSG00000061436 Hipk2 6 38694390 38876165 665.9314876 -0.332289651 5.18E-05 0.00648051
ENSMUSG00000014599 Csf1 3 107741048 107760469 6373.066601 -0.232331652 6.13E-05 0.007508878
ENSMUSG00000019960 Dusp6 10 99263231 99267488 1458.047239 -0.326373965 6.11E-05 0.007508878
ENSMUSG00000027784 Ppm1l 3 69316861 69560802 1226.133439 -0.312585403 6.15E-05 0.007508878
ENSMUSG00000024063 Lbh 17 72918305 72941942 5968.800506 -0.272353716 6.22E-05 0.00754376
ENSMUSG00000018417 Myo1b 1 51749765 51916071 3252.137917 -0.275719851 6.41E-05 0.007660451
ENSMUSG00000028020 Glrb 3 80843599 80913660 517.4559555 0.350691936 6.41E-05 0.007660451
ENSMUSG00000041731 Pgm5 19 24683016 24861855 1560.220208 -0.29522535 6.52E-05 0.00772979
ENSMUSG00000045868 Gvin1 7 106156556 106215326 150.3620541 -0.429998848 6.66E-05 0.007837066
ENSMUSG00000031402 Mpp1 X 75109733 75131016 3314.569525 -0.268792302 6.75E-05 0.007883692
ENSMUSG00000020689 Itgb3 11 104608000 104670476 1835.907719 0.303754982 6.88E-05 0.007980378
ENSMUSG00000021136 Smoc1 12 81026808 81186414 841.914684 -0.331993122 7.05E-05 0.008115114
ENSMUSG00000068566 Myadm 7 3289080 3300442 6560.488938 -0.269199501 7.29E-05 0.008332777
ENSMUSG00000007888 Crlf1 8 70493158 70504081 2377.07306 0.27690881 7.40E-05 0.008339329
ENSMUSG00000030220 Arhgdib 6 136923655 136941899 2558.09283 -0.346019869 7.38E-05 0.008339329
ENSMUSG00000039959 Hip1 5 135406531 135545120 1776.904422 -0.267606779 7.73E-05 0.008659126
ENSMUSG00000047281 Sfn 4 133600556 133602168 234.8185726 0.403430665 7.79E-05 0.008659126
ENSMUSG00000031626 Sorbs2 8 45507788 45827906 893.4432762 -0.371446086 8.12E-05 0.008964671
ENSMUSG00000027907 S100a11 3 93520488 93526287 1319.236656 -0.290411744 8.27E-05 0.009067171
ENSMUSG00000034751 Mast4 13 102732486 103334497 1499.619075 -0.287294782 8.35E-05 0.009092464
ENSMUSG00000026888 Grb14 2 64912476 65024987 1268.542177 -0.340881473 8.51E-05 0.009204501
ENSMUSG00000059493 Nhs X 161833296 162159730 734.9067199 -0.360515757 8.98E-05 0.009648686
ENSMUSG00000039953 Clstn1 4 149586468 149648899 3021.383186 0.240765896 9.25E-05 0.00987881
ENSMUSG00000022665 Ccdc80 16 45093402 45127924 31870.09798 0.262016907 9.51E-05 0.010086494
ENSMUSG00000006205 Htra1 7 130936111 130985660 11635.7386 0.310798347 9.97E-05 0.010504556
ENSMUSG00000047216 Cdh19 1 110888326 110977584 103.4778863 0.419109547 0.000100422 0.010514971
ENSMUSG00000004655 Aqp1 6 55336432 55348555 1026.026556 -0.360718472 0.000102744 0.010688651
ENSMUSG00000026482 Rgl1 1 152516760 152766351 1739.430927 -0.291312114 0.000105462 0.010831697
ENSMUSG00000032899 Styk1 6 131299142 131353597 739.0761148 -0.370668564 0.00010538 0.010831697
ENSMUSG00000073418 C4b 17 34728380 34743882 295.7249142 0.415841583 0.000106753 0.010894861
ENSMUSG00000030249 Abcc9 6 142587862 142702315 100.8621008 -0.417078809 0.000108542 0.01100783
ENSMUSG00000040274 Cdk6 5 3341485 3531008 2303.302049 -0.29497398 0.000109611 0.011046692
ENSMUSG00000040033 Stat2 10 128270576 128292849 886.9793467 -0.339267923 0.000112133 0.01123069
ENSMUSG00000027188 Pamr1 2 102550012 102643041 673.8500103 0.357283484 0.00011416 0.011363198
ENSMUSG00000035245 Eogt 6 97110024 97149182 1237.435728 -0.27063652 0.000115141 0.011390455
ENSMUSG00000028179 Cth 3 157894248 157925077 1382.400807 0.315337014 0.000116205 0.01142561
ENSMUSG00000002257 Def6 17 28207778 28228608 362.8016127 -0.371431311 0.000118449 0.011575747
ENSMUSG00000041073 Nacad 11 6597823 6606053 195.0115986 -0.401982975 0.000119436 0.011601802
ENSMUSG00000106106 Rn18s-rs5 17 39846353 39848827 768.5767177 -0.336579553 0.000120649 0.0116495
ENSMUSG00000078606 Gm4070 7 105895139 105953967 107.6709642 -0.413170185 0.000124578 0.011957292
ENSMUSG00000048503 Tmem136 9 43108653 43116570 107.9589146 -0.411627267 0.000126652 0.012084444
ENSMUSG00000021319 Sfrp4 13 19623175 19632821 226.6674115 0.40658048 0.000128062 0.012100689
ENSMUSG00000040957 Cables1 18 11839220 11945627 161.5661405 0.404403477 0.000128324 0.012100689
ENSMUSG00000079481 Nhsl2 X 101849385 102092055 213.5507486 -0.393969876 0.000133797 0.01254345
ENSMUSG00000029322 Plac8 5 100553725 100572245 668.0818713 -0.315656023 0.000134913 0.012575002
ENSMUSG00000033676 Gabrb3 7 57419692 57828802 188.7221149 0.391536604 0.000136172 0.012619394
ENSMUSG00000026051 1500015O10Rik 1 43730602 43742578 1105.319963 -0.330290134 0.000137779 0.012695389
ENSMUSG00000028019 Pdgfc 3 81036416 81214040 2188.305776 0.267165672 0.000140971 0.012909162
ENSMUSG00000028607 Cpt2 4 107903981 107923610 1271.275856 0.290472155 0.000141784 0.012909162
ENSMUSG00000047143 Dmrta2 4 109978053 109983687 40.29223962 0.386907185 0.000143302 0.012909162
ENSMUSG00000047747 Rnf150 8 82863356 83091271 2408.867219 -0.244716183 0.000143271 0.012909162
ENSMUSG00000031722 Hp 8 109575130 109579172 48.48509068 -0.379262085 0.000144483 0.012943307
ENSMUSG00000033306 Lpp 16 24393350 24992576 26133.48462 -0.258091395 0.000150963 0.013449061
ENSMUSG00000029636 Wasf3 5 146384985 146473615 191.0510972 -0.402308398 0.000152482 0.013509767
ENSMUSG00000028037 Ifi44 3 151730922 151749960 129.4130241 -0.40663702 0.000154545 0.01361766
ENSMUSG00000027656 Wisp2 2 163820861 163833146 7796.061746 0.387647517 0.000159766 0.014001253
ENSMUSG00000021250 Fos 12 85473890 85477273 340.9705728 -0.386409887 0.000161057 0.014038067
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ENSMUSG00000005125 Ndrg1 15 66929321 66969640 1135.068111 0.269804131 0.000167494 0.014366181
ENSMUSG00000040170 Fmo2 1 162874317 162898726 100.8261271 -0.388305903 0.00016695 0.014366181
ENSMUSG00000062488 Ifit3b 19 34607970 34613401 75.5191183 -0.399052809 0.000166459 0.014366181
ENSMUSG00000067219 Nipal1 5 72647795 72671078 543.5785269 -0.34525465 0.000172063 0.014680021
ENSMUSG00000017724 Etv4 11 101769742 101785371 414.1297662 -0.362580522 0.000176194 0.014953309
ENSMUSG00000030921 Trim30a 7 104409025 104465193 221.6307452 -0.402761637 0.000179156 0.014968316
ENSMUSG00000041959 S100a10 3 93555080 93564643 4636.464742 -0.227480355 0.000178169 0.014968316
ENSMUSG00000046982 Tshz1 18 84011627 84086404 1513.986668 -0.25060169 0.000178768 0.014968316
ENSMUSG00000020431 Adcy1 11 7063489 7178506 595.6419584 -0.333864684 0.000182784 0.015192721
ENSMUSG00000021403 Serpinb9b 13 33027416 33041884 658.096708 -0.362498345 0.000183734 0.015193381
ENSMUSG00000049502 Dtx3l 16 35926511 35939151 509.0817086 -0.328275341 0.000185473 0.015258953
ENSMUSG00000004098 Col5a3 9 20770050 20815067 2672.743647 0.317517761 0.000191231 0.015573792
ENSMUSG00000009418 Nav1 1 135434580 135607295 562.4667028 -0.327180148 0.000191232 0.015573792
ENSMUSG00000045573 Penk 4 4133531 4138819 2865.544352 -0.39015596 0.000193127 0.015649147
ENSMUSG00000044948 Cfap43 19 47737561 47919299 1844.978907 -0.277466512 0.000196729 0.015801259
ENSMUSG00000075707 Dio3 12 110279068 110281097 235.1630199 0.39132347 0.000196965 0.015801259
ENSMUSG00000006800 Sulf2 2 166073089 166155663 5671.017392 -0.292277661 0.000202443 0.016080716
ENSMUSG00000037736 Limch1 5 66745827 67057158 1936.418908 0.286264548 0.000202144 0.016080716
ENSMUSG00000033207 Mamdc2 19 23302609 23448322 559.6013832 -0.353274159 0.000210227 0.016617231
ENSMUSG00000061666 Gdpd1 11 87033867 87074062 501.5603093 -0.331197813 0.000211643 0.016647539
ENSMUSG00000027397 Slc20a1 2 129198764 129211616 8154.937877 0.252068947 0.000215104 0.016837628
ENSMUSG00000023034 Nr4a1 15 101266846 101274792 466.3078692 -0.366276412 0.000220283 0.017058734
ENSMUSG00000054293 A630033H20Rik X 107148927 107173661 98.64921243 -0.39755261 0.000220298 0.017058734
ENSMUSG00000060126 Tpt1 14 75845093 75848525 39058.33849 0.211140365 0.000221102 0.017058734
ENSMUSG00000107317 Gm19719 5 149282752 149287868 23.26159872 -0.29642032 0.000227919 0.017500932
ENSMUSG00000027035 Cers6 2 68861441 69114282 4696.031381 -0.229094776 0.000246682 0.018501118
ENSMUSG00000030107 Usp18 6 121245906 121270917 109.6395469 -0.387941536 0.000245807 0.018501118
ENSMUSG00000045083 Lingo2 4 35706647 36951747 214.3763946 -0.38085041 0.000244083 0.018501118
ENSMUSG00000054793 Cadm4 7 24482023 24504539 119.971927 0.393946404 0.000244119 0.018501118
ENSMUSG00000063430 Wscd2 5 113490333 113589725 202.6731494 0.394413674 0.000244766 0.018501118
ENSMUSG00000031226 Pbdc1 X 105079756 105117090 1253.824343 0.309226833 0.000256874 0.019087976
ENSMUSG00000074129 Rpl13a 7 45125565 45128745 36584.53348 0.225590862 0.000256864 0.019087976
ENSMUSG00000031465 Angpt2 8 18690263 18741562 462.6833559 -0.348615136 0.000258963 0.019154975
ENSMUSG00000028864 Hgf 5 16553495 16620152 670.1868223 -0.367364639 0.000270375 0.019907723
ENSMUSG00000021892 Sh3bp5 14 31359880 31436078 504.5237297 -0.344394371 0.000272267 0.019955946
ENSMUSG00000020354 Sgcd 11 46896253 47988969 654.465766 -0.31656248 0.000281698 0.020553791
ENSMUSG00000021127 Zfp36l1 12 80107760 80113013 608.7608515 -0.315317327 0.000290394 0.02108427
ENSMUSG00000029207 Apbb2 5 66298703 66618784 3784.415656 -0.225176423 0.000291584 0.02108427
ENSMUSG00000031997 Trpc6 9 8544196 8680565 54.53390216 -0.344947417 0.000295951 0.021209837
ENSMUSG00000055401 Fbxo6 4 148145716 148152140 1129.768982 0.256456968 0.000295621 0.021209837
ENSMUSG00000103472 Pcdhga7 18 37714764 37841873 406.077515 -0.326996018 0.000297289 0.021211472
ENSMUSG00000065254 Gm23973 7 103271550 103271870 5471.865313 0.246147798 0.000300189 0.02132398
ENSMUSG00000000627 Sema4f 6 82911885 82939769 50.66612402 0.3784419 0.00030524 0.021587675
ENSMUSG00000019966 Kitl 10 100015630 100100413 348.4464909 -0.373991093 0.000318786 0.022447246
ENSMUSG00000036782 Klhl13 X 23219271 23365082 1667.795823 0.297838304 0.000324919 0.022779664
ENSMUSG00000030717 Nupr1 7 126623249 126630861 4925.928684 0.244622118 0.000334191 0.023328234
ENSMUSG00000019577 Pdk4 6 5483351 5496309 286.4853213 -0.358799211 0.000357224 0.024828599
ENSMUSG00000025746 Il6 5 30013114 30019981 75.51299278 -0.377899212 0.000365908 0.025323017
ENSMUSG00000037108 Zcwpw1 5 137787798 137822621 154.2482613 0.384004726 0.000375045 0.025844417
ENSMUSG00000030556 Lrrc28 7 67513410 67645268 566.2425385 -0.304985829 0.000379296 0.025915894
ENSMUSG00000062393 Dgkk X 6779306 6948363 105.0975901 -0.382783466 0.000378692 0.025915894
ENSMUSG00000054408 Spcs3 8 54520433 54529998 7081.579715 0.211690994 0.000382514 0.02602549
ENSMUSG00000019929 Dcn 10 97479500 97518162 2353.860352 -0.280209572 0.000388048 0.026291067
ENSMUSG00000028024 Enpep 3 129269175 129332720 424.7652309 -0.358205203 0.000394701 0.026408962
ENSMUSG00000031530 Dusp4 8 34807297 34819894 661.0339332 -0.32031298 0.000394602 0.026408962
ENSMUSG00000036676 Tmtc3 10 100443902 100487350 5078.946528 -0.211809851 0.000392746 0.026408962
ENSMUSG00000036377 C530008M17Rik 5 76656512 76873554 298.5866625 -0.342879251 0.000396755 0.026436693
ENSMUSG00000029826 Zc3hav1 6 38305286 38354603 1765.286199 -0.279198105 0.000401421 0.026637517
ENSMUSG00000030122 Ptms 6 124913681 124920103 3770.488549 -0.251282452 0.000405504 0.026798136
ENSMUSG00000033355 Rtp4 16 23609919 23614222 91.19031189 -0.37496975 0.000454589 0.029919356
ENSMUSG00000053332 Gas5 1 161034422 161038539 7592.96487 0.217857139 0.000458394 0.029925521
ENSMUSG00000064341 mt-Nd1 MT 2751 3707 29504.22525 -0.267637993 0.000458203 0.029925521
ENSMUSG00000025762 Larp1b 3 40950354 41040234 545.1439593 0.299469047 0.00047806 0.031083541
ENSMUSG00000027171 Prrg4 2 104830741 104849876 709.5575315 -0.330503951 0.000483412 0.031305322
ENSMUSG00000034997 Htr2a 14 74640840 74706859 1061.065463 -0.326788287 0.000486212 0.031360684
ENSMUSG00000062991 Nrg1 8 31814551 32884029 1390.620165 0.263869992 0.000491594 0.031581463
ENSMUSG00000020303 Stc2 11 31357307 31370074 439.9714033 0.336512435 0.000498861 0.031921158
ENSMUSG00000006356 Crip2 12 113140236 113145506 1576.092848 -0.249519198 0.000523925 0.03339244
ENSMUSG00000021097 Clmn 12 104763114 104865076 258.9523211 0.367255633 0.000529379 0.033607218
ENSMUSG00000019124 Scrn1 6 54501173 54566489 1487.323047 0.264034434 0.000537263 0.033974007
ENSMUSG00000039316 Rftn1 17 49992257 50190674 927.2332749 -0.276026003 0.000541041 0.034079263
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ENSMUSG00000060969 Irx1 13 71957921 71963723 512.4032745 -0.332451569 0.000558348 0.035032539
ENSMUSG00000019806 Aig1 10 13647054 13868980 1149.511141 -0.26941207 0.000563084 0.035077697
ENSMUSG00000053647 Gper1 5 139423151 139427800 79.88044029 0.372511101 0.000563419 0.035077697
ENSMUSG00000087365 C430049B03Rik X 53055046 53057190 269.5852266 -0.347805465 0.00058231 0.036114449
ENSMUSG00000062661 Ncs1 2 31245823 31295989 2752.064036 -0.214218978 0.000585405 0.036167274
ENSMUSG00000031647 Mfap3l 8 60632827 60676729 911.8002989 -0.262516424 0.000596903 0.036734199
ENSMUSG00000068748 Ptprz1 6 22875502 23052916 1838.692869 -0.25025218 0.000599138 0.036734199
ENSMUSG00000024277 Mapre2 18 23752333 23893861 717.810252 -0.277857049 0.000602773 0.03681712
ENSMUSG00000022090 Pdlim2 14 70164218 70177681 1049.619005 0.257475482 0.000610602 0.037014851
ENSMUSG00000037379 Spon2 5 33198184 33218455 198.8100285 -0.365218175 0.000609366 0.037014851
ENSMUSG00000030753 Prkrir 7 98703103 98718062 3182.277293 -0.205519561 0.000613656 0.037060667
ENSMUSG00000032312 Csk 9 57626647 57645653 1124.687261 -0.253324087 0.000617353 0.037144824
ENSMUSG00000072941 Sod3 5 52363791 52371418 420.4708011 -0.325404636 0.000632423 0.0377697
ENSMUSG00000106918 Mrpl33 5 31596935 31664384 1007.449065 0.265764804 0.000631026 0.0377697
ENSMUSG00000039518 Cdsn 17 35552128 35557180 296.9254502 0.340306029 0.000653783 0.038901281
ENSMUSG00000001349 Cnn1 9 22099281 22109630 9779.731118 0.256343923 0.000665894 0.039476242
ENSMUSG00000006219 Fblim1 4 141576062 141606096 1229.794684 -0.238294406 0.000669353 0.039535984
ENSMUSG00000000325 Arvcf 16 18348182 18407076 709.5390214 0.299410874 0.000684708 0.040148799
ENSMUSG00000096847 Tmem151b 17 45541940 45549677 19.1100961 -0.278773845 0.000682506 0.040148799
ENSMUSG00000046186 Cd109 9 78615546 78716253 6633.658596 -0.242482252 0.00070662 0.041283532
ENSMUSG00000028413 B4galt1 4 40804602 40854005 3545.733926 -0.229663146 0.000711797 0.041435842
ENSMUSG00000018076 Med13l 5 118560679 118765438 1880.746289 -0.22972795 0.000720363 0.041783668
ENSMUSG00000048647 Exd1 2 119516505 119547627 89.05552336 0.360636001 0.000727186 0.042028224
ENSMUSG00000025507 Pidd1 7 141438113 141444025 265.323458 -0.340155614 0.000735849 0.042377007
ENSMUSG00000069874 Irgm2 11 58199618 58222782 255.6965618 -0.347119378 0.000749829 0.043028458
ENSMUSG00000015647 Lama5 2 180176373 180225859 3896.174807 0.258885131 0.000776663 0.044253342
ENSMUSG00000031207 Msn X 96096042 96168552 19390.6378 -0.197519891 0.000774862 0.044253342
ENSMUSG00000038508 Gdf15 8 70629393 70632456 185.9543568 0.344033608 0.000780349 0.044306803
ENSMUSG00000067274 Rplp0 5 115559467 115563727 63270.88582 0.196634836 0.000783728 0.044342494
ENSMUSG00000035493 Tgfbi 13 56609603 56639339 3473.796683 0.235395323 0.000814325 0.045912577
ENSMUSG00000003032 Klf4 4 55527143 55532466 742.1172684 -0.306322312 0.000825173 0.046201106
ENSMUSG00000038886 Man2a2 7 80349097 80371375 2749.176919 -0.249114404 0.000824549 0.046201106
ENSMUSG00000038366 Lasp1 11 97799000 97838764 6961.310983 -0.193621576 0.000833814 0.046523372
ENSMUSG00000042520 Ubap2l 3 90000140 90052628 3661.790285 -0.220162162 0.00084301 0.046874255
ENSMUSG00000067786 Nnat 2 157560078 157562522 132.6289112 -0.359779712 0.000848334 0.047008181
ENSMUSG00000098557 Kctd12 14 102976581 102982637 1888.203368 -0.255471203 0.000856458 0.047295859
ENSMUSG00000037071 Scd1 19 44394451 44407709 5248.92282 -0.261679563 0.00087855 0.048350238
ENSMUSG00000028583 Pdpn 4 143267431 143299564 2865.303963 -0.266596927 0.000882907 0.048424761
ENSMUSG00000015957 Wnt11 7 98835112 98855195 113.8365579 0.356846739 0.00090119 0.04918927
ENSMUSG00000047443 Fam132b 1 91366430 91374217 193.8134177 0.346524775 0.000902947 0.04918927

List of significantly mutated genes
Table 2 List of significantly mutated genes in liver tumours. Genes are ordered by the signifi-
cance of observed mutations for each group: DEN-initiated tumours from Ctcf hemizygous
and wild-type mice, and spontaneously occurring murine tumours. Each group also includes
the top seven genes mutated in other rodent tumours: Hras, Braf, Egfr, Kras, Apc, Ctnnb1,
and Keap1 (unpublished data). For each group, the number of tumours in which each gene
is mutated is stated and the cumulative mutation rate per kb of the gene is given. P-values
are corrected for multiple testing across all genes using the Bonferroni method.
Gene name Ensemble gene ID Gene length (bp) No. tumours mutated Mutations / kb Corrected p value
DEN-induced tumours - wild-type (n = 32)
Braf ENSMUSG00000002413 122227 20 7.657 0
Hras ENSMUSG00000025499 4901 5 6.954 0
Ext2 ENSMUSG00000027198 161541 7 2.922 0
Egfr ENSMUSG00000020122 165956 8 2.086 0
Ahnak2 ENSMUSG00000072812 30464 7 0.525 0
Adamts18 ENSMUSG00000053399 151613 12 3.197 0.045
Ctnnb1 ENSMUSG00000006932 31292 4 1.659 1
Kras ENSMUSG00000030265 33541 3 4.280 1
Apc ENSMUSG00000005871 101266 2 0.223 1
Keap1 ENSMUSG00000003308 9632 0 0 1
DEN-induced tumours - Ctcf hemizygous (n = 34)
Braf ENSMUSG00000002413 122227 21 8.040 0
Hras ENSMUSG00000025499 4901 6 8.345 0
Kras ENSMUSG00000030265 33541 4 5.706 0
Hap1 ENSMUSG00000006930 8802 5 2.508 0
Ros1 ENSMUSG00000019893 149524 18 2.497 0.023
Ctnnb1 ENSMUSG00000006932 31292 4 1.659 1
Apc ENSMUSG00000005871 101266 4 0.447 1
Egfr ENSMUSG00000020122 165956 3 0.782 1
Keap1 ENSMUSG00000003308 9632 2 1.057 1
Spontaneous tumours (n = 6)
Ctnnb1 ENSMUSG00000006932 31292 4 2.074 0
Braf ENSMUSG00000002413 122227 0 0 1
Hras ENSMUSG00000025499 4901 0 0 1
Egfr ENSMUSG00000020122 165956 0 0 1
Kras ENSMUSG00000030265 33541 0 0 1
Apc ENSMUSG00000005871 101266 0 0 1
Keap1 ENSMUSG00000003308 9632 0 0 1
